Referencia número: HY-17394

Cisplatin

Name: Cisplatin
Brand: MedChemExpress
SKU: HY-17394
Price: 25.00 USD
Availability: InStock
Rating: 5 (859 reviews)

(Synonyms: cis-Platinum; CDDP; cis-Diaminodichloroplatinum)

859 Cited Publications

Revisión del cliente

Based on 859 publication(s) in Google Scholar

Cisplatin (CDDP) is an antineoplastic chemotherapy agent by cross-linking with DNA and causing DNA damage in cancer cells. Cisplatin activates ferroptosis and induces autophagy.

Para uso exclusivo en investigación. No vendemos a pacientes.

Pureza : 99.30%
No. CAS: 15663-27-1
Fòrmula: Pt(NH₃)₂Cl₂
Peso molecular:300.05

Almacenamiento:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Cisplatin Chemical Structure

No. CAS: 15663-27-1

Tamaño

Precio

Stock

Cantidad

Amount: USD 0.00

* Seleccione Cantidad antes de agregar artículos.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Actividad biológica
- Descripciòn
- IC₅₀ & Target
- In Vitro
- In Vivo
- Induced Disease Models
- Ensayo clínico
Chemical Information
Publications (859)
Solvente y solubilidad
- In Vitro
- In Vivo
Protocolo (5)
Pureza y Documentación
Referencias
Help & FAQs
Classifications
Bioz

Actividad biológica

Descripciòn

Cisplatin (CDDP) is an antineoplastic chemotherapy agent by cross-linking with DNA and causing DNA damage in cancer cells. Cisplatin activates ferroptosis and induces autophagy^[1]^[2]^[3].

IC₅₀ & Target

DNA Alkylator/Crosslinker^[1]

Ver todos los productos específicos de isoformas Lipoxygenase :

In Vitro

Cisplatin (CDDP) causes apoptosis of HeLa cells in a dose-dependent manner, with a concentration of 30 μM Cisplatin resulting in death of greater than 90% of the cell population by 24 h of treatment. The kinetics of Cisplatin-induced apoptosis are examined using a 30 μM concentration. Cisplatin Activates the MEK/ERK Signaling Pathway, 20 and 30 μM Cisplatin, both of which results in significant apoptosis, leads to strong activation of ERK^[1].
Cisplatin (50 μM) produces time-dependent apoptosis in renal proximal tubular cell (RPTCs), causing cell shrinkage, a 50-fold increase in caspase 3 activity, a 4-fold increase in phosphatidylserine externalization, and 5- and 15-fold increases in chromatin condensation and DNA hypoploidy, respectively^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.

In Vivo

In melanoma-bearing mice, Cisplatin (CDDP; 4 mg/kg B.W.) reduces the size and weight of the solid tumors, and HemoHIM supplementation with Cisplatin enhances the decrease of both the tumor size and weight^[3].
Cisplatin administration results in significant increases in the kidney weight as a percentage of the total body weight, urine volume, serum creatinine, and blood urea nitrogen by about 132, 315, 797, and 556% in comparison with the control rats, respectively^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Induced Disease Models

Note:
Please do not refer to only one article to determine the experimental conditions. It is recommended to determine the optimal experimental conditions (animal strain, age, dosage, frequency and cycle, detection time and indicators, etc.) through preliminary experiments before the formal experiment.

Cisplatin can be used to induce acute kidney injury models^[7]^[8].

Induction of Acute Kidney Injury (AKI)^[7]^[8]

Background

The pathogenesis of Cisplatin-induced acute kidney injury (AKI) is complex and Oxidative stress, mitochondrial dysfunction, inflammation, and apoptosis are all participating in the progression of Cisplatin-induced AKI.Oxidative stress is a predominant mechanism of injury in cisplatin-induced AKI.

Specific Modeling Methods

Mice: C57BL/6 • male • 6-week-old (period: 2 weeks)
Administration: 5 mg/kg • ip • once daily for 2 weeks

Note

(1) Suggest using male mice as female mice are more resistant to renal injury.
(2) Mice can be deprived of food and water for 18 h prior to induction, and food and water are returned after administration.
(3) Cisplatin can be dissolved in sterile saline solution to prepare injection working solution while protecting from light.

Modeling Indicators

Molecular changes: Increased indicators: Serum creatinine (SCr) levels, blood urea nitrogen (BUN) levels, neutrophil gelatinase-associated lipocalin (NGAL), 3-nitrotyrosine.

Correlated Product(s): 84-B10 (HY-44307)

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Ensayo clínico

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

No. CAS 15663-27-1
Appearance Solid
Peso molecular 300.05
Fòrmula Pt(NH₃)₂Cl₂
Color Light yellow to yellow
SMILES

Cl[Pt](Cl)([NH3])[NH3]
Synonyms

cis-Platinum; CDDP; cis-Diaminodichloroplatinum
Envío

Room temperature in continental US; may vary elsewhere.
Almacenamiento

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Publications (859)

All Cell Imaging/StainingELISAIHCWBApoptosis AnalysisIPBio/Physico-chemical AssayIn Vivo Efficacy StudyRT-PCRFlow CytometryIn Vivo ImagingHistological Imaging/StainingIFCell Proliferation/Viability Assay

Sort by:

Journal Impact Factor

Signal Transduct Target Ther

BMX inhibition overcomes small cell lung cancer chemoresistance by stabilizing E2F1 via ERK1/2-Cyclin D1/CDK4/6 axis. [Abstract]

2026 Apr 8;11(1):125. PMID: 41946708

Cisplatin purchased from MedChemExpress. Usage Cited in: Signal Transduct Target Ther. 2026 Apr 8;11(1):125. [Abstract]

Cell proliferation curves of C23084 and LUC22009 cells treated with DMSO, Cisplatin (5 μM), IHMT-15137 (1 μM), or a combination of both.

Cisplatin purchased from MedChemExpress. Usage Cited in: Signal Transduct Target Ther. 2026 Apr 8;11(1):125. [Abstract]

Western blot analysis of DNA damage (γ-H2AX) and apoptosis (cleaved PARP and cleaved caspase-3) in C23084 and LUC22009 cells treated with DMSO, Cisplatin (30 μM), IHMT-15137 (10 μM), or their combination for 24 h.

Cisplatin purchased from MedChemExpress. Usage Cited in: Signal Transduct Target Ther. 2026 Apr 8;11(1):125. [Abstract]

Immunoprecipitation assay analyzing E2F1 ubiquitination levels after 24-h treatment with DMSO, Cisplatin (CDDP, 30 μM), and IHMT-15137 (3 μM) or their combination in C23084 and LUC22009 cells.
Signal Transduct Target Ther

Selective depletion of tumor-associated SAMHD1 enhances chemotherapeutic efficacy and antitumor immune responses. [Abstract]

2025 Dec 15;10(1):406. PMID: 41392286
Signal Transduct Target Ther

PKMYT1 kinase ameliorates cisplatin sensitivity in osteosarcoma. [Abstract]

2025 May 21;10(1):165. PMID: 40393983

Cisplatin purchased from MedChemExpress. Usage Cited in: Signal Transduct Target Ther. 2025 May 21;10(1):165. [Abstract]

HEK293T cells were transfected with indicated siRNAs for 48 h and treated with or without Cisplatin (1 μM) for 24 h before harvesting the cells for co-immunoprecipitation and Western blot.

Cisplatin purchased from MedChemExpress. Usage Cited in: Signal Transduct Target Ther. 2025 May 21;10(1):165. [Abstract]

The mRNA expression level of PKMYT1 in 143B, HOS, and U2OS after treatment with different concentrations of Cisplatin (DDP) for 24 h.

Cisplatin purchased from MedChemExpress. Usage Cited in: Signal Transduct Target Ther. 2025 May 21;10(1):165. [Abstract]

The OS cells (143B and HOS cells) were subjected to treatment with Cisplatin (DDP) for 7–15 days (143B: 0.2 μM, HOS: 0.4 μM). Cell survival was determined by colony formation assay.

Cisplatin purchased from MedChemExpress. Usage Cited in: Signal Transduct Target Ther. 2025 May 21;10(1):165. [Abstract]

The OS cells (U2OS and U2OS/DDP cells) were subjected to treatment with Cisplatin (DDP) for 7–15 days (U2OS: 0.4 μM, U2OS/DDP: 1 μM). Cell survival was determined by colony formation assay.

Cisplatin purchased from MedChemExpress. Usage Cited in: Signal Transduct Target Ther. 2025 May 21;10(1):165. [Abstract]

Apoptosis analysis of PKMYT1 knockout cells treated with Cisplatin (DDP) for 24 h (143B: 1 μM, HOS: 2 μM).

Cisplatin purchased from MedChemExpress. Usage Cited in: Signal Transduct Target Ther. 2025 May 21;10(1):165. [Abstract]

Apoptosis analysis of PKMYT1 knockout cells treated with Cisplatin (DDP) for 24 h (U2OS: 2 μM, U2OS/DDP: 10 μM).

Cisplatin purchased from MedChemExpress. Usage Cited in: Signal Transduct Target Ther. 2025 May 21;10(1):165. [Abstract]

PKMYT1 knockdown U2OS/DDP-Luc cells were orthotopically injected into mice. Starting on day 10, mice were treated with Cisplatin (DDP, 3.5 mg/kg) by i.p. injection once every 4 days for a total of three injections. Representative images of living imaging of xenograft mouse model.

Cisplatin purchased from MedChemExpress. Usage Cited in: Signal Transduct Target Ther. 2025 May 21;10(1):165. [Abstract]

PKMYT1 knockdown U2OS/DDP-Luc cells were orthotopically injected into mice. Starting on day 10, mice were treated with Cisplatin (DDP, 3.5 mg/kg) by i.p. injection once every 4 days for a total of three injections. Representative immunohistochemical images of Ki67 in the indicated xenograft tumors from the xenograft mouse model were shown.
Signal Transduct Target Ther

Elaiophylin triggers paraptosis and preferentially kills ovarian cancer drug-resistant cells by inducing MAPK hyperactivation. [Abstract]

2022 Sep 12;7(1):317. PMID: 36097006
Signal Transduct Target Ther

Drp1-dependent remodeling of mitochondrial morphology triggered by EBV-LMP1 increases cisplatin resistance. [Abstract]

2020 May 20;5(1):56. PMID: 32433544
Cancer Cell

2026 Apr 23:S1535-6108(26)00174-1. PMID: 42030930
Nature

VDAC2 loss elicits tumour destruction and inflammation for cancer therapy. [Abstract]

2025 Apr;640(8060):1062-1071. PMID: 40108474

Cisplatin purchased from MedChemExpress. Usage Cited in: Nature. 2025 Apr;640(8060):1062-1071. [Abstract]

Immunoblot analysis of indicated proteins in B16-OVA tumour cells treated with vehicle, IFNγ (10 ng /lL), Cisplatin (20 μM), or etoposide (20 μM) for 12 h.
J Hematol Oncol

A novel lncRNA ROPM-mediated lipid metabolism governs breast cancer stem cell properties. [Abstract]

2021 Oct 29;14(1):178. PMID: 34715882
Cell

SARM1 senses dsDNA to promote NAD+ degradation and cell death. [Abstract]

2025 Dec 11;188(25):7137-7154.e21. PMID: 41138726

Cisplatin purchased from MedChemExpress. Usage Cited in: Cell. 2025 Dec 11;188(25):7137-7154.e21. [Abstract]

Hindlimb clasping representative images and scores in the mice treated with the noted chemotherapy. Mice were intraperitoneally injected with 6 mg/kg Oxa, 6 mg/kg Cisplatin (CP), 50 mg/kg CBP, or 3 mg/kg VCR once a day for 3 days using physiological saline as Ctrl. The hindlimb positions were scored as follows. 0: no limb clasping; (1) one hindlimb exhibits incomplete splay and loss of mobility; (2) both hindlimbs exhibit incomplete splay and loss of mobility, and toes exhibit normal splay; (3) both hindlimbs exhibit clasping with curled toes and immobility. Arrows indicate that hindlimbs show clasping. n = 10 mice.
Cell

The human proteome with direct physical access to DNA. [Abstract]

2025 Aug 7;188(16):4424-4440.e17. PMID: 40409270

Cisplatin purchased from MedChemExpress. Usage Cited in: Cell. 2025 Aug 7;188(16):4424-4440.e17. [Abstract]

Dose-response curves using the integrated florescence signal over 72 h to determine half-effective concentrations for Cisplatin to induce apoptosis during the duration of the indicated knockdown in MCF7 cells.

Cisplatin purchased from MedChemExpress. Usage Cited in: Cell. 2025 Aug 7;188(16):4424-4440.e17. [Abstract]

Dose-response curves using the integrated florescence signal over 72 h to determine half-effective concentrations for Cisplatin to induce cell death during the duration of the indicated knockdown in MCF7 cells.
Mol Cancer

2026 May 13.
Mol Cancer

Overcoming multi-drug resistance in SCLC: a synergistic approach with venetoclax and hydroxychloroquine targeting the lncRNA LYPLAL1-DT/BCL2/BECN1 pathway. [Abstract]

2024 Oct 31;23(1):243. PMID: 39478582

Cisplatin purchased from MedChemExpress. Usage Cited in: Mol Cancer. 2024 Oct 31;23(1):243. [Abstract]

Cisplatin (2 μg/mL; 24-72 h) combined with Venetoclax (10-160 μM; 12-72 h) and Hydroxychloroquine (12.5-50 μM; 12-72 h) significantly inhibits the growth of H446/cDDP cells.
Mol Cancer

Organoids derived from patients provide a new opportunity for research and individualized treatment of malignant peritoneal mesothelioma. [Abstract]

2024 Jan 10;23(1):12. PMID: 38200517
Mol Cancer

Targeting CXCR2 inhibits the progression of lung cancer and promotes therapeutic effect of cisplatin. [Abstract]

2021 Apr 4;20(1):62. PMID: 33814009

Cisplatin purchased from MedChemExpress. Usage Cited in: Mol Cancer. 2021 Apr 4;20(1):62. [Abstract]

LL2 cells were treated by Cisplatin (2.5 μM and 5 μM) for 24 h and collected. The relative mRNA expression of CXCL1, CXCL2, CXCL3 and MIF of LL2 cells following cisplatin treatment.
Cell Metab

Gut microbial metabolites facilitate anticancer therapy efficacy by modulating cytotoxic CD8+ T cell immunity. [Abstract]

2021 May 4;33(5):988-1000.e7. PMID: 33761313
Cell Res

Mannose antagonizes GSDME-mediated pyroptosis through AMPK activated by metabolite GlcNAc-6P. [Abstract]

2023 Dec;33(12):904-922. PMID: 37460805

Cisplatin purchased from MedChemExpress. Usage Cited in: Cell Res. 2023 Dec;33(12):904-922. [Abstract]

Normal FHs 74 cell lines were pretreated with Mannose (20 mM) for 2 h, and then Cisplatin (10 μg/mL) for 24 h to assess pyroptotic features (including characteristic morphology, GSDME cleavage, and LDH release), and the cleaved caspase-3 and its substrate PARP levels were also detected.

Cisplatin purchased from MedChemExpress. Usage Cited in: Cell Res. 2023 Dec;33(12):904-922. [Abstract]

Normal FHs 74 cell lines were pretreated with Mannose (20 mM) and DON (40 μM) for 2 h, and then Cisplatin (10 μg/mL) for 24 h to assess pyroptotic features (including characteristic morphology, GSDME cleavage, and LDH release), and the cleaved caspase-3 and its substrate PARP levels were also detected.

Cisplatin purchased from MedChemExpress. Usage Cited in: Cell Res. 2023 Dec;33(12):904-922. [Abstract]

Normal NRK-52E cell lines were pretreated with Mannose (20 mM) for 2 h, and then Cisplatin (10 μg/mL) for 24 h to assess pyroptotic features (including characteristic morphology, GSDME cleavage, and LDH release), and the cleaved caspase-3 and its substrate PARP levels were also detected.

Cisplatin purchased from MedChemExpress. Usage Cited in: Cell Res. 2023 Dec;33(12):904-922. [Abstract]

Normal NRK-52E cell lines were pretreated with Mannose (20 mM) and DON (40 μM) for 2 h, and then Cisplatin (10 μg/mL) for 24 h to assess pyroptotic features (including characteristic morphology, GSDME cleavage, and LDH release), and the cleaved caspase-3 and its substrate PARP levels were also detected.
Exploration

Tumor-Mimic Artificial Cell Integrated With In Situ Synthetic Biology for Testing of Antitumor Drug Sensitivity. [Abstract]

2026 May 28;6(3):20240134. PMID: 42382689

Cisplatin purchased from MedChemExpress. Usage Cited in: Exploration. 2026 May 28;6(3):20240134. [Abstract]

Cell toxicity analysis. T24 cells were treated with MK-571 (50 µM; 72 h), PSC-833 (40 µM; 72 h), sulfasalazine (0.25 mM; 72 h). Then treated with different concentration of Cisplatin (DDP, 112-2800 µM; 2 h). Cell viability was assessed by CCK8 assay.

Cisplatin purchased from MedChemExpress. Usage Cited in: Exploration. 2026 May 28;6(3):20240134. [Abstract]

Representative flow cytometric profiles in HeLa cell and HeLa-CCMACs at different concentration of Cisplatin (DDP, 112-2800 µM; 2 h).
Exploration

Caffeic Acid Acts as a Potent Senomorphic and Alleviates Inflammation and Lung Fibrosis by Covalently Targeting Annexin A5 Protein in Mice. [Abstract]

2025 Dec 12;5(6):20240069. PMID: 41476649

Cisplatin purchased from MedChemExpress. Usage Cited in: Exploration. 2025 Dec 12;5(6):20240069. [Abstract]

Identification of senescent cells by SA-β-gal activity assay. Scale bar, 10 μm. Senescence was induced in A549 cells using Cisplatin (15 µM; 72 h) treatment and characterized by senescence‐associated beta‐galactosidase (SA‐β‐gal) staining.
Cancer Discov

An African-specific variant of TP53 reveals PADI4 as a regulator of p53-mediated tumor suppression. [Abstract]

2023 Jul 7;13(7):1696-1719. PMID: 37140445
Cancer Discov

Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma. [Abstract]

2017 Sep;7(9):984-998. PMID: 28588062

Cisplatin purchased from MedChemExpress. Usage Cited in: Cancer Discov. 2017 Sep;7(9):984-998. [Abstract]

Examination of the parental PEO4 cell line, PEO4 cells with the homozygous frameshift RAD51D mutation (c.762_763del, D254E*fs72) in the same exon as the primary mutation and PEO4 cells with the homozygous secondary RAD51D mutation (c.770_776delinsA, S257_R259delinsK) using: Cell viability assay after treatment with Cisplatin for 7 days.
Adv Mater

Neonatal Tissue-derived Extracellular Vesicle Therapy (NEXT): A Potent Strategy for Precision Regenerative Medicine. [Abstract]

2023 Aug;35(33):e2300602. PMID: 37148469
Adv Mater

A Physiologically Responsive Nanocomposite Hydrogel for Treatment of Head and Neck Squamous Cell Carcinoma via Proteolysis-targeting Chimeras Enhanced Immunotherapy. [Abstract]

2023 Mar;35(12):e2210787. PMID: 36656993
Eur Urol

Taxane-induced Attenuation of the CXCR2/BCL-2 Axis Sensitizes Prostate Cancer to Platinum-based Treatment. [Abstract]

2021 Jun;79(6):722-733. PMID: 33153817
Nat Cancer

Targeting the ALK-CDK9-Tyr19 kinase cascade sensitizes ovarian and breast tumors to PARP inhibition via destabilization of the P-TEFb complex. [Abstract]

2022 Oct;3(10):1211-1227. PMID: 36253486
Bioact Mater

Biomimetic hydrogels with mesoscale collagen architecture for patient-derived tumor organoids culture. [Abstract]

2024 May 11:38:384-398. PMID: 38764448
Cancer Res

Tailoring Chemotherapy for the African-Centric S47 Variant of TP53. [Abstract]

2018 Oct 1;78(19):5694-5705. PMID: 30115697

Cisplatin purchased from MedChemExpress. Usage Cited in: Cancer Res. 2018 Oct 1;78(19):5694-5705. [Abstract]

WT and S47 E1A/RAS cells are treated with 10μM CDDP for 24 hours in the presence or absence of the protein synthesis inhibitor Cycloheximide (2.5 g/mL). Cell lysates are subjected to Western blot analysis, and immunoblotted for cleaved caspase-3, p53, p21, and HSP90 (loading control). CDDP: cisplatin

Cisplatin purchased from MedChemExpress. Usage Cited in: Cancer Res. 2018 Oct 1;78(19):5694-5705. [Abstract]

WT and S47 E1A/RAS cells are treated with 10 M Cisplatin (CDDP) for 24 hours. Cells are then fractionated into three fractions: whole cell lysate (W), mitochondria (M), and cytosol (C).
Drug Resist Updat

RCN2 facilitates esophageal squamous cellular carcinoma metastasis and cisplatin resistance through UBR5-mediated PPP2CA ubiquitination and degradation. [Abstract]

2026 Mar:85:101339. PMID: 41411970

Cisplatin purchased from MedChemExpress. Usage Cited in: Drug Resist Updat. 2026 Mar:85:101339. [Abstract]

Lung metastasis mouse model was established in BALB/c nude mice that were randomly divided into 4 groups (5 mice per group). Metastatic tumor growth was visualized through bioluminescence at days 30, 35, and 40. H&E staining was performed on the lungs dissected at the endpoint. Cisplatin (CDDP, 5 mg/kg; once every 5 days for 40 days) and PBS were administrated via oral gavage.

Cisplatin purchased from MedChemExpress. Usage Cited in: Drug Resist Updat. 2026 Mar:85:101339. [Abstract]

Subcutaneous tumor model was established using BALB/c nude mice randomly divided into 4 groups (5 mice per group). Cisplatin (CDDP, 5 mg/kg; once every 5 days for 40 days) and PBS were given via oral gavage. Tumor volume was measured at the indicated time periods, and tumors were weighed at the endpoint after mice were sacrificed.
Drug Resist Updat

Single-cell transcriptome analysis reveals the association between histone lactylation and cisplatin resistance in bladder cancer. [Abstract]

2024 Mar:73:101059. PMID: 38295753

Cisplatin purchased from MedChemExpress. Usage Cited in: Drug Resist Updat. 2024 Mar:73:101059. [Abstract]

Proliferation capacity of cells assessed using colony formation experiments after treatment with 10 μM cisplatin in combination with 10 μM 2-DG or 5 μM oxamate or 15 μM Nala.
2-DG and oxamate synergize with cisplatin could inhibit BCa cell proliferation and colony-forming ability.
Sci Bull

2026 Jun 30.
Bone Res

Targeting AKT as a promising strategy for SOX2-positive, chemoresistant osteosarcoma. [Abstract]

2025 Feb 24;13(1):25. PMID: 39994220

Cisplatin purchased from MedChemExpress. Usage Cited in: Bone Res. 2025 Feb 24;13(1):25. [Abstract]

Cell viability for the ctrl and SOX2 knockdown cells (HOS and 143B cell lines) with Cisplatin (48 h) treatment was assessed. Relative intensity was measured at OD 450 nm.

Cisplatin purchased from MedChemExpress. Usage Cited in: Bone Res. 2025 Feb 24;13(1):25. [Abstract]

Cell viability for ctrl and SOX2 overexpression cells (U2OS and MG63 cell lines) with Cisplatin (48 h) treatment was assessed. Relative intensity was measured at OD 450 nm.

Cisplatin purchased from MedChemExpress. Usage Cited in: Bone Res. 2025 Feb 24;13(1):25. [Abstract]

Cell viability for the ctrl and AKT knockdown cells (HOS and 143B cell lines) with Cisplatin (48 h) treatment was assessed. Relative intensity was measured at OD 450 nm.

Cisplatin purchased from MedChemExpress. Usage Cited in: Bone Res. 2025 Feb 24;13(1):25. [Abstract]

Statistical analysis of tumor volume of PDX tumors model with or without MK2206 (20 mg/kg; i.p.; twice weekly) or Cisplatin (DDP, 4 mg/kg; i.p.; once every 5 days) combinative therapy. The results showed that MK2206 and Cisplatin alone could slightly inhibit the growth of osteosarcoma PDX, and the inhibitory effect was very significant when combined.

Cisplatin purchased from MedChemExpress. Usage Cited in: Bone Res. 2025 Feb 24;13(1):25. [Abstract]

Western blot images showing p-AKT and SOX2 protein level with or without MK2206 (20 mg/kg; i.p.; twice weekly) and Cisplatin (DDP, 4 mg/kg; i.p.; once every 5 days) combination therapy in PDX model.

Cisplatin purchased from MedChemExpress. Usage Cited in: Bone Res. 2025 Feb 24;13(1):25. [Abstract]

Representative immunohistochemical images of p-AKT and SOX2 expression in PDX tumors of four therapeutic groups. Vehicle, Cisplatin (DDP, 4 mg/kg; i.p.; once every 5 days), MK2206 (20 mg/kg; i.p.; twice weekly), and DDP (4 mg/kg; i.p.; once every 5 days)+ MK2206 (20 mg/kg; i.p.; twice weekly). Scale bar, 50 μm (magnification, ×400).
Adv Funct Mater

2023 Apr 14.
Autophagy

CCPG1-mediated reticulophagy promotes tumorigenesis and cisplatin resistance in bladder cancer. [Abstract]

2025 Dec 26:1-17. PMID: 41361995

Cisplatin purchased from MedChemExpress. Usage Cited in: Autophagy. 2025 Dec 26:1-17. [Abstract]

Quantitative analysis of reticulophagy flux by flow cytometry. SV-HUC-1, T24, and 5637 cells were treated with 0, 3.5, or 7 μg/mL Cisplatin (Cis) for 24 h and transfected with mCherry-GFP-CKAP4 or mCherry-GFP-REEP5 plasmids. n = 3. Flow cytometry analysis showed that Cisplatin (Cis) treatment decreased the mCherry:GFP-CKAP4 and mCherry:GFP-REEP5 ratio in T24 and 5637 cells in a dose-dependent manner, while it had no impact on the ratio in control cells.

Cisplatin purchased from MedChemExpress. Usage Cited in: Autophagy. 2025 Dec 26:1-17. [Abstract]

Confocal images of live T24 cells stably expressing mCherry-GFP-REEP5 treated with or without 3.5 μg/mL Cisplatin (Cis) for 24 h. Arrowheads indicate mCherry⁺ GFP⁻ puncta. The results showed that Cisplatin treatment dramatically reduced the number of mCherry⁺ GFP⁻REEP5 puncta in T24 cells. Scale bar: 10 μm.

Cisplatin purchased from MedChemExpress. Usage Cited in: Autophagy. 2025 Dec 26:1-17. [Abstract]

Confocal images of live 5637 cells stably expressing mCherry-GFP-REEP5 treated with or without 3.5 μg/mL Cisplatin (Cis) for 24 h. Arrowheads indicate mCherry⁺ GFP⁻ puncta. The results showed that Cisplatin treatment dramatically reduced the number of mCherry⁺ GFP⁻REEP5 puncta in 5637 cells. Scale bar: 10 μm.

Cisplatin purchased from MedChemExpress. Usage Cited in: Autophagy. 2025 Dec 26:1-17. [Abstract]

Quantitative analysis of the apoptosis rate by flow cytometry. The groups included T24 or 5637 cells transfected with siRNA control (siNC), siRNA targeting CCPG1 alone (siCCPG1), or co-transfected with wt CCPG1 (siCCPG1 + wt CCPG1) or CCPG1^W14A,I17A (siCCPG1 + CCPG1^W14A,I17A). Cells were treated with or without 7 μg/mL Cisplatin (Cis) in T24 and 3.5 μg/mL Cisplatin in 5637 for 48 h. n = 3. The results showed that CCPG1 knockdown further enhanced apoptosis in Cisplatin-treated T24 and 5637 cells.

Cisplatin purchased from MedChemExpress. Usage Cited in: Autophagy. 2025 Dec 26:1-17. [Abstract]

Growth curves of different cell groups. The groups included T24 or 5637 cells transfected with siRNA control (siNC), siRNA targeting CCPG1 alone (siCCPG1), or co-transfected with wt CCPG1 (siCCPG1 + wt CCPG1) or CCPG1^W14A,I17A (siCCPG1 + CCPG1^W14A,I17A). Cells were treated with or without 1 μg/mL Cisplatin (Cis) in T24 and 0.5 μg/mL Cisplatin in 5637 for 5 days. The results showed that CCPG1 knockdown further inhibited cell proliferation in Cisplatin-treated T24 and 5637 cells.

Cisplatin purchased from MedChemExpress. Usage Cited in: Autophagy. 2025 Dec 26:1-17. [Abstract]

Relative mRNA levels of CCPG1 in SV-HUC-1, T24, and 5637 cells, treated with or without 3.5 μg/mL Cisplatin (Cis) for 24 h, measured by qRT-PCR. The results showed that Cisplatin treatment significantly reduced CCPG1 mRNA levels in T24 and 5637 cells, but not in normal epithelial cells.

Cisplatin purchased from MedChemExpress. Usage Cited in: Autophagy. 2025 Dec 26:1-17. [Abstract]

Immunoblot analysis of protein levels of γH2AX, and ATM/ATR-CHEK1/CHEK2 pathway in T24 cells treated with 3.5 μg/mL Cisplatin (Cis) for different times.

Cisplatin purchased from MedChemExpress. Usage Cited in: Autophagy. 2025 Dec 26:1-17. [Abstract]

TEM images of T24 cells. Groups included: T24 cells transfected with vector control (Ctrl), T24 cells transfected with vector control (Ctrl) and treated with 7 μg/mL Cisplatin for 12 h (Cis), T24 cells transfected with wt CCPG1 or CCPG1^W14A,I17A and treated with Cisplatin (Cis) for 12 h (Cis + wt CCPG1, Cis+CCPG1^W14A,I17A). White arrows, normal er in the cytoplasm; red arrows, er fragment engulfed in the autolysosome; blue arrows, autolysosome membrane. er, endoplasmic reticulum; m, mitochondrion; al, autolysosome; N, nucleus. The third row shows reticulophagy and Cisplatin-induced swollen er. Scale bars: 1 µm (first row), 500 nm (second row), and 250 nm (third row).

Cisplatin purchased from MedChemExpress. Usage Cited in: Autophagy. 2025 Dec 26:1-17. [Abstract]

Cisplatin (Cis, 2.5 mg/kg; i.p.; once every 2 days, for a total of 7 times) significantly reduced tumor weight without affecting body weight compared to the control group in the Xenograft BALB/C nude mice model.
Autophagy

The COPS3-FOXO3 positive feedback loop regulates autophagy to promote cisplatin resistance in osteosarcoma. [Abstract]

2023 Jun;19(6):1693-1710. PMID: 36451342
Nat Commun

Ascites protects against ferroptosis and enables the peritoneal growth of ovarian cancer. [Abstract]

2026 May 11;17(1):4190. PMID: 42115216

Cisplatin purchased from MedChemExpress. Usage Cited in: Nat Commun. 2026 May 11;17(1):4190. [Abstract]

Cells treated with 5 µM Cisplatin ± 2% ascites. Lipro-1 (2 µM) used as a control (48 hours).
Nat Commun

Endothelial PDLIM5 promotes tip cell filopodia formation and tumor angiogenesis by regulating ACTN1/ACTN4-dependent actin bundling. [Abstract]

2026 Jan 28;17(1):2103. PMID: 41605926

Cisplatin purchased from MedChemExpress. Usage Cited in: Nat Commun. 2026 Jan 28;17(1):2103. [Abstract]

Tumor-bearing mice were treated with Cisplatin (4 mg/kg; i.p.; once every 3 day, 5 times in total). Representative micrographs of tumor tissue sections stained with Hematoxylin and Eosin (H&E), immunohistochemical (IHC) staining for Ki-67 and cleaved caspase 3 (CC3), and immunofluorescence (IF) staining for CD31. Nuclei are stained with DAPI. Scale bar: 100 μm.

Cisplatin purchased from MedChemExpress. Usage Cited in: Nat Commun. 2026 Jan 28;17(1):2103. [Abstract]

Tumor-bearing mice were treated with Cisplatin (4 mg/kg; i.p.; once every 3 day, 5 times in total). Tumor volume changes in each group (n=5).
Nat Commun

A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. [Abstract]

2026 Jan 8;17(1):1447. PMID: 41507205

Cisplatin purchased from MedChemExpress. Usage Cited in: Nat Commun. 2026 Jan 8;17(1):1447. [Abstract]

C57BL6 mice were administered with an AAV encoding the HEAL system (3 × 10¹¹ vg) via intravenous injection (i.v.). After two weeks, acute kidney injury (AKI) was induced by a single intraperitoneal (i.p.) injection of Cisplatin (25 mg/kg; once daily for 4 days). Non-AKI mice (non-AKI), untreated AKI mice (untreated), and AKI mice treated with AAVNT (AAV-delivered HEAL system with an empty sgRNA vector) served as controls. Relative mRNA expression of Il10 in mouse livers.

Cisplatin purchased from MedChemExpress. Usage Cited in: Nat Commun. 2026 Jan 8;17(1):1447. [Abstract]

C57BL6 mice were administered with an AAV encoding the HEAL system (3 × 10¹¹ vg) via intravenous injection (i.v.). After two weeks, acute kidney injury (AKI) was induced by a single intraperitoneal (i.p.) injection of Cisplatin (25 mg/kg; once daily for 4 days). Non-AKI mice (non-AKI), untreated AKI mice (untreated), and AKI mice treated with AAVNT (AAV-delivered HEAL system with an empty sgRNA vector) served as controls. Serum IL-10 levels.

Cisplatin purchased from MedChemExpress. Usage Cited in: Nat Commun. 2026 Jan 8;17(1):1447. [Abstract]

C57BL6 mice were administered with an AAV encoding the HEAL system (3 × 10¹¹ vg) via intravenous injection (i.v.). After two weeks, acute kidney injury (AKI) was induced by a single intraperitoneal (i.p.) injection of Cisplatin (25 mg/kg; once daily for 4 days). Non-AKI mice (non-AKI), untreated AKI mice (untreated), and AKI mice treated with AAVNT (AAV-delivered HEAL system with an empty sgRNA vector) served as controls. Serum levels of BUN and S-Cre.

Cisplatin purchased from MedChemExpress. Usage Cited in: Nat Commun. 2026 Jan 8;17(1):1447. [Abstract]

C57BL6 mice were administered with an AAV encoding the HEAL system (3 × 10¹¹ vg) via intravenous injection (i.v.). After two weeks, acute kidney injury (AKI) was induced by a single intraperitoneal (i.p.) injection of Cisplatin (25 mg/kg; once daily for 4 days). Non-AKI mice (non-AKI), untreated AKI mice (untreated), and AKI mice treated with AAVNT (AAV-delivered HEAL system with an empty sgRNA vector) served as controls. Representative images of immunohistochemistry (IHC) staining for neutrophil gelatinase associated lipocalin (NGAL) in renal tissue. The images represent typical results from three independent measurements. Black arrows, NGAL-positive regions. Scale bars = 50 µm.

Cisplatin purchased from MedChemExpress. Usage Cited in: Nat Commun. 2026 Jan 8;17(1):1447. [Abstract]

C57BL6 mice were administered with an AAV encoding the HEAL system (3 × 10¹¹ vg) via intravenous injection (i.v.). After two weeks, acute kidney injury (AKI) was induced by a single intraperitoneal (i.p.) injection of Cisplatin (25 mg/kg; once daily for 4 days). Non-AKI mice (non-AKI), untreated AKI mice (untreated), and AKI mice treated with AAVNT (AAV-delivered HEAL system with an empty sgRNA vector) served as controls. TUNEL staining in renal tissue.
Nat Commun

AEBP1 drives fibroblast-mediated T cell dysfunction in tumors. [Abstract]

2025 Sep 1;16(1):8171. PMID: 40890191
Nat Commun

SERBP1-PCIF1 complex-controlled m6Am modification in glutamatergic neurons of the primary somatosensory cortex is required for neuropathic pain in mice. [Abstract]

2025 Aug 5;16(1):7225. PMID: 40764612

Cisplatin purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Aug 5;16(1):7225. [Abstract]

Expression of PCIF1 protein in contralateral S1HL in a model of Cisplatin (2.3 mg/kg/day; i.p. for two cycles of five daily injections followed by 5 days of rest)-induced neuropathic pain (Cisp), diabetic neuropathic pain (DNP) or chronic restraint stress (CRS) (n = 8 mice).
Nat Commun

Helicobacter hepaticus promotes hepatic steatosis through CdtB-induced mitochondrial stress and lipid metabolism reprogramming. [Abstract]

2025 Aug 26;16(1):7954. PMID: 40858606

Cisplatin purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Aug 26;16(1):7954. [Abstract]

Flow cytometry analysis of mitochondrial membrane potential by tetramethylrhodamine methyl ester (TMRM) in Hep3B cells (n = 3 independent experiments) transfected with pCMV-EGFP or pCMV-EGFP-CdtB or treated with Cisplatin (CDDP) (10 μM) for 24 h.
Nat Commun

Oral ENPP1 inhibitor designed using generative AI as next generation STING modulator for solid tumors. [Abstract]

2025 May 23;16(1):4793. PMID: 40410143

Cisplatin purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 May 23;16(1):4793. [Abstract]

Maximal cGAMP release induced by combined use of Cisplatin (20 μM; 48-72 h) with ISM5939 (n = 2 biological replicates, two independent experiments).
Nat Commun

CDK4 inactivation inhibits apoptosis via mitochondria-ER contact remodeling in triple-negative breast cancer. [Abstract]

2025 Jan 9;16(1):541. PMID: 39788939

Cisplatin purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Jan 9;16(1):541. [Abstract]

Representative pictures of DAPI (blue) and γH2AX (red) staining in CDK4-WT and -KO MDA-MB−231 TNBC cells 24 hours after treatment with Vehicle, Cisplatin (10 μM), H202 (250μM-2hours), or Oligomycin and Antimycin (O + A) (1 + 10μM-2hours). Scale bars: 10 μm.

Cisplatin purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Jan 9;16(1):541. [Abstract]

Number of viable CDK4-WT and -KO TNBC cells, pretreated with Vehicle or Abema for 2 days and after 2 days of treatment with Vehicle, Cisplatin (10 μM), 5-FU (20 μM), Dox (5 μM), H202 (250μM-2hours) or Oligomycin and Antimycin (O + A) (1 + 10μM-2hours).

Cisplatin purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Jan 9;16(1):541. [Abstract]

CDK4-WT and -KO MDA-MB-231 TNBC cells were injected in fat pad of the mammary gland of female NSG mice. Randomization was performed when tumor volume reached 80-120mm³ and Cisplatin (4m/kg; i.p.) was performed at D0, D5 and D12, before sacrifice at D14. Tumor volume of CDK4-WT and -KO tumor xenografts, treated with vehicle (Veh) or Cisplatin (4 mg/kg). Tumor volume of CDK4-WT and -KO tumor xenografts at the end of the sacrifice.
Nat Commun

Methylcobalamin protects against liver failure via engaging gasdermin E. [Abstract]

2025 Jan 31;16(1):1233. PMID: 39890804

Cisplatin purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Jan 31;16(1):1233. [Abstract]

HepG2 were pretreatedwithindicated concentrations of each inhibitor for 2 h before adding Cisplatin (DDP, 20 μg/mL) for 16 h, the cytotoxicity of HepG2 cells was determined by LDH release assay.

Cisplatin purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Jan 31;16(1):1233. [Abstract]

HepG2 cells were pretreatedwithindicated concentrations of each inhibitor for 2 h before adding Cisplatin (DDP, 20 μg/mL) for 16 h.Pyroptosis was measured by SYTOX green uptake in the presenceof 20 μM MeCbl or DMF.

Cisplatin purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Jan 31;16(1):1233. [Abstract]

Mice were intraperitoneally injected with 10 mg/kg Cisplatin (DDP) at day 1 and day 5 for serum biochemistry assay, or 20 mg/kg DDP at day 1 for survival analysis, MeCbl (10 mg/kg), DMF (50 mg/kg) were given intragastrically to micedailybefore euthanized. Survival analysis of WT and Gsdme^-/- mice after DDP injectionand treated as indicated, n = 10.

Cisplatin purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Jan 31;16(1):1233. [Abstract]

Mice were intraperitoneally injected with 10 mg/kg Cisplatin (DDP) at day 1 and day 5 for serum biochemistry assay, or 20 mg/kg DDP at day 1 for survival analysis, MeCbl (10 mg/kg), DMF (50 mg/kg) were given intragastrically to micedailybefore euthanized. Representative H&E sections of theliver (scale bar=50 μm). Damaged area was traced with black dash lineandanalyzed using Image J software.
Nat Commun

Synthetic vectors for activating the driving axis of ferroptosis. [Abstract]

2024 Sep 10;15(1):7923. PMID: 39256387
Nat Commun

Autophagy-deficient macrophages exacerbate cisplatin-induced mitochondrial dysfunction and kidney injury via miR-195a-5p-SIRT3 axis. [Abstract]

2024 May 23;15(1):4383. PMID: 38782909
Nat Commun

Single cell sequencing reveals that CD39 inhibition mediates changes to the tumor microenvironment. [Abstract]

2022 Nov 8;13(1):6740. PMID: 36347860
Nat Commun

Genome-wide CRISPR screen identifies ELP5 as a determinant of gemcitabine sensitivity in gallbladder cancer. [Abstract]

2019 Dec 2;10(1):5492. PMID: 31792210
Nat Commun

Genotoxic stress-triggered β-catenin/JDP2/PRMT5 complex facilitates reestablishing glutathione homeostasis. [Abstract]

2019 Aug 21;10(1):3761. PMID: 31434880

Cisplatin purchased from MedChemExpress. Usage Cited in: Nat Commun. 2019 Aug 21;10(1):3761. [Abstract]

IB analysis of the level of cleaved-caspase 3 and cleaved-PARP1 in the indicated chemotherapy-treated xenograft tumors. GAPDH served as the loading control.

Cisplatin purchased from MedChemExpress. Usage Cited in: Nat Commun. 2019 Aug 21;10(1):3761. [Abstract]

Genotoxic stress-induced β-catenin signaling is activated via a TCF- or FOXO-independent mechanism. Representative images of the subcellular localization of β-catenin in the indicated cells treated with CPT (10 μM, 1 h), IR (10 Gy), and CDDP (10 μM, 1 h), as analyzed by immunofluorescence staining.
Int J Oral Sci

LncRNA EUDAL shapes tumor cell response to hypoxia-induced constitutive EGFR activation and promotes chemoresistance in oral cancer. [Abstract]

2025 Sep 12;17(1):64. PMID: 40940319

Cisplatin purchased from MedChemExpress. Usage Cited in: Int J Oral Sci. 2025 Sep 12;17(1):64. [Abstract]

Tumor-bearing mice models were established by inoculating the indicated cell lines. Xenografts were treated with Cisplatin (5 mg/kg; i.p.; once weekly) alone or in combination with STAT3-IN-1, CQ or cetuximab. Tumor inhibition rates were determined in each experimental group.
Exp Mol Med

Cancer-associated fibroblast-derived extracellular vesicles regulate lipophagy through PLIN2 to modulate dormancy in salivary gland adenoid cystic carcinoma cells. [Abstract]

2025 Dec 18. PMID: 41408408

Cisplatin purchased from MedChemExpress. Usage Cited in: Exp Mol Med. 2025 Dec 18. [Abstract]

Dio staining analysis of SACC cells treated with Cisplatin (Cis, 2 μM) at different time points. The results confirmed that SACC cells entered a cellular dormant state after 48 h of Cisplatin treatment.

Cisplatin purchased from MedChemExpress. Usage Cited in: Exp Mol Med. 2025 Dec 18. [Abstract]

Flow cytometry analysis of apoptosis in SACC cells treated with Cisplatin (2 μM; 48 h).

Cisplatin purchased from MedChemExpress. Usage Cited in: Exp Mol Med. 2025 Dec 18. [Abstract]

Western blot analysis of p-AKT, AKT, p-mTOR levels of SACC cells treated with Cisplatin (Cis, 2 μM; 48 h). Cisplatin treatment inhibited the phosphorylation of AKT protein and mTOR, indicating that the inhibition of the AKT pathway caused the high expression of P27, which in turn led to SACC cell cycle arrest and an increase in NR2F1 abundance. Moreover, the mTOR pathway inhibition increased the conversion of LC-I to LC3-II, thereby activating autophagy in dormant SACC cells.
ACS Nano

Targeted Positron Emission Tomography-Tracked Biomimetic Codelivery Synergistically Amplifies Ferroptosis and Pyroptosis for Inducing Lung Cancer Regression and Anti-PD-L1 Immunotherapy Efficacy. [Abstract]

2024 Nov 12;18(45):31401-31420. PMID: 39475541

Cisplatin purchased from MedChemExpress. Usage Cited in: ACS Nano. 2024 Nov 12;18(45):31401-31420. [Abstract]

Cisplatin (5-30 μM; 24 h) exhibits an IC₅₀ value of 14.56 μM for inhibiting the viability of A549 cells.

Cisplatin purchased from MedChemExpress. Usage Cited in: ACS Nano. 2024 Nov 12;18(45):31401-31420. [Abstract]

Cisplatin (5-30 μM; 24 h) demonstrates an IC₅₀ value of 7.41 μM for inhibiting the viability of H1299 cells.
J Adv Res

Renal tubular Nfe2l1 protect cisplatin-induced acute kidney injury via suppressing ACSL4-dependent ferroptosis. [Abstract]

2026 May 3:S2090-1232(26)00381-4. PMID: 42086188
J Adv Res

Gymconopin C exhibits anti-non-small cell lung cancer effect by regulating miR-6777-5p/ADRB2 pathway to promote mitophagy. [Abstract]

2025 Dec 19:S2090-1232(25)01014-8. PMID: 41423048
J Adv Res

Procyanidin C1 inhibits tumor growth and metastasis in colon cancer via modulating miR-501-3p/HIGD1A axis. [Abstract]

2024 Jun:60:215-231. PMID: 37479180
Cell Discov

A positive feedback loop between SMAD3 and PINK1 in regulation of mitophagy. [Abstract]

2025 Mar 11;11(1):22. PMID: 40064862
Trends Biotechnol

2026 Jul 2:S0167-7799(26)00249-0. PMID: 42392927
Redox Biol

p53 and fatty acids collaborate to trigger ferroptosis via the FBXO2-FABP5 axis in colorectal cancer. [Abstract]

2026 Mar:90:104043. PMID: 41604941
Redox Biol

The SGK3-Catalase antioxidant signaling axis drives cervical cancer growth and therapy resistance. [Abstract]

2023 Nov:67:102931. PMID: 37866161
Mol Cell

SLFN5-mediated chromatin dynamics sculpt higher-order DNA repair topology. [Abstract]

2023 Apr 6;83(7):1043-1060.e10. PMID: 36854302
Mol Cell

METTL3 and N6-Methyladenosine Promote Homologous Recombination-Mediated Repair of DSBs by Modulating DNA-RNA Hybrid Accumulation. [Abstract]

2020 Aug 6;79(3):425-442.e7. PMID: 32615088
Gut Microbes

Fusobacterium nucleatum promotes esophageal squamous cell carcinoma progression and chemoresistance by enhancing the secretion of chemotherapy-induced senescence-associated secretory phenotype via activation of DNA damage response pathway. [Abstract]

2023 Jan-Dec;15(1):2197836. PMID: 37017266

Cisplatin purchased from MedChemExpress. Usage Cited in: Gut Microbes. 2023 Jan-Dec;15(1):2197836. [Abstract]

Cisplatin (CDDP; 3.33 μM or 1.67 μM; 96 h) increases the protein expression of p53 and p21 in ECA-109 and KYSE-150 cells (3.33 μM 1 μg/ml in ECA-109 cells, 1.67 μM 0.5 μg/ml in KYSE-150 cells).

Cisplatin purchased from MedChemExpress. Usage Cited in: Gut Microbes. 2023 Jan-Dec;15(1):2197836. [Abstract]

Cisplatin (CDDP; 3.33 μM or 1.67 μM; 96 h) suppresses the proliferation of ECA-109 and KYSE-150 cells (3.33 μM 1 μg/ml in ECA-109 cells, 1.67 μM 0.5 μg/ml in KYSE-150 cells).
J Nanobiotechnology

Engineered biomimetic cisplatin-polyphenol nanocomplex for chemo-immunotherapy of glioblastoma by inducing pyroptosis. [Abstract]

2025 Jan 15;23(1):14. PMID: 39810130

Cisplatin purchased from MedChemExpress. Usage Cited in: J Nanobiotechnology. 2025 Jan 15;23(1):14. [Abstract]

CCK8 assay to examine cell viability in U87-MG cells after 24 h incubation with Cisplatin (CDDP), CuCCT, CuCCT@CM, and CuCCT@CM-Ang. Concentration of CDDP was varied from 0 µM to 100 µM.
Microbiome

Role of nasal microbiota in regulating host anti-influenza immunity in dogs. [Abstract]

2025 Jan 27;13(1):27. PMID: 39871363
Theranostics

KAT6A, a novel regulator of β-catenin, promotes tumorigenicity and chemoresistance in ovarian cancer by acetylating COP1. [Abstract]

2021 Apr 15;11(13):6278-6292. PMID: 33995658
Theranostics

Endogenous glutamate determines ferroptosis sensitivity via ADCY10-dependent YAP suppression in lung adenocarcinoma. [Abstract]

2021 Mar 24;11(12):5650-5674. PMID: 33897873
Theranostics

Activation of TFEB-mediated autophagy by trehalose attenuates mitochondrial dysfunction in cisplatin-induced acute kidney injury. [Abstract]

2020 Apr 27;10(13):5829-5844. PMID: 32483422
Theranostics

SLFN11 inhibits hepatocellular carcinoma tumorigenesis and metastasis by targeting RPS4X via mTOR pathway. [Abstract]

2020 Mar 25;10(10):4627-4643. PMID: 32292519
Theranostics

Metabolic remodeling by TIGAR overexpression is a therapeutic target in esophageal squamous-cell carcinoma. [Abstract]

2020 Feb 10;10(8):3488-3502. PMID: 32206103
Theranostics

HIF-1ɑ-regulated miR-1275 maintains stem cell-like phenotypes and promotes the progression of LUAD by simultaneously activating Wnt/β-catenin and Notch signaling. [Abstract]

2020 Jan 22;10(6):2553-2570. PMID: 32194819
Theranostics

Inhibition of SMYD2 suppresses tumor progression by down-regulating microRNA-125b and attenuates multi-drug resistance in renal cell carcinoma. [Abstract]

2019 Oct 22;9(26):8377-8391. PMID: 31754403
Genes Dis

NADK tetramer defective mutants affect lung cancer response to chemotherapy via controlling NADK activity. [Abstract]

2025 Jan 7;12(4):101510. PMID: 40330153
Acta Pharm Sin B

Disease-derived circulating extracellular vesicle preconditioning: A promising strategy for precision mesenchymal stem cell therapy. [Abstract]

2024 Oct;14(10):4526-4543. PMID: 39525589
Acta Pharm Sin B

Chemical screen identifies shikonin as a broad DNA damage response inhibitor that enhances chemotherapy through inhibiting ATM and ATR. [Abstract]

2022 Mar;12(3):1339-1350. PMID: 35530159
Genes Dis

LncRNA MEG3 promotes chemosensitivity of osteosarcoma by regulating antitumor immunity via miR-21-5p/p53 pathway and autophagy. [Abstract]

2021 Nov 24;10(2):531-541. PMID: 37223512
Acta Pharm Sin B

Intracellular aggregation of peptide-reprogrammed small molecule nanoassemblies enhances cancer chemotherapy and combinatorial immunotherapy. [Abstract]

2021 Apr;11(4):1069-1082. PMID: 33996418
J Biomed Sci

A G-quadruplex-binding platinum complex induces cancer mitochondrial dysfunction through dual-targeting mitochondrial and nuclear G4 enriched genome. [Abstract]

2024 May 13;31(1):50. PMID: 38741159
J Exp Clin Cancer Res

CDK1 drives SOX9-mediated chemotherapeutic resistance in gastric cancer. [Abstract]

2025 Oct 8;44(1):284. PMID: 41063222
J Exp Clin Cancer Res

Functionally-instructed modifiers of response to ATR inhibition in experimental glioma. [Abstract]

2024 Mar 12;43(1):77. PMID: 38475864
J Clin Invest

DNA topoisomerase II inhibition potentiates osimertinib's therapeutic efficacy in EGFR-mutant non-small cell lung cancer models. [Abstract]

2024 Mar 7;134(10):e172716. PMID: 38451729

Cisplatin purchased from MedChemExpress. Usage Cited in: J Clin Invest. 2024 Mar 7;134(10):e172716. [Abstract]

The given cell lines were treated with 250 nM osimertinib (Osim), 1.25 μM Etoposide (VP-16), 125 nM Doxorubicin (DXR), 5 nM Paclitaxel, 10 μM Cisplatin, 25 μM Carboplatin, 25 nM Gemcitabine, 20 nM 5-Fluorouracil (5-FU), 25 μM Cyclophosphamide, 25 μM Capecitabine, or 10 nM Vincristine alone or in combination for 3 days. Cell numbers were then measured using the SRB assay.
J Exp Clin Cancer Res

Deubiquitylase YOD1 regulates CDK1 stability and drives triple-negative breast cancer tumorigenesis. [Abstract]

2023 Sep 4;42(1):228. PMID: 37667382
J Exp Clin Cancer Res

Flavokawain A is a natural inhibitor of PRMT5 in bladder cancer. [Abstract]

2022 Oct 5;41(1):293. PMID: 36199122
J Exp Clin Cancer Res

Stanniocalcin 1 promotes metastasis, lipid metabolism and cisplatin chemoresistance via the FOXC2/ITGB6 signaling axis in ovarian cancer. [Abstract]

2022 Apr 7;41(1):129. PMID: 35392966
J Exp Clin Cancer Res

ZBTB28 induces autophagy by regulation of FIP200 and Bcl-XL facilitating cervical cancer cell apoptosis. [Abstract]

2021 Apr 30;40(1):150. PMID: 33931087
J Exp Clin Cancer Res

KIAA1522 potentiates TNFα-NFκB signaling to antagonize platinum-based chemotherapy in lung adenocarcinoma. [Abstract]

2020 Aug 27;39(1):170. PMID: 32854746
J Exp Clin Cancer Res

Abnormally elevated USP37 expression in breast cancer stem cells regulates stemness, epithelial-mesenchymal transition and cisplatin sensitivity. [Abstract]

2018 Nov 27;37(1):287. PMID: 30482232
Adv Sci (Weinh)

NQO1-Mediated Anoikis Resistance and Immune Evasion Define a High-Risk Multi-Omic Subtype for Precision Management of T1 High-Grade Bladder Cancer. [Abstract]

2026 Jun;13(36):e23605. PMID: 41945867
Adv Sci (Weinh)

NK Cell Activation by Platinum Boosts Immunotherapy in HR+/HER2- Breast Cancer. [Abstract]

2026 Apr;13(20):e18978. PMID: 41691453
Adv Sci (Weinh)

Deep Learning-Powered Scalable Cancer Organ Chip for Cancer Precision Medicine. [Abstract]

2026 Feb 3:e16660. PMID: 41632021
Adv Sci (Weinh)

Efferocytosis-Driven Polyamine Metabolism in Macrophages Enhances Cancer Stem Cell Enrichment after Chemotherapy in Ovarian Cancer. [Abstract]

2025 Nov 21:e12508. PMID: 41271556
Adv Sci (Weinh)

Lactylation Enhances the Activity of Lactate Dehydrogenase A and Promotes the Chemoresistance to Cisplatin Through Facilitating DNA Nonhomologous End Junction in Lung Adenocarcinoma. [Abstract]

2025 Nov 5:e10733. PMID: 41190808
Adv Sci (Weinh)

Genetic and Functional Evidence Links Germline Biallelic Inactivating Variants in WWOX to Histological Mixed-Type Thyroid Cancer. [Abstract]

2025 Oct 22:e07602. PMID: 41124647
Adv Sci (Weinh)

Targeting GPX4 to Induce Ferroptosis Overcomes Chemoresistance Mediated by the PAX8-AS1/GPX4 Axis in Intrahepatic Cholangiocarcinoma. [Abstract]

2025 Aug;12(30):e01042. PMID: 40391780
Adv Sci (Weinh)

EccDNA-Driven VPS41 Amplification Alleviates Genotoxic Stress via Lysosomal KAI1 Degradation. [Abstract]

2025 Jul;12(25):e2501934. PMID: 40271553
MedComm (2020)

Dual MNK/VEGFR2 Inhibitor JDB153 Enhances Immunotherapeutic Efficiency and Chemosensitivity in Lung Cancer. [Abstract]

2025 Apr 29;6(5):e70155. PMID: 40308810
MedComm (2020)

Genomic and Immune Profiling of Esophageal Squamous Cell Carcinoma Undergoing Neoadjuvant Therapy Versus Upfront Surgery Identifies Novel Immunogenic Cell Death-Based Signatures for Predicting Clinical Outcomes. [Abstract]

2025 Apr 2;6(4):e70171. PMID: 40182138
Adv Sci (Weinh)

SREBP1c-Mediated Transcriptional Repression of YME1L1 Contributes to Acute Kidney Injury by Inducing Mitochondrial Dysfunction in Tubular Epithelial Cells. [Abstract]

2025 Feb;12(6):e2412233. PMID: 39680752
Adv Sci (Weinh)

Synthetic Retinoid Sulfarotene Selectively Inhibits Tumor-Repopulating Cells of Intrahepatic Cholangiocarcinoma via Disrupting Cytoskeleton by P-Selectin/PSGL1 N-Glycosylation Blockage. [Abstract]

2025 Jan;12(3):e2407519. PMID: 39605300
Adv Sci (Weinh)

Targeting the SPC25/RIOK1/MYH9 Axis to Overcome Tumor Stemness and Platinum Resistance in Epithelial Ovarian Cancer. [Abstract]

2024 Dec;11(47):e2406688. PMID: 39488790
Adv Sci (Weinh)

Novel CAR-T Cells Specifically Targeting SIA-CIgG Demonstrate Effective Antitumor Efficacy in Bladder Cancer. [Abstract]

2024 Oct;11(40):e2400156. PMID: 39178136
Adv Sci (Weinh)

Methuosis Inducer SGI-1027 Cooperates with Everolimus to Promote Apoptosis and Pyroptosis by Triggering Lysosomal Membrane Permeability in Renal Cancer. [Abstract]

2024 Oct;11(38):e2404693. PMID: 39119834
Adv Sci (Weinh)

KAT6A Condensates Impair PARP1 Trapping of PARP Inhibitors in Ovarian Cancer. [Abstract]

2024 Sep;11(34):e2400140. PMID: 38973255
Adv Sci (Weinh)

Activation of the cGAS-STING-IRF3 Axis by Type I and II Interferons Contributes to Host Defense. [Abstract]

2024 Sep;11(35):e2308890. PMID: 39004913
Adv Sci (Weinh)

Combinatorial Biosynthesis Creates a Novel Aglycone Polyether with High Potency and Low Side Effects Against Bladder Cancer. [Abstract]

2024 Aug;11(32):e2404668. PMID: 38935027
Adv Sci (Weinh)

TAOK3 Facilitates Esophageal Squamous Cell Carcinoma Progression and Cisplatin Resistance Through Augmenting Autophagy Mediated by IRGM. [Abstract]

2023 Oct;10(29):e2300864. PMID: 37705061
Adv Sci (Weinh)

Targeting Squalene Epoxidase Confers Metabolic Vulnerability and Overcomes Chemoresistance in HNSCC. [Abstract]

2023 Sep;10(27):e2206878. PMID: 37490552
Adv Sci (Weinh)

Micro-Engineered Organoid-on-a-Chip Based on Mesenchymal Stromal Cells to Predict Immunotherapy Responses of HCC Patients. [Abstract]

2023 Sep;10(27):e2302640. PMID: 37485650
Adv Sci (Weinh)

Vanguard is a Glucose Deprivation-Responsive Long Non-Coding RNA Essential for Chromatin Remodeling-Reliant DNA Repair. [Abstract]

2022 Oct;9(30):e2201210. PMID: 36047643
Adv Sci (Weinh)

Synthetic Retinoid Kills Drug-Resistant Cancer Stem Cells via Inducing RARγ-Translocation-Mediated Tension Reduction and Chromatin Decondensation. [Abstract]

2022 Aug 28;e2203173. PMID: 36031407
Adv Sci (Weinh)

APAF1-Binding Long Noncoding RNA Promotes Tumor Growth and Multidrug Resistance in Gastric Cancer by Blocking Apoptosome Assembly. [Abstract]

2022 Aug 17;e2201889. PMID: 35975461
Cell Rep Med

Sex-biased intratumoral microbiome influences tumor molecular and immune landscape and disease outcomes. [Abstract]

2026 May 19;7(5):102757. PMID: 42013847
Cell Rep Med

A human patient-derived organoid biobank to model tumor heterogeneity and therapeutic vulnerability for oral squamous cell carcinoma. [Abstract]

2026 Feb 17;7(2):102622. PMID: 41707653
Cell Rep Med

Macrophage efferocytosis mediated by the TP63-RAC2 pathway promotes immunosuppressive remodeling in esophageal cancer. [Abstract]

2025 Dec 18:102529. PMID: 41418775
Cell Rep Med

Single-cell profiles delineate immune cell remodeling and enhanced tumor-fibroblast interaction of hepatoblastoma after chemotherapy. [Abstract]

2025 Oct 21;6(10):102401. PMID: 41038160
Cell Rep Med

CAN-Scan: A multi-omic phenotype-driven precision oncology platform identifies prognostic biomarkers of therapy response for colorectal cancer. [Abstract]

2025 Apr 15;6(4):102053. PMID: 40187357
Cell Rep Med

Using patient-derived organoids to predict locally advanced or metastatic lung cancer tumor response: A real-world study. [Abstract]

2023 Feb 21;4(2):100911. PMID: 36657446
Sci Adv

Repair of female reproductive function by GDF-9-overexpressing extracellular vesicles via ACVR1B/SMAD2 regulation in ovarian granulosa. [Abstract]

2025 Dec 12;11(50):eadw9006. PMID: 41370396
Sci Adv

FAM50A drives breast cancer brain metastasis through interaction with C9ORF78 to enhance ʟ-asparagine production. [Abstract]

2025 Jun 20;11(25):eadt3075. PMID: 40531994

Cisplatin purchased from MedChemExpress. Usage Cited in: Sci Adv. 2025 Jun 20;11(25):eadt3075. [Abstract]

Brain slices of mice were stained with hematoxylin andeosin (H&E) at the endpoint. BCBM model mice, either cisplatin (4 mg/kg, intraperitoneally) or ʟ-ASNase (L-Asparaginase; 0.2 mg per mouse, intraperitoneally) was administered weekly or every 2 days for 2 weeks, respectively.

Cisplatin purchased from MedChemExpress. Usage Cited in: Sci Adv. 2025 Jun 20;11(25):eadt3075. [Abstract]

BLI was conducted at regular intervals. Representative BLI images and line chart of radiance. BCBM model, Mice were administered cisplatin (4 mg/kg, intraperitoneally) weekly or ʟ-ASNase (0.2 mg per mouse, intraperitoneally) every 2 days.
Sci Adv

Label-free, real-time monitoring of cytochrome C drug responses in microdissected tumor biopsies with a multi-well aptasensor platform. [Abstract]

2024 Sep 6;10(36):eadn5875. PMID: 39241078
Sci Adv

Gain-of-function mutations in the catalytic domain of DOT1L promote lung cancer malignant phenotypes via the MAPK/ERK signaling pathway. [Abstract]

2023 Jun 2;9(22):eadc9273. PMID: 37256945
Cell Death Differ

Targeting ADAR1 lactylation activates innate immune and overcomes chemoresistance in ovarian cancer. [Abstract]

2026 May 25. PMID: 42185630
Cell Death Differ

TRIM21-driven K63-linked ubiquitination of RBM38c, as a novel interactor of BECN1, contributes to DNA damage-induced autophagy. [Abstract]

2025 Jul;32(7):1317-1335. PMID: 40133668
Cell Death Differ

p53 transcriptionally activates DCP1B to suppress tumor progression and enhance tumor sensitivity to PI3K blockade in non-small cell lung cancer. [Abstract]

2025 Apr 9. PMID: 40200093
Biomaterials

Nanoradiosentizers with X ray-actuatable supramolecular aptamer building units for programmable immunostimulatory T cell engagement. [Abstract]

2025 Apr:315:122924. PMID: 39489019
Cell Death Differ

The IDH1-R132H mutation aggravates cisplatin-induced acute kidney injury by promoting ferroptosis through disrupting NDUFA1 and FSP1 interaction. [Abstract]

2025 Feb;32(2):242-255. PMID: 39306640
Cell Death Differ

FAAH served a key membrane-anchoring and stabilizing role for NLRP3 protein independently of the endocannabinoid system. [Abstract]

2023 Jan;30(1):168-183. PMID: 36104448
Carbohydr Polym

Chitosan/dextran-based organohydrogel delivers EZH2 inhibitor to epigenetically reprogram chemo/immuno-resistance in unresectable metastatic melanoma. [Abstract]

2024 Dec 15:346:122645. PMID: 39245506
Research (Wash D C)

Combinational Analysis of Metabolomic and O-GlcNAcylation Omics Reveals the HBP Metabolic Regulation of Chemoresistance via GFPT1/NR3C1 O-GlcNAcylation/GPX4 Axis. [Abstract]

2025 Jul 30:8:0809. PMID: 40740652
Research (Wash D C)

Targeting the Exonic Circular OGT RNA/O-GlcNAc Transferase/Forkhead Box C1 Axis Inhibits Asparagine- and Alanine-Mediated Ferroptosis Repression in Neuroblastoma Progression. [Abstract]

2025 May 23:8:0703. PMID: 40416363
Research (Wash D C)

Dual Regulation of Sprouty 4 Palmitoylation by ZDHHC7 and Palmitoyl-Protein Thioesterase 1: A Potential Therapeutic Strategy for Cisplatin-Resistant Osteosarcoma. [Abstract]

2025 May 23:8:0708. PMID: 40416361
Chem Eng J

2025 Sep 15.
Chem Eng J

2024 Sep 15.
Chem Eng J

1 January 2023, 138972.
J Control Release

A biomimetic phase-separating hydrogel potentiates local chemo-virotherapy to eradicate recurrent glioblastoma. [Abstract]

2026 Jul 10:395:114990. PMID: 42097225
J Control Release

Combating cisplatin-resistant lung cancer using a coiled-coil lipopeptides modified membrane fused drug delivery system. [Abstract]

2025 Jan 8:379:45-58. PMID: 39756686
J Control Release

Improving the circulation time and renal therapeutic potency of extracellular vesicles using an endogenous ligand binding strategy. [Abstract]

2022 Dec:352:1009-1023. PMID: 36375619
Cancer Biol Med

The role of a drug-loaded poly (lactic co-glycolic acid) (PLGA) copolymer stent in the treatment of ovarian cancer. [Abstract]

2020 Feb 15;17(1):237-250. PMID: 32296591
Cell Death Dis

2026 Jul 10. PMID: 42431877
Cell Death Dis

Pictilisib and nutrient stress synergize to induce methuosis via PI(4,5)P2-dependent macropinocytic dysregulation in cancer cells. [Abstract]

2026 Jun 16. PMID: 42303628
Cell Death Dis

Selenomethionine as a dual-mechanism ferroptosis inhibitor: selenium-supply-driven GPX4 biosynthesis beyond transsulfuration and reductive-capacity-mediated ROS scavenging independent of GPX4 activity. [Abstract]

2026 Feb 14;17(1):224. PMID: 41688429
Cell Death Dis

PRDM1 restricts bladder cancer progression and enhances chemosensitivity by suppressing OTUD6A-mediated deubiquitination of CDC6. [Abstract]

2026 Feb 23;17(1):247. PMID: 41724787
Cell Death Dis

Targeting TIMM23 to overcome osteosarcoma chemoresistance. [Abstract]

2025 Nov 24;16(1):856. PMID: 41285805
Cell Death Dis

The deubiquitinase USP9X and E3 ligase WWP1 orchestrate IGF2BP2 ubiquitination homeostasis to drive TNBC progression and cisplatin sensitivity. [Abstract]

2025 Oct 6;16(1):703. PMID: 41053085
Cell Death Dis

TSPYL5-driven G3BP1 nuclear membrane translocation facilitates p53 cytoplasm sequestration via accelerating RanBP2-mediated p53 sumoylation and nuclear export in neuroblastoma. [Abstract]

2025 May 3;16(1):358. PMID: 40319028
Cell Death Dis

Interleukin-33 (IL-33) promotes DNA damage-resistance in lung cancer. [Abstract]

2025 Apr 11;16(1):274. PMID: 40216748
Cell Death Dis

Both direct and indirect suppression of MCL1 synergizes with BCLXL inhibition in preclinical models of gastric cancer. [Abstract]

2025 Mar 12;16(1):170. PMID: 40075071
Cell Death Dis

Sensing of endogenous retroviruses-derived RNA by ZBP1 triggers PANoptosis in DNA damage and contributes to toxic side effects of chemotherapy. [Abstract]

2024 Oct 27;15(10):779. PMID: 39465258
Pharmacol Res

Time-dependent proteomics and drug response in expanding cancer cells. [Abstract]

2024 Jun:204:107208. PMID: 38729587
Cell Death Dis

Deprivation of methionine inhibits osteosarcoma growth and metastasis via C1orf112-mediated regulation of mitochondrial functions. [Abstract]

2024 May 20;15(5):349. PMID: 38769167
Cell Death Dis

Transcription factor Sp1 transcriptionally enhances GSDME expression for pyroptosis. [Abstract]

2024 Jan 18;15(1):66. PMID: 38238307
Cell Death Dis

LncRNA ZNF674-AS1 drives cell growth and inhibits cisplatin-induced pyroptosis via up-regulating CA9 in neuroblastoma. [Abstract]

2024 Jan 4;15(1):5. PMID: 38177154
Cell Death Dis

Crotonylated BEX2 interacts with NDP52 and enhances mitophagy to modulate chemotherapeutic agent-induced apoptosis in non-small-cell lung cancer cells. [Abstract]

2023 Sep 30;14(9):645. PMID: 37777549
Pharmacol Res

Brusatol has therapeutic efficacy in non-small cell lung cancer by targeting Skp1 to inhibit cancer growth and metastasis. [Abstract]

2022 Feb:176:106059. PMID: 34998973
Cell Death Dis

RNA-binding protein p54nrb/NONO potentiates nuclear EGFR-mediated tumorigenesis of triple-negative breast cancer. [Abstract]

2022 Jan 10;13(1):42. PMID: 35013116
Cell Death Dis

Mitochondrial dysfunction induces radioresistance in colorectal cancer by activating [Ca2+]m-PDP1-PDH-histone acetylation retrograde signaling. [Abstract]

2021 Sep 6;12(9):837. PMID: 34489398
Pharmacol Res

Metabolomics and integrated network pharmacology analysis reveal Tricin as the active anti-cancer component of Weijing decoction by suppression of PRKCA and sphingolipid signaling. [Abstract]

2021 Sep:171:105574. PMID: 34419228
Cell Death Dis

BTF3 confers oncogenic activity in prostate cancer through transcriptional upregulation of Replication Factor C. [Abstract]

2021 Jan 5;12(1):12. PMID: 33414468
Cancer Lett

TMEM11 promotes cisplatin resistance by inhibiting BNIP3-mediated mitophagy in bladder cancer. [Abstract]

2026 Mar 31:641:218271. PMID: 41570932
Cancer Lett

N6-methyadenosine modified SUV39H2 regulates homologous recombination through epigenetic repression of DUSP6 in gastric cancer. [Abstract]

2023 Apr 1:558:216092. PMID: 36806557
Cancer Lett

ERK inhibitor: A candidate enhancing therapeutic effects of conventional chemo-radiotherapy in esophageal squamous cell carcinoma. [Abstract]

2023 Feb 1:554:216012. PMID: 36470544
Cancer Lett

Copper enhances genotoxic drug resistance via ATOX1 activated DNA damage repair. [Abstract]

2022 Jun 28;536:215651. PMID: 35315340
Cancer Lett

Dual mTORC1/2 inhibitor AZD2014 diminishes myeloid-derived suppressor cells accumulation in ovarian cancer and delays tumor growth. [Abstract]

2021 Dec 28:523:72-81. PMID: 34560229
J Immunother Cancer

Targeting tumor-associated macrophage-derived CD74 improves efficacy of neoadjuvant chemotherapy in combination with PD-1 blockade for cervical cancer. [Abstract]

2024 Aug 6;12(8):e009024. PMID: 39107132
Int J Biol Sci

The Interaction of Calcium-Sensing Receptor with KIF11 Enhances Cisplatin Resistance in Lung Adenocarcinoma via BRCA1/cyclin B1 pathway. [Abstract]

2024 Jul 15;20(10):3892-3910. PMID: 39113697
Int J Biol Sci

Comprehensive Analyses Reveal Effects on Tumor Immune Infiltration and Immunotherapy Response of APOBEC Mutagenesis and Its Molecular Mechanisms in Esophageal Squamous Cell Carcinoma. [Abstract]

2023 May 8;19(8):2551-2571. PMID: 37215984
J Immunother Cancer

Hyperbaric oxygen facilitates teniposide-induced cGAS-STING activation to enhance the antitumor efficacy of PD-1 antibody in HCC. [Abstract]

2022 Aug;10(8):e004006. PMID: 36002188
Int J Biol Sci

The m6A-induced lncRNA CASC8 promotes proliferation and chemoresistance via upregulation of hnRNPL in esophageal squamous cell carcinoma. [Abstract]

2022 Jul 18;18(13):4824-4836. PMID: 35982900
Int J Biol Sci

CIRBP-OGFR axis safeguards against cardiomyocyte apoptosis and cardiotoxicity induced by chemotherapy. [Abstract]

2022 Apr 11;18(7):2882-2897. PMID: 35541895
Int J Biol Sci

RBMS2 Chemosensitizes Breast Cancer Cells to Doxorubicin by Regulating BMF Expression. [Abstract]

2022 Feb 7;18(4):1724-1736. PMID: 35280673
Int J Biol Sci

Discovery and Validation of Nitroxoline as a Novel STAT3 Inhibitor in Drug-resistant Urothelial Bladder Cancer. [Abstract]

2021 Jul 25;17(12):3255-3267. PMID: 34421363
Int J Biol Sci

Deubiquitinase PSMD7 promotes the proliferation, invasion, and cisplatin resistance of gastric cancer cells by stabilizing RAD23B. [Abstract]

2021 Jul 25;17(13):3331-3342. PMID: 34512150
J Immunother Cancer

ATM/NEMO signaling modulates the expression of PD-L1 following docetaxel chemotherapy in prostate cancer. [Abstract]

2021 Jul;9(7):e001758. PMID: 34301812
Cell Commun Signal

Chemotherapy-induced senescent nasopharyngeal carcinoma cells suppress NK cell-mediated antitumor immunity by upregulating EBI3 via mtDNA-cGAS-STING pathway. [Abstract]

2026 Mar 28;24(1):279. PMID: 41904509
Cell Commun Signal

Osimertinib activates TFEB to trigger hepatocyte cytoplasmic vacuolation-associated cell death. [Abstract]

2026 Jan 30;24(1):142. PMID: 41612351
Cell Commun Signal

GPX3 promotes cisplatin resistance in TNBC by manipulating ROS-TGFB1-ZEB2. [Abstract]

2025 Jul 25;23(1):355. PMID: 40713734
Cell Commun Signal

The ester derivative Palmitoylcarnitine abrogates cervical cancer cell survival by enhancing lipotoxicity and mitochondrial dysfunction. [Abstract]

2025 May 3;23(1):213. PMID: 40319292
Cell Commun Signal

Extracellular vesicles containing MFGE8 from colorectal cancer facilitate macrophage efferocytosis. [Abstract]

2024 May 27;22(1):295. PMID: 38802814
J Exp Med

WEE1 inhibition induces anti-tumor immunity by activating ERV and the dsRNA pathway. [Abstract]

2022 Jan 3;219(1):e20210789. PMID: 34825915
Phytomedicine

Eupatilin inhibits non-small cell lung cancer metastasis by suppressing Netrin-1-mediated epithelial-mesenchymal transition. [Abstract]

2026 Aug:158:158320. PMID: 42284640
Phytomedicine

Polyphyllin VI induces Forkhead box O3 nuclear liquid-liquid phase separation to promote mitophagy in breast cancer. [Abstract]

2026 Jun:155:158166. PMID: 41985230
Phytomedicine

Huaier-derived arnicolide D induces ferroptosis in gastric cancer via SRC/TNF-mediated GPX4 inactivation. [Abstract]

2026 May:154:158029. PMID: 41818944
Phytomedicine

Indole-3-carbinol attenuates cisplatin-induced premature ovarian failure by activating Nrf2 through competitive binding of Keap1. [Abstract]

2026 May:154:158040. PMID: 41818942
Phytomedicine

Baohuoside I induces GSDME-dependent pyroptosis and synergistically inhibits lung adenocarcinoma with cisplatin. [Abstract]

2026 Apr:153:157899. PMID: 41643445
Phytomedicine

Formononetin enhances cisplatin chemotherapy sensitivity in osteosarcoma by inducing ferroptosis and reconstructing the immune microenvironment. [Abstract]

2025 Sep:145:156960. PMID: 40543234
Phytomedicine

YiQiChuTan formula (YQCTF) inhibit the progression of non-small cell lung cancer via down-regulating EGFR/ITGB2 signaling: Triangulated evidence from network pharmacology, proteomic profiling, and experimental validation. [Abstract]

2025 Aug:144:156950. PMID: 40505482
Phytomedicine

Curcuminoids WM03 inhibits ovarian cancer cisplatin-resistant cells proliferation and reverses cisplatin resistance by targeting DYRK2. [Abstract]

2025 Jul:142:156632. PMID: 40315643
Phytomedicine

Melittin suppresses ovarian cancer growth by regulating SREBP1-mediated lipid metabolism. [Abstract]

2025 Feb:137:156367. PMID: 39798341
Phytomedicine

Yi-Fei-San-Jie Chinese medicine formula reverses immune escape by regulating deoxycholic acid metabolism to inhibit TGR5/STAT3/PD-L1 axis in lung cancer. [Abstract]

2024 Dec:135:156175. PMID: 39515098
Phytomedicine

Hypocrellin A against intrahepatic Cholangiocarcinoma via multi-target inhibition of the PI3K-AKT-mTOR, MAPK, and STAT3 signaling pathways. [Abstract]

2024 Dec:135:156022. PMID: 39284270
Phytomedicine

Celastrol induces DNA damage and cell death in BCR-ABL T315I-mutant CML by targeting YY1 and HMCES. [Abstract]

2024 Nov:134:155937. PMID: 39255723
Phytomedicine

Targeting MCL1 with Sanggenon C overcomes MCL1-driven adaptive chemoresistance via dysregulation of autophagy and endoplasmic reticulum stress in cervical cancer. [Abstract]

2024 Oct:133:155935. PMID: 39126925
Phytomedicine

Daphnetin induces ferroptosis in ovarian cancer by inhibiting NAD(P)H:Quinone oxidoreductase 1 (NQO1). [Abstract]

2024 Sep:132:155876. PMID: 39032284
Phytomedicine

Ailanthone inhibits non-small cell lung cancer growth and metastasis through targeting UPF1/GAS5/ULK1 signaling pathway. [Abstract]

2024 Jun:128:155333. PMID: 38518633
Phytomedicine

Acetylation of MOB1 mediates polyphyllin II-reduced lysosome biogenesis in breast cancer by promoting the cytoplasmic retention of the YAP/TFEB coactivator complex. [Abstract]

2024 Jan:122:155152. PMID: 37922793
Phytomedicine

Matrine induces ferroptosis in cervical cancer through activation of piezo1 channel. [Abstract]

2024 Jan:122:155165. PMID: 37922791
Phytomedicine

Xanthatin suppresses pancreatic cancer cell growth via the ROS/RBL1 signaling pathway: In vitro and in vivo insights. [Abstract]

2023 Oct:119:155004. PMID: 37562091
Phytomedicine

Agrimonolide inhibits cancer progression and induces ferroptosis and apoptosis by targeting SCD1 in ovarian cancer cells. [Abstract]

2022 Jul;101:154102. PMID: 35526323
Phytomedicine

Daphnetin triggers ROS-induced cell death and induces cytoprotective autophagy by modulating the AMPK/Akt/mTOR pathway in ovarian cancer. [Abstract]

2021 Feb:82:153465. PMID: 33486268
J Pharm Anal

2026 Jun 8.
J Pharm Anal

2026 Apr 2.
EBioMedicine

Analysis of multiple programmed cell death-related prognostic genes and functional validations of necroptosis-associated genes in oesophageal squamous cell carcinoma. [Abstract]

2024 Jan:99:104920. PMID: 38101299
Adv Healthc Mater

Hepatocellular Carcinoma-on-a-Chip Based on Microfluidic Well Array for Personalized Drug Evaluation. [Abstract]

2026 Jul;15(26):e71327. PMID: 42237206
Mater Today Bio

Dominant follicle-targeted nanocarriers for GH delivery to alleviate premature ovarian insufficiency. [Abstract]

2025 Jun 11:33:101930. PMID: 40600179
Mater Today Bio

Metal-organic framework-mediated siRNA delivery and sonodynamic therapy for precisely triggering ferroptosis and augmenting ICD in osteosarcoma. [Abstract]

2024 Apr 10:26:101053. PMID: 38654934
Clin Cancer Res

2026 Jul 21. PMID: 42478960
Clin Cancer Res

Spermidine Secreted by Apoptotic Cells Enhances Chemotherapy Resistance by Modulating β-Catenin Activity in Osteosarcoma. [Abstract]

2025 Nov 20. PMID: 41263700
Acta Biomater

Mechanically heterogeneous nanofibrous hydrogel drives Piezo1-mediated cell aggregation and collective migration. [Abstract]

2026 Jul:218:244-260. PMID: 42270027
Cell Death Discov

2026 Jul 8. PMID: 42420245
Cell Death Discov

NAT10 promotes cisplatin resistance and immune escape by increasing the expression of DUSP1 and PD-L1 in gastric cancer. [Abstract]

2026 Apr 10;12(1):237. PMID: 41956987
Acta Pharmacol Sin

SOCS1 depletion drives osteosarcoma stemness and chemoresistance by suppressing ACTN4 degradation. [Abstract]

2025 Sep 1. PMID: 40890444
Acta Biomater

Impact of scaffold material choice on osteosarcoma phenotype and drug responses in 3D. [Abstract]

2025 Aug 27:S1742-7061(25)00640-3. PMID: 40882907
Acta Pharmacol Sin

DNMT inhibition epigenetically restores the cGAS-STING pathway and activates RIG-I/MDA5-MAVS to enhance antitumor immunity. [Abstract]

2025 Aug 19. PMID: 40830678
Acta Pharmacol Sin

NSCLC cells sustain phase separation of cytoplasmic membrane-less organelles to protect themselves against cisplatin treatment. [Abstract]

2025 Apr 17. PMID: 40247038
Cell Death Discov

hMOF induces cisplatin resistance of ovarian cancer by regulating the stability and expression of MDM2. [Abstract]

2023 Jun 8;9(1):179. PMID: 37291112
Cell Death Discov

Cisplatin remodels the tumor immune microenvironment via the transcription factor EB in ovarian cancer. [Abstract]

2021 Jun 5;7(1):136. PMID: 34091590
Cell Death Discov

Reduced O-GlcNAcylation of SNAP-23 promotes cisplatin resistance by inducing exosome secretion in ovarian cancer. [Abstract]

2021 May 18;7(1):112. PMID: 34001861
Acta Pharmacol Sin

Osimertinib successfully combats EGFR-negative glioblastoma cells by inhibiting the MAPK pathway. [Abstract]

2021 Jan;42(1):108-114. PMID: 32398685
NPJ Precis Oncol

2026 Jul 2. PMID: 42393274
NPJ Precis Oncol

Targeting the DYRK1A kinase prevents cancer progression and metastasis and promotes cancer cells response to G1/S targeting chemotherapy drugs. [Abstract]

2024 Jun 5;8(1):128. PMID: 38839871
NPJ Precis Oncol

Multiplexed drug testing of tumor slices using a microfluidic platform. [Abstract]

2020 May 19:4:12. PMID: 32435696
J Transl Med

Cisplatin-mediated activation of NF-κB promotes lung cancer stem cell formation via DNA repair pathways. [Abstract]

2025 Nov 21;23(1):1336. PMID: 41272697
J Transl Med

Pharmacologic inhibition of CSF-1R suppresses intrinsic tumor cell growth in osteosarcoma with CSF-1R overexpression. [Abstract]

2025 Aug 12;23(1):900. PMID: 40797330
J Transl Med

FOSL1 transcriptionally dictates the Warburg effect and enhances chemoresistance in triple-negative breast cancer. [Abstract]

2025 Jan 2;23(1):1. PMID: 39748430
J Transl Med

Effect and underlying mechanism of a photochemotherapy dual-function nanodrug delivery system for head and neck squamous cell carcinoma. [Abstract]

2024 Nov 19;22(1):1043. PMID: 39563418
J Transl Med

CDK1 serves as a therapeutic target of adrenocortical carcinoma via regulating epithelial-mesenchymal transition, G2/M phase transition, and PANoptosis. [Abstract]

2022 Oct 2;20(1):444. PMID: 36184616
Proc Natl Acad Sci U S A

Inactivation of the tumor suppressor p53 by long noncoding RNA RMRP. [Abstract]

2021 Jul 20;118(29):e2026813118. PMID: 34266953
Dev Cell

Mitochondrial CCN1 drives ferroptosis via fatty acid β-oxidation. [Abstract]

2025 Apr 18:S1534-5807(25)00206-0. PMID: 40280135
Chin Med J (Engl)

Inhibitory effect of blestriarene C on triple-negative breast cancer: Inducing ferroptosis and mitophagy via SESN2/AKT/FOXO4 axis. [Abstract]

2026 Mar 5;139(5):699-709. PMID: 41527177
Oncogene

An H4K12la/CEBPB-AKR1C2 signaling axis modulates the mTOR pathway to regulate cisplatin resistance in lung cancer. [Abstract]

2026 Feb;45(5):650-662. PMID: 41501211
Oncogene

Targeting FZD6 creates therapeutically actionable vulnerabilities for advanced prostate cancer. [Abstract]

2025 Dec;44(50):4868-4877. PMID: 41286306
Oncogene

BMAL1 collaborates with CLOCK to directly promote DNA double-strand break repair and tumor chemoresistance. [Abstract]

2023 Mar;42(13):967-979. PMID: 36725890
Oncogene

Inhibiting Importin 4-mediated nuclear import of CEBPD enhances chemosensitivity by repression of PRKDC-driven DNA damage repair in cervical cancer. [Abstract]

2020 Aug;39(34):5633-5648. PMID: 32661323
Cell Chem Biol

A highly potent bi-thiazole inhibitor of LOX rewires collagen architecture and enhances chemoresponse in triple-negative breast cancer. [Abstract]

2024 Nov 21;31(11):1926-1941.e11. PMID: 39043186
Apoptosis

Role of Escin in breast cancer therapy: potential mechanism for inducing ferroptosis and synergistic antitumor activity with cisplatin. [Abstract]

2023 Aug;28(7-8):1154-1167. PMID: 37149513
Int J Biol Macromol

2026 Aug:373:153251. PMID: 42372894
Int J Biol Macromol

Regulation of SLC7A11 by METTL3 induces cisplatin resistance in esophageal cancer. [Abstract]

2026 May:361:151921. PMID: 41967541
Int J Biol Macromol

Acetylation of GPRC5A at Lys348 facilitates cisplatin resistance and promotes the recurrence and poor prognosis in ovarian cancer. [Abstract]

2026 May:362:152113. PMID: 42009151
Int J Biol Macromol

The STING-OLA1-Keap1-Nrf2 axis regulates ferroptosis in premature ovarian failure. [Abstract]

2025 Dec 4;337(Pt 1):149424. PMID: 41352507
Int J Biol Macromol

Deubiquitinase USP45 stabilizes RTCB and DDX1, promoting tumorigenesis and chemoresistance. [Abstract]

2025 Dec 28;339(Pt 2):149970. PMID: 41468936
Int J Biol Macromol

Heme oxygenase-1 (HO-1) depletion promotes ferroptosis to reverse cisplatin-resistance via enhancing NCOA4-mediated ferritinophagy in ovarian cancer. [Abstract]

2025 Sep 2;327(Pt 2):147257. PMID: 40907917
Int J Biol Macromol

Ribophorin II potentiates P-glycoprotein- and ABCG2-mediated multidrug resistance via activating ERK pathway in gastric cancer. [Abstract]

2019 May 1:128:574-582. PMID: 30710584
Int J Mol Med

SENP1 promotes p27kip1 nuclear export though enhanced SUMOylation in cholangiocarcinoma leading to increased cell proliferation and chemoresistance. [Abstract]

2025 Sep;56(3):141. PMID: 40682835
Int J Mol Med

Hesperetin induces apoptosis in lung squamous carcinoma cells via G2/M cycle arrest, inhibition of the Notch1 pathway and activation of endoplasmic reticulum stress. [Abstract]

2025 May;55(5):77. PMID: 40084686
Int J Mol Med

Osteosarcoma stem cells resist chemotherapy by maintaining mitochondrial dynamic stability via DRP1. [Abstract]

2025 Jan;55(1):10. PMID: 39513621
JACS Au

DefNEtTrp: An Iron Dual Chelator Approach for Anticancer Application. [Abstract]

2024 Dec 4;4(12):4799-4808. PMID: 39735911
Mol Ther Oncol

Galunisertib promotes bevacizumab-induced vascular normalization in nasopharyngeal carcinoma: Multi-parameter MRI evaluation. [Abstract]

2024 Aug 8;32(3):200858. PMID: 39280586
Int J Mol Med

Identification of inflammatory response and alternative splicing in acute kidney injury and experimental verification of the involvement of RNA‑binding protein RBFOX1 in this disease. [Abstract]

2022 Mar;49(3):32. PMID: 35059728
Int J Mol Med

XPD inhibits cell growth and invasion and enhances chemosensitivity in esophageal squamous cell carcinoma by regulating the PI3K/AKT signaling pathway. [Abstract]

2020 Jul;46(1):201-210. PMID: 32377720
Sens Actuators B Chem

2024 Jan 15, 399, 134872.
Nephrol Dial Transplant

Bombesin receptor-activated protein exacerbates cisplatin-induced AKI by regulating the degradation of SIRT2. [Abstract]

2022 Nov 23;37(12):2366-2385. PMID: 35488871
Phytother Res

Quercetin Overcomes Cisplatin Resistance by Inducing Ferroptosis via the DDB2-AS1/miR-4728-5p/p53 Axis. [Abstract]

2026 Mar;40(3):1230-1251. PMID: 41562315
Phytother Res

Fresh Ginseng Reduces Sphingosine Secretion Through Ubiquitin Degradation of SPTLC2 to Antagonize the Progression of Non-Small Cell Lung Cancer. [Abstract]

2025 Nov 20. PMID: 41265852
Phytother Res

6-Shogaol Reduces Renal Macrophage Infiltration by Targeting the STING Pathway to Alleviate Cisplatin Induced Renal Injury. [Abstract]

2025 Jul 29. PMID: 40728195
Phytother Res

Polyphyllin VII induces autophagy-dependent ferroptosis in human gastric cancer through targeting T-lymphokine-activated killer cell-originated protein kinase. [Abstract]

2023 Dec;37(12):5803-5820. PMID: 37632389
Phytother Res

Daidzein alleviates cisplatin-induced muscle atrophy by regulating Glut4/AMPK/FoxO pathway. [Abstract]

2021 Aug;35(8):4363-4376. PMID: 33876509
Drug Deliv

Liposome-mediated delivery of a ruthenium-based metallodrug to overcome cisplatin resistance in osteosarcoma. [Abstract]

2026 Dec 31;33(1):2671485. PMID: 42116576
Free Radic Biol Med

Ginsenoside Rk1 suppresses osteosarcoma progression by coordinately activating ferritinophagy and disrupting antioxidant defense to induce ferroptosis. [Abstract]

2026 Jun 27:S0891-5849(26)00907-X. PMID: 42364854
Free Radic Biol Med

Cepharanthine-induced mitophagy through regulation of FBXL4-BNIP3 drives ferroptosis leading to robust anti-lung cancer efficacy. [Abstract]

2026 Jan:242:345-363. PMID: 41177235
Free Radic Biol Med

Crucial roles of asprosin in cisplatin-induced ferroptosis and acute kidney injury. [Abstract]

2024 Dec 9:227:296-311. PMID: 39653130
Free Radic Biol Med

Isorhamnetin alleviates cisplatin-induced acute kidney injury via enhancing fatty acid oxidation. [Abstract]

2024 Feb 20:212:22-33. PMID: 38101584
Free Radic Biol Med

Canagliflozin reduces chemoresistance in hepatocellular carcinoma through PKM2-c-Myc complex-mediated glutamine starvation. [Abstract]

2023 Nov 1:208:571-586. PMID: 37696420
Free Radic Biol Med

Endogenous production of ω-3 polyunsaturated fatty acids mitigates cisplatin-induced myelosuppression by regulating NRF2-MDM2-p53 signaling pathway. [Abstract]

2023 May 20:201:14-25. PMID: 36906190
Free Radic Biol Med

Polygalacin D suppresses esophageal squamous cell carcinoma growth and metastasis through regulating miR-142-5p/Nrf2 axis. [Abstract]

2021 Feb 20:164:58-75. PMID: 33307164
Clin Transl Med

Oncogenic driver and therapeutic target: Prolactin signalling axis in retroperitoneal sarcoma. [Abstract]

2026 May;16(5):e70669. PMID: 42083506
Clin Transl Med

TMEM92 shields DDX3X from TTC3-mediated degradation to confer chemoresistance in triple-negative breast cancer. [Abstract]

2026 May;16(5):e70681. PMID: 42138474
Cancer Immunol Res

PIKfyve inhibition induces antitumor immunogenicity by attenuating STING trafficking and lysosomal degradation. [Abstract]

2025 Aug 1;13(8):1266-1283. PMID: 40403159
Clin Transl Med

Identifying squalene epoxidase as a metabolic vulnerability in high-risk osteosarcoma using an artificial intelligence-derived prognostic index. [Abstract]

2024 Feb;14(2):e1586. PMID: 38372422
EMBO Mol Med

Thioparib inhibits homologous recombination repair, activates the type I IFN response, and overcomes olaparib resistance. [Abstract]

2023 Mar 8;15(3):e16235. PMID: 36652375
Clin Transl Med

Tumour cells are sensitised to ferroptosis via RB1CC1-mediated transcriptional reprogramming. [Abstract]

2022 Feb;12(2):e747. PMID: 35220675
Clin Transl Med

LncRNA LINC00942 promotes chemoresistance in gastric cancer by suppressing MSI2 degradation to enhance c-Myc mRNA stability. [Abstract]

2022 Jan;12(1):e703. PMID: 35073459
EMBO Mol Med

Conformational change of adenine nucleotide translocase-1 mediates cisplatin resistance induced by EBV-LMP1. [Abstract]

2021 Dec 7;13(12):e14072. PMID: 34755470
Clin Transl Med

CK1δ stimulates ubiquitination-dependent proteasomal degradation of ATF4 to promote chemoresistance in gastric Cancer. [Abstract]

2021 Oct;11(10):e587. PMID: 34709767
Cancer Immunol Res

Blocking P2X7-Mediated Macrophage Polarization Overcomes Treatment Resistance in Lung Cancer. [Abstract]

2020 Nov;8(11):1426-1439. PMID: 32933967
ACS Appl Mater Interfaces

Kidney Targeting Liposomes Loaded with the Antioxidant Pinocembrin for Treatment of Acute Kidney Injury. [Abstract]

2026 Jan 21;18(2):3527-3538. PMID: 41510988
Stem Cell Res Ther

AMSC-EVs attenuate acute kidney injury through TXNIP-IKKα/NFκB signaling-mediated renal CX3CR1+ macrophage polarization. [Abstract]

2025 Nov 14;16(1):639. PMID: 41239483
ACS Appl Mater Interfaces

Feedback-Amplified Drug Delivery of αPD-L1-Modified Lipoplatin for Chronological Synergy in NSCLC through PD-L1 Upregulation. [Abstract]

2025 Oct 8;17(40):55861-55875. PMID: 40997865
ACS Appl Mater Interfaces

Highly Strong and Transparent Hydrogel Elastomers Microfabricated for 3D Microphysiological Systems. [Abstract]

2025 Jul 23;17(29):42394-42406. PMID: 40637032
Stem Cell Res Ther

Epiregulin increases stemness-associated genes expression and promotes chemoresistance of non-small cell lung cancer via ERK signaling. [Abstract]

2022 May 12;13(1):197. PMID: 35551652
Br J Cancer

Isocitrate dehydrogenase 2 contributes to radiation resistance of oesophageal squamous cell carcinoma via regulating mitochondrial function and ROS/pAKT signalling. [Abstract]

2020 Jul;123(1):126-136. PMID: 32367071
Cell Rep

2026 Jul 28;45(7):117686. PMID: 42441405
Cell Rep

Gasdermin C reprograms metabolism through the CAMKK2-AMPK axis to promote lung adenocarcinoma progression and radioresistance. [Abstract]

2026 May 22;45(6):117427. PMID: 42176271
Cell Rep

Nociceptive neurons protect cancer cells against oxidative stress. [Abstract]

2026 Mar 24;45(3):117086. PMID: 41831232
World J Gastroenterol

Chaperonin-containing tailless complex polypeptide 1 subunit 6A negatively regulates autophagy and protects colorectal cancer cells from cisplatin-induced cytotoxicity. [Abstract]

2025 May 14;31(18):105729. PMID: 40496362
Cell Rep

p53-responsive CMBL reprograms glucose metabolism and suppresses cancer development by destabilizing phosphofructokinase PFKP. [Abstract]

2023 Nov 14;42(11):113426. PMID: 37967006
World J Gastroenterol

18β-glycyrrhetinic acid inhibits proliferation of gastric cancer cells through regulating the miR-345-5p/TGM2 signaling pathway. [Abstract]

2023 Jun 21;29(23):3622-3644. PMID: 37398884
Cell Rep

Pharmacological boosting of cGAS activation sensitizes chemotherapy by enhancing antitumor immunity. [Abstract]

2023 Mar 20;42(3):112275. PMID: 36943864
Cell Rep

The deubiquitinase OTUD1 noncanonically suppresses Akt activation through its N-terminal intrinsically disordered region. [Abstract]

2023 Jan 31;42(1):111916. PMID: 36640312
Cancer Drug Resist

Corosolic acid increases the therapeutic effect of cisplatin on gastric cancer by regulating Gpx4-dependent ferroptosis. [Abstract]

2025 Aug 7:8:40. PMID: 40843357
Cell Prolif

L-Se-methylselenocysteine sensitizes lung carcinoma to chemotherapy. [Abstract]

2021 May;54(5):e13038. PMID: 33793020
Cell Prolif

Blockage of SLC31A1-dependent copper absorption increases pancreatic cancer cell autophagy to resist cell death. [Abstract]

2019 Mar;52(2):e12568. PMID: 30706544
Br J Pharmacol

Inhibition of GRK2 mitigates cisplatin-induced acute and chronic nephrotoxicity by targeting the NADPH oxidase 4/oxidative stress axis. [Abstract]

2026 Mar 5. PMID: 41782455
Brain Behav Immun

Depression-related chronic stress promotes ovarian cancer progression via metabolic dysfunction and IRF1-mediated immune suppression. [Abstract]

2026 Jan 26:134:106471. PMID: 41605304
Br J Pharmacol

Sculponeatin A induces mitochondrial dysfunction in non-small cell lung cancer through WWP2-mediated degradation of mitochondrial STAT3. [Abstract]

2025 Jun;182(12):2662-2681. PMID: 39993792
Br J Pharmacol

Leonurine alleviates ferroptosis in cisplatin-induced acute kidney injury by activating the Nrf2 signalling pathway. [Abstract]

2022 Aug;179(15):3991-4009. PMID: 35303762
Chin J Nat Med

Two cardenolide glycosides from the seed fairs of Asclepias curassavica and their cytotoxic activities. [Abstract]

2022 Mar;20(3):202-209. PMID: 35369964
Chin Med

Dipeptide PA3264 derived from rare and endangered Squama Manis is a novel bioactive peptide for the treatment of triple-negative breast cancer. [Abstract]

2024 Aug 21;19(1):112. PMID: 39169391
Int J Radiat Oncol Biol Phys

High dose ionizing radiation accelerates atherosclerotic plaque progression by regulating P38/NCOA4-mediated ferritinophagy/ferroptosis of endothelial cells. [Abstract]

2023 Sep 1;117(1):223-236. PMID: 37059236
Int J Radiat Oncol Biol Phys

Ionizing Radiation Triggers the Antitumor Immunity by Inducing Gasdermin E-Mediated Pyroptosis in Tumor Cells. [Abstract]

2023 Feb 1;115(2):440-452. PMID: 35918054
J Med Chem

Design, Synthesis, and Antitumor Evaluation of Novel Shikonin Derivatives: Discovery of 3k as a Dual Activator of the Integrated Stress Response and ROS in Gastric Cancer. [Abstract]

2026 Jun 11;69(11):13121-13140. PMID: 42205055
Int J Oncol

Discovery of the late autophagy inhibitor FZU‑0045‑053 and its anti‑breast cancer and immunomodulatory effects. [Abstract]

2026 Jan;68(1):10. PMID: 41312734
J Med Chem

Discovery of Potent STING Inhibitors Bearing a Difluorobenzodioxol Structural Motif as Potent Anti-Inflammatory Agents. [Abstract]

2025 Apr 6. PMID: 40188441
Int J Oncol

LncRNA MALAT1 potentiates autophagy‑associated cisplatin resistance by regulating the microRNA‑30b/autophagy‑related gene 5 axis in gastric cancer. [Abstract]

2019 Jan;54(1):239-248. PMID: 30365113
Cancer Cell Int

Characterization of G2/M checkpoint classifier for personalized treatment in uterine corpus endometrial carcinoma. [Abstract]

2025 Feb 7;25(1):34. PMID: 39920729
Cancer Cell Int

Organoids as a model system for researching human neuroendocrine tumor of the breast. [Abstract]

2024 Dec 27;24(1):433. PMID: 39731167
Cancer Cell Int

Wee1 inhibitor PD0166285 sensitized TP53 mutant lung squamous cell carcinoma to cisplatin via STAT1. [Abstract]

2024 Sep 13;24(1):315. PMID: 39272147
Cancer Cell Int

Capsaicin combined with cisplatin inhibits TGF-β1-induced EMT and TSCC cells migration via the Claudin-1/PI3K/AKT/mTOR signaling pathway. [Abstract]

2024 Aug 28;24(1):300. PMID: 39198820
Front Immunol

GLIPR2: a potential biomarker and therapeutic target unveiled - Insights from extensive pan-cancer analyses, with a spotlight on lung adenocarcinoma. [Abstract]

2024 Feb 26:15:1280525. PMID: 38476239
Cancer Cell Int

ALDOA inhibits cell cycle arrest induced by DNA damage via the ATM-PLK1 pathway in pancreatic cancer cells. [Abstract]

2021 Sep 26;21(1):514. PMID: 34565365
Mol Cancer Ther

TNIK overexpression is sufficient for chemoradiation resistance in limited-stage small cell lung cancer. [Abstract]

2026 Mar 16. PMID: 41838988
PLoS Biol

FOXA3 regulates cholesterol metabolism to compensate for low uptake during the progression of lung adenocarcinoma. [Abstract]

2024 May 28;22(5):e3002621. PMID: 38805565
Mol Cancer Ther

MTX-13, a Novel PTK7-Directed Antibody-Drug Conjugate with Widened Therapeutic Index Shows Sustained Tumor Regressions for a Broader Spectrum of PTK7-Positive Tumors. [Abstract]

2023 Oct 2;22(10):1128-1143. PMID: 37352387
J Ethnopharmacol

Targeting GRB2-Akt-SREBP1 signaling axis by saponins from Paris polyphylla Smith var. yunnanensis (Franch.) Hand.-Mazz to overcome cisplatin resistance in bladder cancer. [Abstract]

2026 Jan 10:354:120502. PMID: 40882789
Neurosci Bull

Inhibition of the cGAS‑STING Pathway Reduces Cisplatin-Induced Inner Ear Hair Cell Damage. [Abstract]

2025 Mar;41(3):359-373. PMID: 39676140
Antioxid Redox Signal

The antioxidant ergothioneine alleviates cisplatin-induced hearing loss through the Nrf2 pathway. [Abstract]

2025 Jan;42(1-3):97-114. PMID: 38770822
J Ethnopharmacol

Centipeda minima extracts and the active sesquiterpene lactones have therapeutic efficacy in non-small cell lung cancer by suppressing Skp2/p27 signaling pathway. [Abstract]

2025 Jan 31:340:119277. PMID: 39722328
J Ethnopharmacol

A metabolomics approach reveals metabolic disturbance of human cholangiocarcinoma cells after parthenolide treatment. [Abstract]

2024 Jun 28:328:118075. PMID: 38513779
J Ethnopharmacol

Gastrodin alleviates cisplatin nephrotoxicity by inhibiting ferroptosis via the SIRT1/FOXO3A/GPX4 signaling pathway. [Abstract]

2024 Jan 30;319(Pt 3):117282. PMID: 37802374
J Ethnopharmacol

Huaier suppresses cisplatin resistance in non-small cell lung cancer by inhibiting the JNK/JUN/IL-8 signaling pathway. [Abstract]

2024 Jan 30;319(Pt 2):117270. PMID: 37832810
J Ethnopharmacol

The preventative effect of Baihe Gujin Pill on cisplatin-induced acute kidney injury by activating the PI3K/AKT and suppressing the NF-κB/MAPK pathways. [Abstract]

2023 Aug 22;318(Pt B):117071. PMID: 37619855
J Ethnopharmacol

Prediction of the mechanisms of action of Zhibai Dihaung Granule in cisplatin-induced acute kidney injury: A network pharmacology study and experimental validation. [Abstract]

2022 Jun 28;292:115241. PMID: 35351575
J Ethnopharmacol

Combination of Compound Kushen Injection and cisplatin shows synergistic antitumor activity in p53-R273H/P309S mutant colorectal cancer cells through inducing apoptosis. [Abstract]

2022 Jan 30:283:114690. PMID: 34597653
J Ethnopharmacol

The anti-tumor effect of OP-B on ovarian cancer in vitro and in vivo, and its mechanism: An investigation using network pharmacology-based analysis. [Abstract]

2022 Jan 30:283:114706. PMID: 34614446
J Agric Food Chem

Resveratrol Derivatives with a Urea Backbone Exert Anticancer Effects against Liver Cancer via Apoptosis Induction and Metastasis Inhibition. [Abstract]

2025 Dec 10;73(49):31429-31443. PMID: 41324234
Talanta

High-throughput single-cell metabolites profiling reveals metabolic reprogramming confers cisplatin resistance in lung cancer. [Abstract]

2025 Apr 1:285:127355. PMID: 39673986
Eur J Med Chem

Design, synthesis and biological evaluation of novel β-carbolines as antitumor agents via targeting autophagy in colorectal cancer. [Abstract]

2025 Feb 5:283:117145. PMID: 39653623
Talanta

A smart tablet-phone-based high-performance pancreatic cancer cell biosensing system for drug screening. [Abstract]

2024 Oct 1:278:126484. PMID: 38941810
Eur J Med Chem

Novel PHD2/HDACs hybrid inhibitors protect against cisplatin-induced acute kidney injury. [Abstract]

2022 Feb 15:230:114115. PMID: 35033824
Ecotoxicol Environ Saf

PPARγ-responsive luciferase reporter system for high-throughput screening of chemical toxins with potential pulmonary fibrosis effects. [Abstract]

2025 Nov 15:307:119433. PMID: 41273832
Ecotoxicol Environ Saf

Excessive selenium affects neural development and locomotor behavior of zebrafish embryos. [Abstract]

2022 Jun 15;238:113611. PMID: 35526456
Biochem Pharmacol

RNA polymerase I inhibitor CX-5461 suppresses cervical cancer cell growth by inducing DNA damage and mitotic catastrophe and enhances cisplatin sensitivity. [Abstract]

2026 Jun:248:117828. PMID: 41730388
Biochem Pharmacol

Secukinumab: A new Hope for precision treatment of Acute kidney injury. [Abstract]

2026 Jun:248:117834. PMID: 41724274
Biochem Pharmacol

Pharmacological activation of GPX4 by selenomethionine attenuates cisplatin-induced ototoxicity and hearing loss. [Abstract]

2026 Jun:248:117816. PMID: 41698483
Biochem Pharmacol

Ginkgetin alleviates cisplatin-induced muscle atrophy via inhibition of the macrophage cGAS-STING pathway. [Abstract]

2026 Mar 8:249:117879. PMID: 41806931
Biochem Pharmacol

Senolytic elimination of therapy-induced senescent cells by ABT-263 improves chemotherapeutic efficacy in esophageal squamous cell carcinoma. [Abstract]

2026 Mar:245:117659. PMID: 41423036
Biochem Pharmacol

PCDH7 promotes EMT and chemoresistance by stabilizing ZEB1 via inhibition of TRIM26-mediated ubiquitination in lung adenocarcinoma. [Abstract]

2026 Jan;243(Pt 2):117554. PMID: 41271034
Biochem Pharmacol

Estradiol alleviated chemotherapy-induced premature ovarian failure by blocking the ferroptosis via activating ESR2/Sirt1/Nrf2 pathway. [Abstract]

2025 Oct 29;243(Pt 1):117481. PMID: 41173058
Biochem Pharmacol

Chemoproteomics-based profiling reveals the targeting molecular mechanism of reversal of cisplatin resistance by baicalin in head and neck squamous cell carcinoma. [Abstract]

2025 Sep 21;242(Pt 3):117360. PMID: 40987408
Biochem Pharmacol

Oridonin combined with cisplatin synergistically induces apoptosis by activating the NOXA-BCL2 axis in esophageal squamous cell carcinoma. [Abstract]

2025 Jul:237:116953. PMID: 40250733
Biochem Pharmacol

STM2457 decreases m6A methylation to reduce cisplatin-induced ototoxicity via MAPK signaling. [Abstract]

2025 May:235:116820. PMID: 39983847
Cell Mol Life Sci

The inhibition of ZC3H13 attenuates G2/M arrest and apoptosis by alleviating NABP1 m6A modification in cisplatin-induced acute kidney injury. [Abstract]

2025 Feb 22;82(1):86. PMID: 39985591
Cell Mol Life Sci

Nuclear translocation of ISG15 regulated by PPP2R2B inhibits cisplatin resistance of bladder cancer. [Abstract]

2024 Jul 8;81(1):292. PMID: 38976080
Biochem Pharmacol

Helicobacter pylori infection induces POU5F1 upregulation and SPP1 activation to promote chemoresistance and T cell inactivation in gastric cancer cells. [Abstract]

2024 Jul:225:116253. PMID: 38701869
Biochem Pharmacol

Jolkinolide B synergistically potentiates the antitumor activity of GPX4 inhibitors via inhibiting TrxR1 in cisplatin-resistant bladder cancer cells. [Abstract]

2024 May:223:116194. PMID: 38583812
Biochem Pharmacol

A novel L-shaped ortho-quinone analog as PLK1 inhibitor blocks prostate cancer cells in G2 phase. [Abstract]

2024 Jan:219:115960. PMID: 38049008
Biochem Pharmacol

The multitargeted kinase inhibitor KW-2449 ameliorates cisplatin-induced nephrotoxicity by targeting RIPK1-mediated necroptosis. [Abstract]

2021 Jun:188:114542. PMID: 33819469
Biochem Pharmacol

The Bcr-Abl inhibitor GNF-7 inhibits necroptosis and ameliorates acute kidney injury by targeting RIPK1 and RIPK3 kinases. [Abstract]

2020 Jul;177:113947. PMID: 32247850
Mol Ther Nucleic Acids

lncRNA TUG1 Promotes Cisplatin Resistance by Regulating CCND2 via Epigenetically Silencing miR-194-5p in Bladder Cancer. [Abstract]

2019 Jun 7:16:257-271. PMID: 30925453
Life Sci

A protective role of ECSIT in chemotherapy-induced intestinal mucositis by maintaining Lgr5+ intestinal stem cells and gut homeostasis. [Abstract]

2026 Mar 15:389:124236. PMID: 41611204
Cancer Gene Ther

ECT2 promotes malignant phenotypes through the activation of the AKT/mTOR pathway and cisplatin resistance in cervical cancer. [Abstract]

2023 Jan;30(1):62-73. PMID: 36056253
Life Sci

RETRACTED: Oridonin elevates sensitivity of ovarian carcinoma cells to cisplatin via suppressing cisplatin-mediated autophagy. [Abstract]

2019 Sep 15:233:116709. PMID: 31369760
Food Funct

Corn silk extract ameliorates cisplatin-induced cardiac injury by restoring mitochondrial function and suppressing ferroptosis. [Abstract]

2026 May 12;17(9):4090-4109. PMID: 41989386
Biomed J

Bavachinin Suppresses Growth and Metastasis of Oral Squamous Cell Carcinoma through GSK-3β/β-Catenin Pathway: Potential for Synergistic Anticancer Therapy with Cisplatin. [Abstract]

2026 Apr 7:100975. PMID: 41956246
Mol Cell Proteomics

Lactylome Reprogramming Mediates Therapeutic Response and Adaptation to Neoadjuvant Chemotherapy in Esophageal Squamous Cell Carcinoma. [Abstract]

2026 Mar 31:101561. PMID: 41933727
Lab Chip

Microdissected "cuboids" for microfluidic drug testing of intact tissues. [Abstract]

2021 Jan 5;21(1):122-142. PMID: 33174580
Bioeng Transl Med

Enhancement of the therapeutic efficacy of the MAP regimen using thiamine pyrophosphate-decorated albumin nanoclusters in osteosarcoma treatment. [Abstract]

2022 Dec 26;8(6):e10472. PMID: 38023714
RSC Adv

Nano-delivery of miRNA inhibiting CENPF combined with cisplatin for bladder cancer treatment. [Abstract]

2025 Jun 13;15(25):20183-20191. PMID: 40519684
Gastric Cancer

Anthracycline chemicals with anthracyclinone structure exert antitumor effects by inhibiting angiogenesis and lymphangiogenesis in a xenografted gastric tumor model. [Abstract]

2023 Nov;26(6):863-877. PMID: 37344705
J Cell Biol

Real-time imaging of RNA polymerase I activity in living human cells. [Abstract]

2023 Jan 2;222(1):e202202110. PMID: 36282216
Cells

Punicic Acid in Ovarian Cancer: Anticancer Activity and Mechanistic Insights. [Abstract]

2026 Jan;15(9):792. PMID: 42121893
ACS Biomater Sci Eng

Three-Dimensional-Printed In Vitro Model of Colorectal Cancer with Immune Microenvironment and Reprogramming Capabilities. [Abstract]

2025 Oct 13;11(10):5991-6003. PMID: 41032858
Oncogenesis

Chemotherapy-induced executioner caspase activation increases breast cancer malignancy through epigenetic de-repression of CDH12. [Abstract]

2023 Jun 24;12(1):34. PMID: 37355711
Cells

SQSTM1/p62 Knockout by Using the CRISPR/Cas9 System Inhibits Migration and Invasion of Hepatocellular Carcinoma. [Abstract]

2023 Apr 25;12(9):1238. PMID: 37174639
Oncogenesis

Spindle function and Wnt pathway inhibition by PBX1 to suppress tumor progression via downregulating DCDC2 in colorectal cancer. [Abstract]

2023 Feb 4;12(1):3. PMID: 36739270
Cells

ML216 Prevents DNA Damage-Induced Senescence by Modulating DBC1-BLM Interaction. [Abstract]

2022 Dec 29;12(1):145. PMID: 36611939
Cells

2-Deoxy-D-glucose Alleviates Cancer Cachexia-Induced Muscle Wasting by Enhancing Ketone Metabolism and Inhibiting the Cori Cycle. [Abstract]

2022 Sep 25;11(19):2987. PMID: 36230949
Cells

Regulation Networks of Non-Coding RNA-Associated ceRNAs in Cisplatin-Induced Acute Kidney Injury. [Abstract]

2022 Sep 23;11(19):2971. PMID: 36230932
Neurobiol Dis

Curcumin attenuates cognitive impairment by enhancing autophagy in chemotherapy. [Abstract]

2020 Mar:136:104715. PMID: 31843707
Cancer Metab

WTAP contributes to platinum resistance in high-grade serous ovarian cancer by up-regulating malic acid: insights from liquid chromatography and mass spectrometry analysis. [Abstract]

2025 Mar 17;13(1):14. PMID: 40098185
Cancer Immunol Immunother

Overcoming NK cell resistance in triple-negative breast cancer via adcc with a humanized anti-CD147 antibody. [Abstract]

2025 Oct 22;74(11):342. PMID: 41123660
Commun Biol

Inhibition of inner ear macrophage phagocytosis alleviates cisplatin-induced ototoxicity. [Abstract]

2025 Jul 30;8(1):1134. PMID: 40739377
Commun Biol

CAF-derived GLUT1 and its role in modulating ovarian cancer progression: a multi-dimensional analysis of the tumor microenvironment. [Abstract]

2025 Jul 8;8(1):1020. PMID: 40629043
Polymers

Effects of Chitosan on Drug Load and Release for Cisplatin-Hydroxyapatite-Gelatin Composite Microspheres. [Abstract]

2025 May 27;17(11):1485. PMID: 40508728
Commun Biol

RBAP48 facilitates the oral squamous cell carcinoma process in an androgen receptor-dependent and independent manners. [Abstract]

2025 May 30;8(1):829. PMID: 40442479
Commun Biol

SRC enhanced cisplatin resistance in bladder cancer by reprogramming glycolysis and pentose phosphate pathway. [Abstract]

2025 Jan 10;8(1):36. PMID: 39794543
Commun Biol

Small GTP-binding protein GDP dissociation stimulator influences cisplatin-induced acute kidney injury via PERK-dependent ER stress. [Abstract]

2024 Sep 5;7(1):1091. PMID: 39237614
Mol Cancer Res

PIK3CA and p53 Mutations Promote 4NQO-Initated Head and Neck Tumor Progression and Metastasis in Mice. [Abstract]

2020 Jun;18(6):822-834. PMID: 32152233
Cancer Biol Ther

Identification of coilin in bone marrow as a potential neuroblastoma tumor progression marker transcriptionally regulated by MYCN. [Abstract]

2026 Dec 31;27(1):2600709. PMID: 41423806
Eur J Pharmacol

Leonurine attenuates cisplatin-induced AKI-CKD transition via Nrf2-Mediated ferroptosis suppression. [Abstract]

2026 Jan 30:1013:178508. PMID: 41448263
J Zhejiang Univ Sci B

Depleting CBR1 increases chemosensitivity by reducing stemness and quiescence traits in non-small cell lung cancer. [Abstract]

2025 Dec 17;26(12):1216-1232. PMID: 41490728
Pharmaceuticals (Basel)

Photothermal Therapy Combined with Chemotherapy and Anti-Inflammation Therapy Weakens the Immunosuppression of Cervical Cancer. [Abstract]

2025 Nov 1;18(11):1657. PMID: 41304902
Eur J Pharmacol

VOPP1, a determinant of the sensitivity of non-small cell lung cancer cells to NAE inhibitors. [Abstract]

2025 Sep 15:1003:177942. PMID: 40651787
Pharmaceuticals (Basel)

A COX-2-Targeted Platinum(lV) Prodrug Induces Apoptosis and Reduces Inflammation in Bladder Cancer Models. [Abstract]

2025 Aug 12;18(8):1185. PMID: 40872576
Eur J Pharmacol

Dihydrotanshinone I potentiates the anti-tumor activity of cisplatin by activating ROS-mediated ER stress through targeting HSPD1 in lung cancer cells. [Abstract]

2025 May 5:994:177378. PMID: 39952584
Pharmaceuticals (Basel)

Identification of 3-[(4-Acetylphenyl)(4-Phenylthiazol-2-Yl)Amino]Propanoic Acid Derivatives as Promising Scaffolds for the Development of Novel Anticancer Candidates Targeting SIRT2 and EGFR. [Abstract]

2025 May 16;18(5):733. PMID: 40430551
Mar Life Sci Technol

Nitrobenzoyl-insulicolide A: a novel dinitrobenzoyl sesquiterpenoid, induces autophagic cell death in small cell lung cancer cells. [Abstract]

2025 May 12;7(4):949-961. PMID: 41322261
Pharmaceuticals (Basel)

Preclinical Efficacy and Safety of an Oncolytic Adenovirus KD01 for the Treatment of Bladder Cancer. [Abstract]

2025 Mar 31;18(4):511. PMID: 40283946
Cell Biol Toxicol

GRK2 mediates cisplatin-induced acute liver injury via the modulation of NOX4. [Abstract]

2024 Nov 15;40(1):98. PMID: 39546067
Mar Drugs

Identification of Penexanthone A as a Novel Chemosensitizer to Induce Ferroptosis by Targeting Nrf2 in Human Colorectal Cancer Cells. [Abstract]

2024 Aug 6;22(8):357. PMID: 39195474
Eur J Pharmacol

Compound Z526 alleviates chemotherapy-induced cachectic muscle loss by ameliorating oxidative stress-driven protein metabolic imbalance and apoptosis. [Abstract]

2024 Jul 5:974:176538. PMID: 38552940
Pharmaceuticals (Basel)

Rapamycin as a Potential Alternative Drug for Squamous Cell Gingiva Carcinoma (Ca9-22): A Focus on Cell Cycle, Apoptosis and Autophagy Genetic Profile. [Abstract]

2024 Jan 19;17(1):131. PMID: 38276004
Cell Biol Toxicol

Long non-coding RNA CTSLP8 mediates ovarian cancer progression and chemotherapy resistance by modulating cellular glycolysis and regulating c-Myc expression through PKM2. [Abstract]

2022 Dec;38(6):1027-1045. PMID: 34510316
Int Immunopharmacol

Targeting NBL1/PI3K/AKT axis to enhance the chemosensitivity and radiosensitivity of esophageal squamous cell carcinoma. [Abstract]

2026 Jul 1:180:116665. PMID: 42030890
Int Immunopharmacol

Ebselen's role in overcoming cisplatin resistance in colorectal Cancer via SQSTM1 ubiquitination modulation. [Abstract]

2026 Jul 15:181:116705. PMID: 42085841
Biomolecules

Aloperine Suppresses the Tumorigenicity of Esophageal Squamous Cell Carcinoma by Targeting the AP-1/IL-6/STAT3 Signaling Axis. [Abstract]

2026 Jun;16(6):791. PMID: 42352257
Int J Mol Sci

Identification of β-Lapachone as a Potent USP22 Inhibitor That Suppresses Cancer Stemness and Enhances Chemosensitivity in Lung Adenocarcinoma. [Abstract]

2026 Jun 19;27(12):5561. PMID: 42353275
Int Immunopharmacol

CHK1 inhibition by prexasertib sensitizes cisplatin-resistant malignant tumor cells via checkpoint abrogation and STAT1-driven PD-L1 upregulation. [Abstract]

2026 Feb 15:171:116126. PMID: 41477994
Int Immunopharmacol

A small-molecule compound cocktail for tumor reprogramming therapy for breast cancer. [Abstract]

2025 Oct 10:163:115273. PMID: 40743622
Int Immunopharmacol

RNF180 suppressed aggressiveness by degrading NOTCH1, TRIM24 and FOXC1, and chemoresistance by degrading ACC1 and ACLY in colorectal cancer. [Abstract]

2025 Sep 6:165:115445. PMID: 40915184
Int Immunopharmacol

Theaflavin suppresses necroptosis by attenuating RIPK1-RIPK3-MLKL signaling and mitigates cisplatin-induced kidney injury in mice. [Abstract]

2025 Jun 5:157:114761. PMID: 40318271
Int Immunopharmacol

Dracorhodin perochlorate sensitizes colorectal cancer to ferroptosis by activating HMOX1 and inhibiting the SLC7A11/GPX4 axis. [Abstract]

2025 Jun 17:158:114827. PMID: 40359890
Int J Mol Sci

Polyphyllin I Inhibits the Metastasis of Cervical Cancer Through the Regulation of the β-Catenin Signaling Pathway. [Abstract]

2025 May 12;26(10):4630. PMID: 40429774
Biomolecules

Mechanism of Mitophagy to Protect Yak Kidney from Hypoxia-Induced Fibrosis Damage by Regulating Ferroptosis Pathway. [Abstract]

2025 Apr 9;15(4):556. PMID: 40305351
Int Immunopharmacol

Bergenin inhibits ferritinophagy and ferroptosis in cisplatin-induced acute kidney injury by activating the p-GSK3β/Nrf2/PPARγ pathway. [Abstract]

2025 Feb 6:147:114004. PMID: 39793228
Int Immunopharmacol

Manganese improves CD8+ T cell recruitment via cGAS-STING in hepatocellular carcinoma. [Abstract]

2024 Nov 15;143(Pt 3):113591. PMID: 39549546
Int J Mol Sci

A Mulberry Diels-Alder-Type Adduct, Kuwanon M, Triggers Apoptosis and Paraptosis of Lung Cancer Cells through Inducing Endoplasmic Reticulum Stress. [Abstract]

2023 Jan 5;24(2):1015. PMID: 36674530
Int J Mol Sci

Ferroptosis and Apoptosis Are Involved in the Formation of L-Selenomethionine-Induced Ocular Defects in Zebrafish Embryos. [Abstract]

2022 Apr 26;23(9):4783. PMID: 35563172
Int J Mol Sci

A Novel CDK4/6 and PARP Dual Inhibitor ZC-22 Effectively Suppresses Tumor Growth and Improves the Response to Cisplatin Treatment in Breast and Ovarian Cancer. [Abstract]

2022 Mar 7;23(5):2892. PMID: 35270034
Int J Mol Sci

The Mitochondrial PHB2/OMA1/DELE1 Pathway Cooperates with Endoplasmic Reticulum Stress to Facilitate the Response to Chemotherapeutics in Ovarian Cancer. [Abstract]

2022 Jan 25;23(3):1320. PMID: 35163244
Int Immunopharmacol

LIGHT deficiency aggravates cisplatin-induced acute kidney injury by upregulating mitochondrial apoptosis. [Abstract]

2020 Dec;89(Pt A):106999. PMID: 33045563
Cell Oncol (Dordr)

The PI3K/mTOR dual inhibitor GSK458 potently impedes ovarian cancer tumorigenesis and metastasis. [Abstract]

2020 Aug;43(4):669-680. PMID: 32382996
Int J Mol Sci

Cisplatin Synergistically Enhances Antitumor Potency of Conditionally Replicating Adenovirus via p53 Dependent or Independent Pathways in Human Lung Carcinoma. [Abstract]

2019 Mar 5;20(5):1125. PMID: 30841620
Front Pharmacol

Amentoflavone protects against cisplatin-induced acute kidney injury by modulating Nrf2-mediated oxidative stress and ferroptosis and partially by activating Nrf2-dependent PANoptosis. [Abstract]

2025 Mar 5:16:1508047. PMID: 40110131
Inflammation

Combined Plasma Olink Proteomics and Transcriptomics Identifies CXCL1 and TNFRSF12A as Potential Predictive and Diagnostic Inflammatory Markers for Acute Kidney Injury. [Abstract]

2024 Oct;47(5):1547-1563. PMID: 38472598
Front Pharmacol

PFKFB3 deprivation attenuates the cisplatin resistance via blocking its autophagic elimination in colorectal cancer cells. [Abstract]

2024 Sep 4:15:1433137. PMID: 39295937
Colloids Surf A Physicochem Eng Asp

2024 Mar 16, 133748.
Front Pharmacol

Oroxylin A ameliorates AKI-to-CKD transition through maintaining PPARα-BNIP3 signaling-mediated mitochondrial homeostasis. [Abstract]

2022 Aug 23;13:935937. PMID: 36081929
Front Pharmacol

Caryophyllene Oxide Induces Ferritinophagy by Regulating the NCOA4/FTH1/LC3 Pathway in Hepatocellular Carcinoma. [Abstract]

2022 Jul 11;13:930958. PMID: 35899120
Front Pharmacol

Sporoderm-Broken Spores of Ganoderma lucidum Sensitizes Ovarian Cancer to Cisplatin by ROS/ERK Signaling and Attenuates Chemotherapy-Related Toxicity. [Abstract]

2022 Feb 21:13:826716. PMID: 35264959
Front Pharmacol

Guaiazulene Triggers ROS-Induced Apoptosis and Protective Autophagy in Non-small Cell Lung Cancer. [Abstract]

2021 Apr 15:12:621181. PMID: 33935713
Front Pharmacol

Isoorientin Attenuates Cisplatin-Induced Nephrotoxicity Through the Inhibition of Oxidative Stress and Apoptosis via Activating the SIRT1/SIRT6/Nrf-2 Pathway. [Abstract]

2020 Mar 18:11:264. PMID: 32256355
Front Pharmacol

PHD Finger Protein 19 Enhances the Resistance of Ovarian Cancer Cells to Compound Fuling Granule by Protecting Cell Growth, Invasion, Migration, and Stemness. [Abstract]

2020 Feb 28;11:150. PMID: 32180719
J Enzyme Inhib Med Chem

Shikonin suppresses diffuse large B-cell lymphoma progression by inducing ferritinophagy and ferroptosis via lncRNA ADPGK-AS1 downregulation. [Abstract]

2026 Dec;41(1):2674446. PMID: 42295078
J Ovarian Res

Interference with CHD1L inhibits the malignant progression and enhances cisplatin sensitivity of ovarian cancer cells by binding PLK1. [Abstract]

2025 Feb 24;18(1):38. PMID: 39994669
Arab J Chem

2024 May, 17, 5, 105731.
Arab J Chem

21 September 2022, 104281.
Front Cell Dev Biol

Exosomal miR-92b-3p Promotes Chemoresistance of Small Cell Lung Cancer Through the PTEN/AKT Pathway. [Abstract]

2021 May 31:9:661602. PMID: 34136482
ACS Omega

2026 Jun 23.
Chem Biol Interact

Acetyl alkannin, a Shikonin monomer, inhibits the ATM/DDR pathway by targeting ATM and sensitizes cisplatin in solid tumors. [Abstract]

2025 Aug 25:417:111559. PMID: 40389196
ACS Omega

Predictive Significance of Glycosyltransferase-Related lncRNAs in Endometrial Cancer: A Comprehensive Analysis and Experimental Validation. [Abstract]

2025 Feb 24;10(8):8023-8041. PMID: 40060793
Chem Biol Interact

f25, a novel synthetic quinoline derivative, inhibits tongue cancer cell invasion and survival by the PPAR pathway in vitro and vivo. [Abstract]

2024 Mar 1:391:110891. PMID: 38278315
Chem Biol Interact

Epimedokoreanin B inhibits the growth of lung cancer cells through endoplasmic reticulum stress-mediated paraptosis accompanied by autophagosome accumulation. [Abstract]

2022 Oct 1:366:110125. PMID: 36027945
Chem Biol Interact

Cisplatin-induced pyroptosis is mediated via the CAPN1/CAPN2-BAK/BAX-caspase-9-caspase-3-GSDME axis in esophageal cancer. [Abstract]

2022 Jul 1;361:109967. PMID: 35525317
Bioorg Chem

Pomalidomide sensitizes lung cancer cells to TRAIL/CDDP-induced apoptosis via directly targeting electron transfer flavoprotein alpha subunit. [Abstract]

2024 Dec:153:107815. PMID: 39265523
Eur J Pharm Sci

Chemotherapy drug combinations induced maternal ovarian damage and long-term effect on fetal reproductive system in mice. [Abstract]

2024 Oct 1:201:106860. PMID: 39043317
Molecules

Hazel Leaf Polyphenol Extract Alleviated Cisplatin-Induced Acute Kidney Injury by Reducing Ferroptosis through Inhibiting Hippo Signaling. [Abstract]

2024 Apr 11;29(8):1729. PMID: 38675549
Molecules

Induction of Apoptosis via Inactivating PI3K/AKT Pathway in Colorectal Cancer Cells Using Aged Chinese Hakka Stir-Fried Green Tea Extract. [Abstract]

2022 Nov 27;27(23):8272. PMID: 36500365
J Mol Med (Berl)

Tyrosine hydroxylase as a therapeutic target: insights from adrenergic nerve and TNBC cell interactions. [Abstract]

2026 Mar 19;104(1):53. PMID: 41857421
Biochim Biophys Acta Mol Basis Dis

ClC-3 inhibition induces autophagy to reverse cisplatin resistance in cervical cancer via the Akt/mTOR pathway. [Abstract]

2025 Sep 2;1872(1):168030. PMID: 40907802
Mol Med Rep

Triptolide reverses cis‑diamminedichloroplatinum resistance in esophageal squamous cell carcinoma by suppressing glycolysis and causing mitochondrial malfunction. [Abstract]

2025 Mar;31(3):74. PMID: 39886972
Biochim Biophys Acta Mol Basis Dis

Triiodothyronine promotes the proliferation and chemoresistance of cholangiocarcinoma cells via HIF-1α/Glut1-stimulated glycolysis. [Abstract]

2025 Mar 31;1871(5):167814. PMID: 40168755
Int J Bioprint

2023 Jun 23.
Mol Med Rep

Exosomal‑miR‑1184 derived from mesenchymal stem cells alleviates cisplatin‑associated acute kidney injury. [Abstract]

2021 Nov;24(5):795. PMID: 34515319
Mol Med Rep

miR‑133b affects cell proliferation, invasion and chemosensitivity in renal cell carcinoma by inhibiting the ERK signaling pathway. [Abstract]

2020 Jul;22(1):67-76. PMID: 32377748
Mol Med Rep

Suppression of CLEC3A inhibits osteosarcoma cell proliferation and promotes their chemosensitivity through the AKT1/mTOR/HIF1α signaling pathway. [Abstract]

2020 Apr;21(4):1739-1748. PMID: 32319617
J Mol Struct

2026 Jun 23;1375:146898.
Sci Rep

Activating GPR55 protects cochlear hair cells against cisplatin-induced ototoxicity via inhibiting MAPK pathway. [Abstract]

2026 Apr 14;16(1):17287. PMID: 41981055
Sci Rep

Cancer-associated fibroblasts -derived Tenascin-C activates the Hippo/TAZ pathway to suppress ferroptosis and confer cisplatin resistance in esophageal cancer. [Abstract]

2026 Apr 27. PMID: 42045517
Sci Rep

Cancer-Associated fibroblasts regulate the development of cholangiocarcinoma through IL-6/STAT3/AKR1C3 signaling axis. [Abstract]

2026 Feb 25;16(1):10467. PMID: 41735359
Sci Rep

Indirubin treatment was associated with modulation of the PI3K/AKT and MAPK pathways and induction of apoptosis and autophagy. [Abstract]

2026 Jan 13;16(1):5155. PMID: 41530396
Sci Rep

Pembrolizumab promotes degradation of cyclin dependent kinase 6 and suppresses ovarian cancer progression in vitro. [Abstract]

2025 Jul 12;15(1):25283. PMID: 40652113
Sci Rep

KLF5-regulated ZDHHC8 reduces chemosensitivity in high-grade serous ovarian cancer through β-catenin signaling. [Abstract]

2025 Jul 18;15(1):26176. PMID: 40681764
Sci Rep

Exploration of the antitumor effect and mechanism of gambogic acid on osteosarcoma through network pharmacology and experimental pharmacology study. [Abstract]

2025 Jul 1;15(1):21647. PMID: 40594358
Biol Proced Online

Establishment of a mouse lung cancer organoid model and its applications for therapeutic screening. [Abstract]

2025 Jun 16;27(1):21. PMID: 40524168
Sci Rep

Characterisation of an autochthonous mouse ccRCC model of immune checkpoint inhibitor therapy resistance. [Abstract]

2025 Jun 5;15(1):19818. PMID: 40473819
Sci Rep

Neddylation status determines the therapeutic sensitivity of tyrosine kinase inhibitors in chronic myeloid leukemia. [Abstract]

2025 May 30;15(1):18978. PMID: 40447744
Toxics

Mitophagy Protects Against Cisplatin-Induced Injury in Granulosa Cells. [Abstract]

2025 Apr 23;13(5):332. PMID: 40423411
Sci Rep

MT1H inhibits the growth of gastric cancer by regulating SLC6A19/TTC39B/ADM2 and activating p53-dependent autophagy. [Abstract]

2025 Mar 18;15(1):9339. PMID: 40102553
Sci Rep

Biological and genetic characterization of a newly established human primary multidrug-resistant distal cholangiocarcinoma cell line, CBC3T-6. [Abstract]

2024 Nov 29;14(1):29661. PMID: 39613883
J Mol Struct

2024 Sep 21.
Cancer Sci

FoxG1/BNIP3 axis promotes mitophagy and blunts cisplatin resistance in osteosarcoma. [Abstract]

2024 Aug;115(8):2565-2577. PMID: 38932521
Sci Rep

Monolayer culture alters EGFR inhibitor response through abrogation of microRNA-mediated feedback regulation. [Abstract]

2024 Mar 27;14(1):7303. PMID: 38538642
Mol Pharm

Construction of SLC16A1/3 Targeted Gallic Acid-Iron-Embelin Nanoparticles for Regulating Glycolysis and Redox Pathways in Cervical Cancer. [Abstract]

2023 Sep 4;20(9):4574-4586. PMID: 37307591
Cancer Sci

D-1553: A novel KRASG12C inhibitor with potent and selective cellular and in vivo antitumor activity. [Abstract]

2023 Jul;114(7):2951-2960. PMID: 37158138
Int J Cancer

Dickkopf-1 expression is repressed by oncogenic human papillomaviruses (HPVs) and regulates the Cisplatin sensitivity of HPV-positive cancer cells in a JNK-dependent manner. [Abstract]

2022 Dec 15;151(12):2215-2228. PMID: 36094276
APL Bioeng

Glutathione-sensitive nanoparticles enhance the combined therapeutic effect of checkpoint kinase 1 inhibitor and cisplatin in prostate cancer. [Abstract]

2022 Nov 21;6(4):046106. PMID: 36440378
Bioelectrochemistry

Moderate intensity static magnetic fields affect mitotic spindles and increase the antitumor efficacy of 5-FU and Taxol. [Abstract]

2016 Jun:109:31-40. PMID: 26775206
Eur J Med Res

RHBDD1 induces cell cycle arrest in TP53-mutant NSCLC cells by promoting endoplasmic reticulum-associated degradation of p53 and DNA-PKcs. [Abstract]

2025 Sep 26;30(1):859. PMID: 41013641
Eur J Med Res

Long non-coding RNA NORAD serves as a promoter of oncogenesis and inhibits ferroptosis via miR-144-3p-mTOR-ferritinophagy axis in cancer. [Abstract]

2025 Aug 4;30(1):704. PMID: 40760677
Antib Ther

Directed protein engineering identifies a human TIM-4 blocking antibody that enhances anti-tumor response to checkpoint inhibition in murine colon carcinoma. [Abstract]

2024 Sep 23;7(4):324-334. PMID: 39678260
Cancers (Basel)

DKK1 Promotes Epithelial-Mesenchymal Transition and Cisplatin Resistance in Gastric Cancer via Activation of the PI3K/AKT Pathway. [Abstract]

2023 Sep 27;15(19):4756. PMID: 37835450
Neoplasia

Regorafenib induces NOX5-mediated endoplasmic reticulum stress and potentiates the anti-tumor activity of cisplatin in non-small cell lung cancer cells. [Abstract]

2023 May:39:100897. PMID: 36940556
Cancers (Basel)

TFAP2C Knockdown Sensitizes Bladder Cancer Cells to Cisplatin Treatment via Regulation of EGFR and NF-κB. [Abstract]

2022 Sep 30;14(19):4809. PMID: 36230734
Cancers (Basel)

Second Generation Small Molecule Inhibitors of Gankyrin for the Treatment of Pediatric Liver Cancer. [Abstract]

2022 Jun 22;14(13):3068. PMID: 35804840
Cancers (Basel)

Cinnamaldehyde Enhances Antimelanoma Activity through Covalently Binding ENO1 and Exhibits a Promoting Effect with Dacarbazine. [Abstract]

2020 Jan 29;12(2):311. PMID: 32013122
Cell Signal

Geniposide enhances cisplatin sensitivity in non-small cell lung cancer through PUMA-mediated apoptotic pathway. [Abstract]

2026 Jul:143:112486. PMID: 41833771
Oncol Rep

2026 Jun 10;56(2):1-7.
Curr Res Toxicol

Loss of KLF15 expression characterizes proximal tubule injury in cisplatin-induced acute kidney injury: A multi-omics study. [Abstract]

2026 May 19:10:100300. PMID: 42238184
J Cell Mol Med

Inactivation of CDK12 Enhances Mitochondrial Efficiency to Suppress DNA Damage. [Abstract]

2026 Apr;30(7):e71101. PMID: 41896195
J Cell Mol Med

Betulinic Acid Suppresses UBE2T Expression via MAPK/ERK Inhibition to Block FANCI and FANCD2 Monoubiquitination in Glioblastoma. [Abstract]

2026 Jan;30(1):e71000. PMID: 41486508
Cell Signal

Targeting CDK12 rescues C/EBPβ-mediated platinum and PARP inhibitor resistance in ovarian cancer. [Abstract]

2025 Dec 16:112328. PMID: 41412562
Mol Cell Biochem

A new gold(I) phosphine complex induces apoptosis in prostate cancer cells by increasing reactive oxygen species. [Abstract]

2025 Apr;480(4):2265-2276. PMID: 38782835
Adv Ther

2024 Jul 18.
Cell Signal

Curcumin derivative NL01 induces ferroptosis in ovarian cancer cells via HCAR1/MCT1 signaling. [Abstract]

2023 Sep:109:110791. PMID: 37406786
J Cell Mol Med

Integrated analysis identifies RAC3 as an immune-related prognostic biomarker associated with chemotherapy sensitivity in endometrial cancer. [Abstract]

2023 Aug;27(16):2385-2397. PMID: 37386813
Cell Signal

Gastric cancer derived mesenchymal stem cells promoted DNA repair and cisplatin resistance through up-regulating PD-L1/Rad51 in gastric cancer. [Abstract]

2023 Jun:106:110639. PMID: 36842523
Cell Signal

Exosomal microRNA-506 inhibits biological activity of lung adenocarcinoma cells and increases sensitivity to cisplatin-based hyperthermia. [Abstract]

2022 Dec:100:110469. PMID: 36115547
Med Oncol

Src inhibitor dasatinib sensitized gastric cancer cells to cisplatin. [Abstract]

2022 Dec 16;40(1):49. PMID: 36525117
Oncol Rep

Synergistic effects of thalidomide and cisplatin are mediated via the PI3K/AKT and JAK1/STAT3 signaling pathways in cervical cancer. [Abstract]

2022 Oct;48(4):169. PMID: 35920185
J Cell Mol Med

Matrine alleviates cisplatin-induced acute kidney injury by inhibiting mitochondrial dysfunction and inflammation via SIRT3/OPA1 pathway. [Abstract]

2022 Jul;26(13):3702-3715. PMID: 35650472
Med Oncol

SNRPB is a mediator for cellular response to cisplatin in non-small-cell lung cancer. [Abstract]

2021 Apr 9;38(5):57. PMID: 33835288
Oncol Rep

Repurposing of a monoamine oxidase A inhibitor‑heptamethine carbocyanine dye conjugate for paclitaxel‑resistant non‑small cell lung cancer. [Abstract]

2021 Mar;45(3):1306-1314. PMID: 33650669
Oncol Rep

Mesenchymal stem cells promote chemoresistance by activating autophagy in intrahepatic cholangiocarcinoma. [Abstract]

2021 Jan;45(1):107-118. PMID: 33155663
Oncol Rep

Suppression of DRP1‑mediated mitophagy increases the apoptosis of hepatocellular carcinoma cells in the setting of chemotherapy. [Abstract]

2020 Mar;43(3):1010-1018. PMID: 32020220
Cell Signal

Subcellular distribution of RAD23B controls XPC degradation and DNA damage repair in response to chemotherapy drugs. [Abstract]

2017 Aug:36:108-116. PMID: 28473198

Cisplatin purchased from MedChemExpress. Usage Cited in: Cell Signal. 2017 Aug:36:108-116. [Abstract]

PAQR3 affects DNA damage repair. AGS cells are treated with different doses of VP-16 (for 24 h), Cisplatin (for 24 h) and NSC 123127 (for 10 h) as indicated, followed by immunoblotting with the antibodies.
Oncol Res

The FN1-ITGB4 Axis Drives Acquired Chemoresistance in Bladder Cancer by Activating FAK Signaling. [Abstract]

2026 Jan 19;34(2):21. PMID: 41613793
Oncol Res

TROP-2 Promotes Cell Proliferation via the AKT-Mediated PKC α Pathway and Is a Novel Target for Antibody-Drug Conjugates in Penile Carcinoma. [Abstract]

2025 Nov 27;33(12):3973-3989. PMID: 41425706
Oncol Res

Gallic acid suppresses esophageal squamous cell carcinoma progression and enhances cisplatin chemosensitivity through IL-6/STAT3/Notch pathway. [Abstract]

2025 May 29;33(6):1473-1484. PMID: 40486873
Oncol Res

Proteasome Inhibitor MG132 Enhances Cisplatin-Induced Apoptosis in Osteosarcoma Cells and Inhibits Tumor Growth. [Abstract]

2018 May 7;26(4):655-664. PMID: 29191257
iScience

ATP6V0D2 drives triple-negative breast cancer progression and inhibits cisplatin sensitivity by promoting PHLPP2 lysosomal degradation. [Abstract]

2025 Oct 27;28(11):113853. PMID: 41312388
iScience

Zinc finger protein 593 promotes breast cancer development by ensuring DNA damage repair and cell-cycle progression. [Abstract]

2024 Dec 3;27(12):111513. PMID: 39758980
Biomedicines

Metformin Inhibited GSDME to Suppress M2 Macrophage Pyroptosis and Maintain M2 Phenotype to Mitigate Cisplatin-Induced Intestinal Inflammation. [Abstract]

2024 Nov 4;12(11):2526. PMID: 39595093
iScience

Dynamic regulation of P-TEFb by 7SK snRNP is integral to the DNA damage response to regulate chemotherapy sensitivity. [Abstract]

2022 Aug 4;25(9):104844. PMID: 36034227
Acta Biochim Biophys Sin (Shanghai)

FOXO1 and FOXO3a sensitize non-small-cell lung cancer cells to cisplatin-induced apoptosis independent of Bim. [Abstract]

2020 Dec 29;52(12):1348-1359. PMID: 33167006
Langmuir

Rapid Fabrication of Diverse Hydrogel Microspheres for Drug Evaluation on a Rotating Microfluidic System. [Abstract]

2025 Mar 27. PMID: 40150939
Process Biochem

2025 Jan.
BMC Complement Med Ther

Rauwolfia vomitoria extract suppresses benign prostatic hyperplasia by inducing autophagic apoptosis through endoplasmic reticulum stress. [Abstract]

2022 May 5;22(1):125. PMID: 35513857
Front Mol Biosci

Network-Based Expression Analyses and Experimental Verifications Reveal the Involvement of STUB1 in Acute Kidney Injury. [Abstract]

2021 Jun 28;8:655361. PMID: 34262937
Biochim Biophys Acta Mol Cell Res

DHCR7 promotes granulosa cells ferroptosis and represents a potential therapeutic target in premature ovarian insufficiency. [Abstract]

2026 Jun 1;1873(6):120168. PMID: 42218966
FASEB J

Simvastatin Restores Cisplatin Sensitivity by Suppressing the Caveolin-1-Mediated PI3K/AKT Signaling Pathway in Cisplatin-Resistant Cervical Cancer Cells. [Abstract]

2026 May 15;40(9):e71873. PMID: 42087353
FASEB J

Penicillide Triggers Immunogenic Pyroptosis in Tumor Cells via Oxidative Stress/NF-κB/GSDMD Signaling Axis. [Abstract]

2026 Mar 31;40(6):e71636. PMID: 41842655
Mol Divers

Discovery of isoindoline-2(1H)-carboxamide STING inhibitors as anti-inflammatory agents. [Abstract]

2025 Dec 11. PMID: 41379298
FASEB J

USP44 Regulates Chemoresistance Induced by ROS and the MAPK/NF-κB Pathway Through the Stabilization of ITGB4 in Gastric Cancer. [Abstract]

2025 Aug 31;39(16):e70945. PMID: 40824171
Biochim Biophys Acta Mol Cell Res

Cancer-associated fibroblasts secreting IL-6 inhibit the cisplatin and docetaxel killing effect in lung squamous cell carcinoma. [Abstract]

2025 Jul 31;1872(8):120029. PMID: 40752594
FASEB J

Spartin Promotes Smurf1-Mediated Ubiquitination Modification of YWHAZ to Inhibit Cisplatin Resistance in Ovarian Cancer. [Abstract]

2025 May 31;39(10):e70658. PMID: 40386996
FASEB J

DNMT1 determines osteosarcoma cell resistance to apoptosis by associatively modulating DNA and mRNA cytosine-5 methylation. [Abstract]

2023 Dec;37(12):e23284. PMID: 37905981
Saudi Pharm J

Blockade of store-operated calcium entry sensitizes breast cancer cells to cisplatin therapy via modulating inflammatory response. [Abstract]

2023 Feb;31(2):245-254. PMID: 36942275
FEBS J

The sulfonamide anticancer agent indisulam enhances the chemosensitivity of gastric cancer cells by targeting FKBP8. [Abstract]

2026 Mar 20. PMID: 41860182
FEBS J

Single-cell RNA sequencing reveals the protective role of renal Cx3cr1+ macrophages in cisplatin-induced acute kidney injury. [Abstract]

2025 Oct 28. PMID: 41147753
Macromol Biosci

Drug-Loaded Mitochondrial Targeted Nanoparticles for Tumor Imaging and PDT/PTT Combined Chemotherapy in Muscle-Invasive Bladder Cancer. [Abstract]

2025 Jul;25(7):e2400575. PMID: 40162874
Fish Shellfish Immunol

Molecular identification and functional analysis of X-linked inhibitor of apoptosis -associated factor-1 (XAF1) in grass carp, Ctenopharyngodon idella. [Abstract]

2023 Mar:134:108635. PMID: 36822382
Curr Issues Mol Biol

2026 Jul 9;48(7):697. PMID: 42510937
J Food Sci

Protective Effects of Tuber sinoaestivum-Derived Exosome-Like Nanovesicles Against Cisplatin-Induced Acute Liver Injury and Acute Kidney Injury. [Abstract]

2026 Jul;91(7):e71262. PMID: 42423006
J Biol Chem

Mitotic spindle-organizing protein 2A (MZT2A) promotes cisplatin resistance through NEMO ubiquitination and NF-κB activation in lung adenocarcinoma. [Abstract]

2026 Apr;302(4):111330. PMID: 41763311
BMC Cancer

Individualized drug screening in cholangiocarcinoma using organoid models and patient-derived tumor xenograft. [Abstract]

2025 Dec 31. PMID: 41469951
BMC Cancer

Preclinical studies of the falnidamol as a highly potent and specific active ABCB1 transporter inhibitor. [Abstract]

2025 Jan 7;25(1):24. PMID: 39773145
Curr Issues Mol Biol

Transcriptomic Profiling of Carboplatin- and Paclitaxel-Resistant Lung Adenocarcinoma Cells Reveals CSF3 as a Potential Biomarker for the Carboplatin Plus Paclitaxel Doublet Regimens. [Abstract]

2024 Dec 11;46(12):13951-13969. PMID: 39727962
Front Biosci (Landmark Ed)

Cisplatin Disrupts Proteasome Bounce-Back Effect through Suppressing ZEB1/Nfe2l1 in Cholangiocarcinoma. [Abstract]

2024 Mar 15;29(3):106. PMID: 38538281
Clin Immunol

Integrated analysis of tumour-derived exosome-related immune genes to predict progression and immune status of hepatocellular carcinoma. [Abstract]

2023 Nov:256:109774. PMID: 37774907
BMC Cancer

Kayadiol exerted anticancer effects through p53-mediated ferroptosis in NKTCL cells. [Abstract]

2022 Jul 2;22(1):724. PMID: 35778693
Clin Immunol

Cisplatin inhibits the progression of bladder cancer by selectively depleting G-MDSCs: A novel chemoimmunomodulating strategy. [Abstract]

2018 Aug:193:60-69. PMID: 29410331
Funct Integr Genomics

2026 Jul 21;26(1):197. PMID: 42479258
Naunyn Schmiedebergs Arch Pharmacol

Pharmacovigilance assessment of drug-induced hypokalemia: from systemic risk screening to multi-dataset bioinformatics analysis focused on cisplatin. [Abstract]

2026 Mar 12. PMID: 41817748
Cancer Res Commun

Targeting uPARAP with an antibody-drug conjugate exhibits efficacy against mesothelioma and synergizes with cisplatin. [Abstract]

2025 Dec 10. PMID: 41366685
Naunyn Schmiedebergs Arch Pharmacol

Medicarpin reduces cisplatin resistance and causes apoptosis by inhibiting the AKT/Bcl2 pathway in breast cancer. [Abstract]

2025 Oct 24. PMID: 41134353
Naunyn Schmiedebergs Arch Pharmacol

Phytochemical characterization and multi-target mechanism of Gleditsia sinensis Fructus in lung adenocarcinoma treatment. [Abstract]

2025 Oct 29. PMID: 41160117
Naunyn Schmiedebergs Arch Pharmacol

Paeonol protects against cisplatin-induced premature ovarian failure via anti-inflammatory and antioxidant activities: an integrated approach of network pharmacology, molecular dynamics simulation, and experimental validation. [Abstract]

2025 Jul 24. PMID: 40705082
Naunyn Schmiedebergs Arch Pharmacol

ent-8(14),15-Pimaradiene-2β,19-diol, a diterpene from Aleuritopteris albofusca, inhibits growth and induces protective autophagy in hepatocellular carcinoma cells. [Abstract]

2024 Sep;397(9):6867-6878. PMID: 38568289
Naunyn Schmiedebergs Arch Pharmacol

Integrative approach using network pharmacology, bioinformatics, and experimental methods to explore the mechanism of cantharidin in treating colorectal cancer. [Abstract]

2024 Sep;397(9):6745-6761. PMID: 38507104
Funct Integr Genomics

SORL1 stabilizes ABCB1 to promote cisplatin resistance in ovarian cancer. [Abstract]

2023 May 5;23(2):147. PMID: 37145301
J Cell Physiol

Inhibition of tumor propellant glutathione peroxidase 4 induces ferroptosis in cancer cells and enhances anticancer effect of cisplatin. [Abstract]

2020 Apr;235(4):3425-3437. PMID: 31556117
J Hepatocell Carcinoma

Integrative Multi-Omics and Functional Validation Reveal the Role of the TACE Refractoriness-Associated Gene ATP1B3 in Hepatocellular Carcinoma. [Abstract]

2025 Nov 19:12:2565-2583. PMID: 41293558
Cell Cycle

NEDD4 is a biomarker of a poor prognosis that contributes to the progression and chemoresistance in small cell lung cancer. [Abstract]

2025 Aug 6:1-16. PMID: 40767383
J Hepatocell Carcinoma

Inhibitory Effects of Esculetin on Liver Cancer Through Triggering NCOA4 Pathway-Mediation Ferritinophagy in vivo and in vitro. [Abstract]

2023 Apr 11:10:611-629. PMID: 37069958
J Funct Foods

November 2021, 104714.
Ren Fail

Bergamottin pretreatment attenuates cisplatin-induced acute kidney injury in mice by inhibiting BACE-1-mediated ferroptosis. [Abstract]

2026 Dec;48(1):2641847. PMID: 41967926
Ren Fail

Dihydromyricetin protects against cisplatin-induced renal injury and mitochondria-mediated apoptosis via the EGFR/HSP27/STAT3 signaling pathway. [Abstract]

2025 Dec;47(1):2490202. PMID: 40230054
Carcinogenesis

SOCS1 acts as a ferroptosis driver to inhibit the progression and chemotherapy resistance of triple-negative breast cancer. [Abstract]

2023 Dec 2;44(8-9):708-715. PMID: 37665951
Carcinogenesis

ID4 predicts poor prognosis and promotes BDNF-mediated oncogenesis of colorectal cancer. [Abstract]

2021 Jul 16;42(7):951-960. PMID: 33993270
Pathol Res Pract

PTEN-low associated mismatch repair deficiency and nuclear PD-L1 expression in basal-type bladder cancer. [Abstract]

2026 Jul:283:156509. PMID: 42097083
J Bioenerg Biomembr

DNA hypermethylation drives BVES-mediated autophagy to promote cisplatin resistance in lung adenocarcinoma. [Abstract]

2026 Apr 15;58(1):24. PMID: 41984391
Int J Med Sci

Integrative analysis identifies PIGK as an oncogenic glycosylphosphatidylinositol transamidase subunit with prognostic, immunological, and therapeutic relevance in head and neck cancer. [Abstract]

2026 Jan 1;23(1):161-176. PMID: 41399371
Clin Exp Metastasis

Cold atmospheric plasma-activated liquid inhibits peritoneal metastasis in drug-resistant ovarian cancer by targeting the epithelial-mesenchymal transition. [Abstract]

2025 Aug 7;42(5):46. PMID: 40772995
Int J Med Sci

Modulation of Chemotherapy Sensitivity of Breast Cancer Cells through Transforming Growth Factor-beta Pathway-mediated Alterations in DNA Damage Response. [Abstract]

2025 Mar 31;22(9):2031-2039. PMID: 40303493
Breast Cancer

Quercetin Promote the Chemosensitivity in Organoids Derived from Patients with Breast Cancer. [Abstract]

2024 Dec 20:16:993-1004. PMID: 39720358
J Pharm Pharmacol

Ganoderic acid A suppresses autophagy by regulating the circFLNA/miR-486-3p/CYP1A1/XRCC1 axis to strengthen the sensitivity of lung cancer cells to cisplatin. [Abstract]

2024 Apr 3;76(4):354-367. PMID: 38330446
Pathol Res Pract

MiR-375 promotes cisplatin sensitivity of lung adenocarcinoma. [Abstract]

2023 Sep:249:154765. PMID: 37625279
J Pharm Pharmacol

Jie Geng Tang reverses cisplatin resistance through the Nrf2 pathway in lung cancer. [Abstract]

2023 Jun 5;75(6):784-805. PMID: 36971498
J Med Virol

Long noncoding RNA TSPOAP1 antisense RNA 1 negatively modulates type I IFN signaling to facilitate influenza A virus replication. [Abstract]

2022 Feb;94(2):557-566. PMID: 30968963
J Nat Prod

Gunnilactams A-C, Macrocyclic Tetralactams from the Mycelial Culture of the Entomogenous Fungus Paecilomyces gunnii. [Abstract]

2017 Jun 23;80(6):1935-1938. PMID: 28562046
Toxicol Appl Pharmacol

Scoparone alleviates cisplatin-induced acute kidney injury by inhibiting 5-lipoxygenase-mediated ferroptosis. [Abstract]

2026 Jun:511:117821. PMID: 41967610
Toxicol Appl Pharmacol

7,8-Dihydroxyflavone attenuates cisplatin-induced cardiomyocyte apoptosis and mitochondrial dysfunction via the p53/Nrf2 pathway. [Abstract]

2025 Dec:505:117578. PMID: 40992637
Toxicol Appl Pharmacol

Copper ionophore enhanced cisplatin efficiency through DLAT-cuprotosis. [Abstract]

2025 Oct:503:117496. PMID: 40749953
J Bone Oncol

Groenlandicine enhances cisplatin sensitivity in cisplatin-resistant osteosarcoma cells through the BAX/Bcl-2/Caspase-9/Caspase-3 pathway. [Abstract]

2024 Aug 24:48:100631. PMID: 39263651
Toxicol Appl Pharmacol

Esketamine induces apoptosis of nasopharyngeal carcinoma cells through the PERK/CHOP pathway. [Abstract]

2024 Feb:483:116800. PMID: 38219984
Toxicol Appl Pharmacol

Dihydromyricetin attenuates cisplatin-induced acute kidney injury by reducing oxidative stress, inflammation and ferroptosis. [Abstract]

2023 Aug 15:473:116595. PMID: 37328118
J Biochem Mol Toxicol

microRNA-486-5p is implicated in the cisplatin-induced apoptosis and acute inflammation response of renal tubular epithelial cells by targeting HAT1. [Abstract]

2022 Jun;36(6):e23039. PMID: 35279909
Toxicol Appl Pharmacol

MS-275 combined with cisplatin exerts synergistic antitumor effects in human esophageal squamous cell carcinoma cells. [Abstract]

2020 May 15:395:114971. PMID: 32217144
Stem Cells Int

Therapeutic Effects of Human Urine-Derived Stem Cells in a Rat Model of Cisplatin-Induced Acute Kidney Injury In Vivo and In Vitro. [Abstract]

2019 Nov 22:2019:8035076. PMID: 31885626
Bioorg Med Chem

Discovery of the thieno[2,3-b][1,4]thiazin-2(3H)-one STING inhibitors. [Abstract]

2026 Jan 16:135:118571. PMID: 41564501
Cell Biol Int

PRMT5 Inhibition Enhances Therapeutic Efficacy of Cisplatin via Mediating miR-29b-3p-Mcl-1 Expression in Lung Adenocarcinoma. [Abstract]

2025 Apr;49(4):407-418. PMID: 39891587
ChemMedChem

Elucidating the High Affinity Copper(II) Complexation by the Iron Chelator Deferasirox Provides Therapeutic and Toxicity Insight. [Abstract]

2025 Apr 1;20(7):e202400937. PMID: 39714988
Cancer Med

LMAN2 Promotes Breast Cancer Tumorigenesis and Drug Resistance by Interacting With MAPK9 via Activation of the MAPK Pathway. [Abstract]

2024 Dec;13(23):e70448. PMID: 39618331
Mol Carcinog

Curcuminoid PBPD induces cuproptosis and endoplasmic reticulum stress in cervical cancer via the Notch1/RBP-J/NRF2/FDX1 pathway. [Abstract]

2024 Aug;63(8):1449-1466. PMID: 38801356
Cell Biol Int

Capsaicin reverses cisplatin resistance in tongue squamous cell carcinoma by inhibiting the Warburg effect and facilitating mitochondrial-dependent apoptosis via the AMPK/AKT/mTOR axis. [Abstract]

2024 Aug;48(8):1097-1110. PMID: 38706122
Exp Cell Res

Colorectal cancer-derived extracellular vesicles containing HSP70 enhance macrophage phagocytosis by up-regulating MARCO expression. [Abstract]

2023 Mar 22;426(2):113565. PMID: 36958650
Exp Cell Res

FANCD2 promotes the malignant behavior of endometrial cancer cells and its prognostic value. [Abstract]

2022 Dec 15;421(2):113388. PMID: 36257352
Exp Cell Res

12 T high static magnetic field suppresses osteosarcoma cells proliferation by regulating intracellular ROS and iron status. [Abstract]

2022 Aug 15;417(2):113223. PMID: 35643180
Arch Biochem Biophys

FAM98A promotes resistance to 5-fluorouracil in colorectal cancer by suppressing ferroptosis. [Abstract]

2022 Jun 15;722:109216. PMID: 35421356
Exp Cell Res

HNRNPUL1 inhibits cisplatin sensitivity of esophageal squamous cell carcinoma through regulating the formation of circMAN1A2. [Abstract]

2021 Dec 1;409(1):112891. PMID: 34688610
Exp Cell Res

GRIM-19 inhibits proliferation and induces apoptosis in a p53-dependent manner in colorectal cancer cells through the SIRT7/PCAF/MDM2 axis. [Abstract]

2021 Oct 1;407(1):112799. PMID: 34461110
Mol Carcinog

CtBP1 transactivates RAD51 and confers cisplatin resistance to breast cancer cells. [Abstract]

2020 May;59(5):512-519. PMID: 32124501
J

Electrochem. Soc. 2018 165(5): D196-D205
Phytochemistry

Chenietains A-G, undescribed phenylpropanoid-related compounds from Cheniella touranensis and their cytotoxic potential in vitro. [Abstract]

2026 Sep:249:114953. PMID: 42106133
Phytochemistry

Dracacochins A-H, undescribed flavonoid dimers and monomers from the red resin of Dracaena cochinchinensis and their anti-renal fibrosis activities. [Abstract]

2026 May 18:250:114971. PMID: 42155757
Phytochemistry

Phytochemical study of Fissistigma fulgens (Hook.f. & Thomson) Merr. leaves: Previously undescribed dihydrochalcone derivatives and their biological activities. [Abstract]

2026 Mar:243:114735. PMID: 41344390
Transl Lung Cancer Res

Development of a 3D-3 co-culture microbead consisting of cancer-associated fibroblasts and human umbilical vein endothelial cells for the anti-tumor drug assessment of lung cancer. [Abstract]

2025 Jun 30;14(6):2159-2179. PMID: 40673102
Invest New Drugs

A novel CDK4 inhibitor for myeloid protection in chemotherapy-treated triple-negative breast Cancer. [Abstract]

2025 Jun;43(3):728-741. PMID: 40478388
Transl Lung Cancer Res

Construction of a lung cancer 3D culture model based on alginate/gelatin micro-beads for drug evaluation. [Abstract]

2024 Oct 31;13(10):2698-2712. PMID: 39507032
J Cancer

KYNU Expression Promotes Cisplatin Resistance in Esophageal Cancer. [Abstract]

2024 Mar 11;15(9):2475-2485. PMID: 38577600
J Pharm Biomed Anal

Integrative analysis of transcriptome and metabolome provide new insights into mechanisms of Capilliposide A against cisplatin-induced nephrotoxicity. [Abstract]

2024 Jan 20:238:115814. PMID: 37976990
J Cancer

Tanshinone IIA inhibits cell viability and promotes PUMA-mediated apoptosis of oral squamous cell carcinoma. [Abstract]

2023 Aug 6;14(13):2481-2490. PMID: 37670974
J Cancer

Reduced FANCE Confers Genomic Instability and Malignant Behavior by Regulating Cell Cycle Progression in Endometrial Cancer. [Abstract]

2023 Aug 28;14(14):2670-2685. PMID: 37779877
Opt Express

Optical tweezers study of membrane fluidity in small cell lung cancer cells. [Abstract]

2021 Apr 12;29(8):11976-11986. PMID: 33984967
Front Oncol

Targeting ACLY Attenuates Tumor Growth and Acquired Cisplatin Resistance in Ovarian Cancer by Inhibiting the PI3K-AKT Pathway and Activating the AMPK-ROS Pathway. [Abstract]

2021 Mar 17:11:642229. PMID: 33816292
Front Oncol

Wilms' Tumor 1-Associated Protein Contributes to Chemo-Resistance to Cisplatin Through the Wnt/β-Catenin Pathway in Endometrial Cancer. [Abstract]

2021 Feb 16:11:598344. PMID: 33680959
Front Oncol

SIRT5 Promotes Cisplatin Resistance in Ovarian Cancer by Suppressing DNA Damage in a ROS-Dependent Manner via Regulation of the Nrf2/HO-1 Pathway. [Abstract]

2019 Aug 13:9:754. PMID: 31456942
Chem Biol Drug Des

Revealing the Action Mechanism of the FOXA2-LAMC2 Axis in Driving Cisplatin Resistance of Head and Neck Squamous Cell Carcinoma via Based Multi-Omic Analysis and Experimental Validation. [Abstract]

2026 Jun;107(6):e70328. PMID: 42319071
Chem Biol Drug Des

Alantolactone facilitates ferroptosis in non-small cell lung cancer through promoting FTH1 ubiquitination and degradation. [Abstract]

2024 Aug;104(2):e14560. PMID: 39175059
J Cancer Res Clin Oncol

Targeting CD73 limits tumor progression and enhances anti-tumor activity of anti-PD-1 therapy in intrahepatic cholangiocarcinoma. [Abstract]

2024 Jul 13;150(7):348. PMID: 39002018
SLAS Discov

Development of a high-throughput screening platform to identify new therapeutic agents for Medulloblastoma Group 3. [Abstract]

2024 Feb 12;29(2):100147. PMID: 38355016
Biochem Biophys Rep

Peroxiredoxin-1 as a molecular chaperone that regulates glutathione S-transferase P1 activity and drives mutidrug resistance in ovarian cancer cells. [Abstract]

2024 Jan 14:37:101639. PMID: 38288281
J Cancer Res Clin Oncol

Repurposing of triamterene as a histone deacetylase inhibitor to overcome cisplatin resistance in lung cancer treatment. [Abstract]

2023 Aug;149(10):7217-7234. PMID: 36905422
Breast Cancer Res Treat

KMT2C is a potential biomarker of prognosis and chemotherapy sensitivity in breast cancer. [Abstract]

2021 Sep;189(2):347-361. PMID: 34240274
Food Chem Toxicol

2026 Jul 21:217:116290. PMID: 42480692
Adv Ther (Weinh)

2025 Dec 8;8(12):e00322.
Food Chem Toxicol

Paeoniflorin attenuates cisplatin induced ototoxicity by inhibiting ferroptosis mediated by HMGB1/NRF2/GPX4 pathway. [Abstract]

2025 Aug:202:115550. PMID: 40374000
Mol Biol Rep

Mechanisms of autophagy and endoplasmic reticulum stress in the reversal of platinum resistance of epithelial ovarian cancer cells by naringin. [Abstract]

2023 Aug;50(8):6457-6468. PMID: 37326754
Plasma Process Polym

2021 Feb 12.
S Afr J Bot

2026 Feb 9.
Cell Tissue Res

Phenothiazine alleviates cisplatin-mediated acute kidney injury by inhibiting ferroptosis. [Abstract]

2026 Jan 23;403(1):12. PMID: 41575591
Chin J Integr Med

Honeysuckle-Derived Exosome-Like Nanovesicles Alleviate Cisplatin-Induced Acute Kidney Injury by Anti-Inflammation and Mitochondrial Function Protection. [Abstract]

2025 Nov 18. PMID: 41252116
Oral Dis

Metformin overcomes chemoresistance by regulating stemness via KLF4 in oral squamous cell carcinoma. [Abstract]

2025 Feb;31(2):468-481. PMID: 39039738
Epigenomics

EZH2 inhibition enhances the activity of Carboplatin in aggressive-variant prostate cancer cell lines. [Abstract]

2025 Feb;17(3):145-154. PMID: 39878501
Am J Cancer Res

Loss of Lipocalin2 confers cisplatin vulnerability through modulating NF-ĸB mediated ferroptosis via ferroportin. [Abstract]

2024 May 15;14(5):2088-2102. PMID: 38859845
Integr Cancer Ther

Curcumol Enhances the Sensitivity of Gastric Cancer to Cisplatin Resistance by Inducing Ferroptosis Through the P62/KEAP1/NRF2 Pathway. [Abstract]

2024 Jan-Dec:23:15347354241294043. PMID: 39511708
Immunobiology

Quercetin acts as a novel anti-cancer drug to suppress cancer aggressiveness and cisplatin-resistance in nasopharyngeal carcinoma (NPC) through regulating the yes-associated protein/Hippo signaling pathway. [Abstract]

2023 Mar;228(2):152324. PMID: 36608594
Life Sci Alliance

Tanshinone functions as a coenzyme that confers gain of function of NQO1 to suppress ferroptosis. [Abstract]

2022 Nov 1;6(1):e202201667. PMID: 36319062
Tissue Cell

Tetratricopeptide repeat domain 36 protects renal tubular cells from cisplatin-induced apoptosis potentially via maintaining mitochondrial homeostasis. [Abstract]

2022 Jun:76:101749. PMID: 35176677
Free Radic Res

Luteolin attenuated cisplatin-induced cardiac dysfunction and oxidative stress via modulation of Keap1/Nrf2 signaling pathway. [Abstract]

2022 Feb;56(2):209-221. PMID: 35468014
Toxicol Lett

Autophagy-dependent ferroptosis contributes to cisplatin-induced hearing loss. [Abstract]

2021 Oct 10:350:249-260. PMID: 34302894
FEBS Lett

Fbxo6 confers drug-sensitization to cisplatin via inhibiting the activation of Chk1 in non-small cell lung cancer. [Abstract]

2019 Jul;593(14):1827-1836. PMID: 31140586
Mol Pharmacol

Predictive modeling and functional characterization of the ceRNA regulatory network in cisplatin resistance of non-small cell lung cancer. [Abstract]

2025 Nov 7;107(12):100087. PMID: 41308543
Cell Biochem Biophys

T-Box Transcription Factor 2 Mediates Chemoresistance of Endometrial Cancer via Regulating FSP1-involved Ferroptosis. [Abstract]

2025 Mar;83(1):1313-1320. PMID: 39325362
J Cell Biochem

Identification of reciprocal microRNA-mRNA pairs associated with metastatic potential disparities in human prostate cancer cells and signaling pathway analysis. [Abstract]

2019 Oct;120(10):17779-17790. PMID: 31127646
Biochim Biophys Acta Gen Subj

Pharmacological role of MLN4924 in cisplatin-induced acute kidney injury. [Abstract]

2025 Sep;1869(10):130842. PMID: 40664338
BMC Nephrol

A low-dose pemetrexed-cisplatin combination regimen induces significant nephrotoxicity in mice. [Abstract]

2024 Oct 21;25(1):370. PMID: 39434019
PeerJ

Prognostic and chemotherapeutic implications of a novel four-gene pyroptosis model in head and neck squamous cell carcinoma. [Abstract]

2024 May 13:12:e17296. PMID: 38756442
Toxicol Res (Camb)

8-Formylophiopogonanone B induces ROS-mediated apoptosis in nasopharyngeal carcinoma CNE-1 cells. [Abstract]

2021 Sep 6;10(5):1052-1063. PMID: 34733490
Discov Oncol

2026 Jun 23. PMID: 42334677
Daru

ALKBH5 promotes the progression of cisplatin-resistant oral squamous cell carcinoma by regulating FOXA1 expression via m6A RNA methylation : Funding. [Abstract]

2026 Jun 6;34(2):31. PMID: 42251238
PLoS One

The Physicochemical Synergy Effect of Nanosecond Pulsed Electric Fields (nsPEF) and cisplatin on reversing chemoresistance of bladder cancer. [Abstract]

2026 Apr 16;21(4):e0346699. PMID: 41990096
Hum Cell

Exosomal miR-145-5p impairs neoadjuvant chemotherapy by suppressing TFRC-mediated macrophage iron uptake and driving M2 polarization in esophageal cancer. [Abstract]

2025 Dec 24;39(1):27. PMID: 41444464
Discov Oncol

TRIM19 enhances the chemosensitivity of endometrial cancer by regulating the TBX2/NRF2 axis. [Abstract]

2025 Jun 4;16(1):997. PMID: 40465083
Int J Immunopathol Pharmacol

Chemotherapy elevates cell surface PD-L1 and MHC-I expression in apoptotic gastric cancer cells. [Abstract]

2025 Jan-Dec:39:3946320251338662. PMID: 40380807
Polyhedron

2025 Jul 1.
Physiol Res

The Role of Mdivi-1 in Reducing Mitochondrial Fission via the NF-kappaB/JNK/SIRT3 Signaling Pathway in Acute Kidney Injury. [Abstract]

2025 Mar 24;74(1):79-92. PMID: 40126145
Mutat Res Genet Toxicol Environ Mutagen

FTO regulates the DNA damage response via effects on cell-cycle progression. [Abstract]

2023 Apr:887:503608. PMID: 37003652
Vet Microbiol

CircRNA_0050463 promotes influenza A virus replication by sponging miR-33b-5p to regulate EEF1A1. [Abstract]

2021 Mar:254:108995. PMID: 33517193
Clin Transl Oncol

Transcriptome analysis of key genes and pathways associated with cisplatin resistance in oral squamous cell carcinoma Cal27 cells. [Abstract]

2025 Apr 14. PMID: 40227535
Gene

RFWD2 increases proliferation and CDDP resistance of osteosarcoma cells. [Abstract]

2025 Jan 15:933:148973. PMID: 39349111
Technol Cancer Res Treat

COLEC12 Promotes Tumor Progression and Is Correlated With Poor Prognosis in Gastric Cancer. [Abstract]

2023 Jan-Dec:22:15330338231218163. PMID: 38112409
Prostate

Melittin inhibits tumor cell migration and enhances cisplatin sensitivity by suppressing IL-17 signaling pathway gene LCN2 in castration-resistant prostate cancer. [Abstract]

2023 Nov;83(15):1430-1445. PMID: 37517867
Clin Transl Oncol

Establishment of an acquired lorlatinib-resistant cell line of non-small cell lung cancer and its mediated resistance mechanism. [Abstract]

2022 Nov;24(11):2231-2240. PMID: 35852680
FEBS Open Bio

CSNK2A1-mediated phosphorylation of HMGA2 modulates cisplatin resistance in cervical cancer. [Abstract]

2021 Aug;11(8):2245-2255. PMID: 34115920
FEBS Open Bio

Long noncoding RNA MALAT1 promotes the stemness of esophageal squamous cell carcinoma by enhancing YAP transcriptional activity. [Abstract]

2019 Aug;9(8):1392-1402. PMID: 31116509
FEBS Open Bio

LncRNA MALAT1 increases the stemness of gastric cancer cells via enhancing SOX2 mRNA stability. [Abstract]

2019 Jul;9(7):1212-1222. PMID: 31037832
FEBS Open Bio

LncRNA THOR increases osteosarcoma cell stemness and migration by enhancing SOX9 mRNA stability. [Abstract]

2019 Mar 20;9(4):781-790. PMID: 30984551
J Mol Histol

Lasiokaurin suppresses hepatocellular carcinoma proliferation and induces apoptosis via the JAK2/STAT3 pathway. [Abstract]

2026 Jul 4;57(4):221. PMID: 42399563
J Nat Med

2026 Jul 20. PMID: 42477307
J Mol Histol

Hesperetin ameliorates mitochondrial dysfunction in acute kidney injury by mediating autophagy and inhibiting the cGAS-STING pathway. [Abstract]

2025 Sep 27;56(5):330. PMID: 41014382
Hereditas

Carnosic acid enhances cisplatin sensitivity and suppresses gastric cancer progression via the TP53/SLC7A11/ALOX12 axis. [Abstract]

2025 Jul 23;162(1):139. PMID: 40696490
Hereditas

LncRNA FLG-AS1 inhibits esophageal squamous cell carcinoma by regulating the miR-23a-3p/HOXD10 axis. [Abstract]

2025 Jun 3;162(1):96. PMID: 40462237
DNA Cell Biol

The Role of Ferroptosis Signature in Overall Survival and Chemotherapy of Pancreatic Adenocarcinoma. [Abstract]

2022 Feb;41(2):116-127. PMID: 34898275
Cancer Manag Res

Exosome-Reversed Chemoresistance to Cisplatin in Non-Small Lung Cancer Through Transferring miR-613. [Abstract]

2020 Sep 3:12:7961-7972. PMID: 32943930
Odontology

Accumulated cytotoxicity of CDK inhibitor dinaciclib with first-line chemotherapy drugs in salivary adenoid cystic carcinoma cells. [Abstract]

2020 Apr;108(2):300-311. PMID: 31529315
Biochem Biophys Res Commun

Protection by maslinic acid against cisplatin-induced ototoxicity: rescue of ferroptosis by targeting the SLC7A11-GSH-GPX4 pathway. [Abstract]

2026 Apr 16:809:153480. PMID: 41722247
Biochem Biophys Res Commun

The role of Drp1-Pink1-Parkin mediated mitophagy in cisplatin-induced damage to primary cochlear SV pericytes. [Abstract]

2026 Jan 8:795:153090. PMID: 41365163
Biochem Biophys Res Commun

Repurposing HIV protease inhibitors as senotherapeutic agents in cervical cancer: Dual targeting of CDK1/6-cell cycle arrest and p53/p21/p16 signaling axis. [Abstract]

2025 Jul 22:771:152040. PMID: 40403681
Biochem Biophys Res Commun

Bufalin: A promising therapeutic drug against the cisplatin-resistance of ovarian cancer by targeting the USP36/c-Myc axis. [Abstract]

2024 Nov 12:733:150440. PMID: 39067250
Anal Cell Pathol

Shikonin Induces Autophagy and Apoptosis in Esophageal Cancer EC9706 Cells by Regulating the AMPK/mTOR/ULK Axis. [Abstract]

2024 Oct 29:2024:7752299. PMID: 39502521
Biochem Biophys Res Commun

Evaluation of the tumor-targeting specific imaging and killing effect of a CEA-targeting nanoparticle in colorectal cancer. [Abstract]

2024 Jul 30:719:150084. PMID: 38733742
Biochem Biophys Res Commun

Acidic solvent improves cisplatin action in in-vitro. [Abstract]

2024 Jun 18:712-713:149936. PMID: 38640736
Biochem Biophys Res Commun

Pemigatinib, a selective FGFR inhibitor overcomes ABCB1-mediated multidrug resistance in cancer cells. [Abstract]

2024 Jan 8:691:149314. PMID: 38039831
J Immunotoxicol

Vitamin D/Vitamin D receptor mitigates cisplatin-induced acute kidney injury by down-regulating C5aR. [Abstract]

2023 Dec;20(1):2248267. PMID: 37667858
Biochem Biophys Res Commun

ANXA2 and Rac1 negatively regulates autophagy and osteogenic differentiation in osteosarcoma cells to confer CDDP resistance. [Abstract]

2023 Oct 8:676:198-206. PMID: 37536195
Biochem Biophys Res Commun

Cloning, expression of porcine GSDME and identification of its site cleaved by caspase-3. [Abstract]

2023 Aug 20:669:61-67. PMID: 37267861

Cisplatin purchased from MedChemExpress. Usage Cited in: Biochem Biophys Res Commun. 2023 Aug 20:669:61-67. [Abstract]

Cisplatin (25, 50 μM; 24 h) significantly increases the expression of caspase-3 in PK-15 cells.
Biochem Biophys Res Commun

FGD5 facilitates tumor growth by regulating EGFR ubiquitination in gastric cancer. [Abstract]

2021 Jul 12:562:43-49. PMID: 34034092
Anal Cell Pathol

Activation of MEK1/2/Nrf-2 Signaling Pathway by Epstein-Barr Virus-Latent Membrane Protein 1 Enhances Autophagy and Cisplatin Resistance in T-Cell Lymphoma. [Abstract]

2021 Jun 18:2021:6668947. PMID: 34239803
Biochem Biophys Res Commun

miR-324-3p reverses cisplatin resistance by inducing GPX4-mediated ferroptosis in lung adenocarcinoma cell line A549. [Abstract]

2021 Apr 16:549:54-60. PMID: 33662669
Biochem Biophys Res Commun

Daurisoline inhibits hepatocellular carcinoma progression by restraining autophagy and promoting cispaltin-induced cell death. [Abstract]

2021 Jan 1:534:1083-1090. PMID: 33213840
Biochem Biophys Res Commun

Pivalopril improves anti-cancer efficiency of cDDP in breast cancer through inhibiting proliferation, angiogenesis and metastasis. [Abstract]

2020 Dec 17;533(4):853-860. PMID: 33008601
Biochem Biophys Res Commun

Gomisin J inhibits the glioma progression by inducing apoptosis and reducing HKII-regulated glycolysis. [Abstract]

2020 Aug 13;529(1):15-22. PMID: 32560813
Biochem Biophys Res Commun

Poziotinib suppresses ovarian cancer stem cell growth via inhibition of HER4-mediated STAT5 pathway. [Abstract]

2020 May 21;526(1):158-164. PMID: 32201081
Biochem Biophys Res Commun

Veliparib overcomes multidrug resistance in liver cancer cells. [Abstract]

2020 Jan 15;521(3):596-602. PMID: 31679697
Biol Methods Protoc

Optimizing drug sensitivity assays in patient-derived tumor organoids: a comparison of IC50 estimation methods and experimental parameters. [Abstract]

2025 Feb 13;10(1):bpaf012. PMID: 40060949
Am J Med Sci

Blocking of SIRT7/FOXO3a axis by miR-152-3p enhances cisplatin sensitivity in breast cancer. [Abstract]

2024 Sep 4:S0002-9629(24)01444-7. PMID: 39241827
Onco Targets Ther

The Anti-Breast Cancer Effect and Mechanism of Glimepiride-Metformin Adduct. [Abstract]

2020 May 4:13:3777-3788. PMID: 32440146
J Oral Pathol Med

Rapamycin Targets Cancer Stem Cells to Decrease Cisplatin Resistance in a Head and Neck Cancer Mouse Xenograft Model. [Abstract]

2026 Jun 9. PMID: 42261974
Arch Oral Biol

Comparative analysis of patient-derived organoids among oral squamous cell carcinoma and mucosa identifies the distinct features. [Abstract]

2026 Apr:184:106520. PMID: 41564798
Drug Chem Toxicol

Physcion alleviates cisplatin-induced apo in HK-2 cells by activating the apo signaling for treating acute kidney injury: Integrating network pharmacology and informatics. [Abstract]

2025 Oct 14:1-9. PMID: 41084754
Mol Genet Genomics

AL137246.1 inhibits esophageal squamous cell carcinoma cisplatin resistance by suppressing the transcriptional activity of GLI2 on ABCC1. [Abstract]

2025 Oct 14;300(1):96. PMID: 41085663
Cytotechnology

Astragalus polysaccharide regulates the cervical cancer cell cycle and inhibits cisplatin resistance by blocking the Wnt/β-catenin pathway through the PPARD/CDC20 axis. [Abstract]

2025 Aug;77(4):126. PMID: 40538591
Exp Ther Med

Zinc oxide nanoparticles inhibit malignant progression and chemotherapy resistance of ovarian cancer cells by activating endoplasmic reticulum stress and promoting autophagy. [Abstract]

2023 Sep 14;26(5):508. PMID: 37840563
Int Urol Nephrol

Natural killer cells strengthen antitumor activity of cisplatin by immunomodulation and ameliorate cisplatin-induced side effects. [Abstract]

2023 Aug;55(8):1957-1970. PMID: 37253929
Exp Ther Med

Proteasome inhibitor MG132 enhances the sensitivity of human OSCC cells to cisplatin via a ROS/DNA damage/p53 axis. [Abstract]

2023 Mar 30;25(5):224. PMID: 37123203
Biochem Cell Biol

Resveratrol upregulates miR-455-5p to antagonize cisplatin ototoxicity via modulating the PTEN-PI3K-AKT axis. [Abstract]

2021 Jun;99(3):385-395. PMID: 34077275
Exp Ther Med

FGFR3S249C mutation promotes chemoresistance by activating Akt signaling in bladder cancer cells. [Abstract]

2019 Aug;18(2):1226-1234. PMID: 31316618
Neurosci Lett

Low-dose cisplatin causes growth inhibition and loss of autophagy of rat astrocytes in vitro. [Abstract]

2018 Aug 24:682:112-117. PMID: 29913197

Cisplatin purchased from MedChemExpress. Usage Cited in: Neurosci Lett. 2018 Aug 24:682:112-117. [Abstract]

After treatment of CDDP with or without the autophagy inhibitor CQ, the expression of LC3-II in the CQ+CDDP group is less than that in the CQ group but is higher than that in the CDDP group at 24 h and 96 h.
Oncol Lett

LINC00473 modulates protein expression to promote ovarian cancer progression and overcome cisplatin resistance. [Abstract]

2026 Jan 12;31(3):103. PMID: 41560976
Oncol Lett

Knockdown of ASF1B inhibits cell proliferation, migration, invasion and cisplatin resistance in gastric cancer through the Myc pathway. [Abstract]

2023 Apr 20;25(6):242. PMID: 37153049
Oncol Lett

Transcriptomic analysis of the effects of the HPV18 E6E7 gene on the cell death mode in esophageal squamous cell carcinoma. [Abstract]

2023 Mar 8;25(4):167. PMID: 36960186
Oncol Lett

Cordycepin inhibits the proliferation and progression of NPC by targeting the MAPK/ERK and β-catenin pathways. [Abstract]

2022 Jan;23(1):20. PMID: 34858524
Anatol J Cardiol

Protective effects of trimetazidine and coenzyme Q10 on cisplatin-induced cardiotoxicity by alleviating oxidative stress and mitochondrial dysfunction. [Abstract]

2019 Nov;22(5):232-239. PMID: 31674935
Oncol Lett

MDIG promotes cisplatin resistance of lung adenocarcinoma by regulating ABC transporter expression via activation of the WNT/β-catenin signaling pathway. [Abstract]

2019 Oct;18(4):4294-4307. PMID: 31579066
Oncol Lett

An overactive neddylation pathway serves as a therapeutic target and MLN4924 enhances the anticancer activity of cisplatin in pancreatic cancer. [Abstract]

2019 Sep;18(3):2724-2732. PMID: 31404297
Oncol Lett

Co-inhibition of BMI1 and Mel18 enhances chemosensitivity of esophageal squamous cell carcinoma in vitro and in vivo. [Abstract]

2019 Jun;17(6):5012-5022. PMID: 31186712
Oncol Lett

Lenalidomide improvement of cisplatin antitumor efficacy on triple-negative breast cancer cells in vitro. [Abstract]

2018 May;15(5):6469-6474. PMID: 29616116

Cisplatin purchased from MedChemExpress. Usage Cited in: Oncol Lett. 2018 May;15(5):6469-6474. [Abstract]

MDA-MB-231 cells are grown and treated with CC-5013 (Len), Cisplatin (Cis), or their combination for 72 h and then subjected to western blot analysis.
Oncol Lett

Neddylation inhibitor MLN4924 induces G2 cell cycle arrest, DNA damage and sensitizes esophageal squamous cell carcinoma cells to cisplatin. [Abstract]

2018 Feb;15(2):2583-2589. PMID: 29434977

Cisplatin purchased from MedChemExpress. Usage Cited in: Oncol Lett. 2018 Feb;15(2):2583-2589. [Abstract]

MLN4924 increases CDDP induced apoptosis of esophageal cancer cells. EC1 and Kyse450 cells are treated with 1.6 μg/mL CDDP alone or in combina¬tion with 0.3 μM MLN for 72 h. Cleaved PARP are detected by western blotting.
In Vitro Cell Dev Biol Anim

2026 Jul 24. PMID: 42498919
In Vitro Cell Dev Biol Anim

MOF promotes cisplatin resistance in lung cancer cells by enhancing WSTF acetylation. [Abstract]

2025 Nov 18. PMID: 41252101
Anticancer Drugs

Upregulation of CDC25B by transcription factor TEAD4 drives invasion and inhibits cisplatin sensitivity through cell adhesion in stomach adenocarcinoma. [Abstract]

2024 Nov 1;35(10):922-931. PMID: 39079173
Cell J

High Expression of G9a Induces Cisplatin Resistance in Hepatocellular Carcinoma. [Abstract]

2023 Feb 1;25(2):118-125. PMID: 36840458
Anticancer Drugs

Purvalanol A induces apoptosis and reverses cisplatin resistance in ovarian cancer. [Abstract]

2023 Jan 1;34(1):29-43. PMID: 35946506
Cell J

Inhibition of MAT2A-Related Methionine Metabolism Enhances The Efficacy of Cisplatin on Cisplatin-Resistant Cells in Lung Cancer. [Abstract]

2022 Apr;24(4):204-211. PMID: 35674024
Anticancer Drugs

miR-26b-5p suppresses chemoresistance in breast cancer by targeting serglycin. [Abstract]

2022 Mar 1;33(3):308-319. PMID: 34924500
In Vitro Cell Dev Biol Anim

Breast cancer organoids from malignant pleural effusion-derived tumor cells as an individualized medicine platform. [Abstract]

2021 May;57(5):510-518. PMID: 33950403
Oncology

Design of a Neonatal Orthotopic Metastatic Xenograft Model of Hepatoblastoma in Mice. [Abstract]

2025 Jul 18:1-15. PMID: 40684764
Biochem Genet

Targeting Mitochondrial Cholesterol Efflux via TCF21/ABCA10 Pathway to Enhance Cisplatin Efficacy in Ovarian Cancer. [Abstract]

2024 Oct 22. PMID: 39438390
Braz J Med Biol Res

NLRP1 inhibits lung adenocarcinoma growth through mediating mitochondrial dysregulation in an inflammasome-independent manner. [Abstract]

2024 Sep 6:57:e13885. PMID: 39258674
Braz J Med Biol Res

FRAX486, a PAK inhibitor, overcomes ABCB1-mediated multidrug resistance in breast cancer cells. [Abstract]

2024 Jul 1:57:e13357. PMID: 38958364
Hum Mutat

2026 Jul 6;2026(1):5598948.
Am J Transl Res

RACGAP1 knockdown synergizes and enhances the effects of chemotherapeutics on ovarian cancer. [Abstract]

2024 May 15;16(5):2132-2146. PMID: 38883382
Nat Prod Res

Two new triterpenes isolated from Maytenus guangxiensis C. Y. Cheng et W. L. Sha and their antiproliferative activities. [Abstract]

2023 May;37(9):1498-1504. PMID: 35014566
J Toxicol Sci

Salvianolic acid B attenuated cisplatin-induced cardiac injury and oxidative stress via modulating Nrf2 signal pathway. [Abstract]

2021;46(5):199-207. PMID: 33952797
Am J Transl Res

Upregulation of CSF-1 is correlated with elevated TAM infiltration and poor prognosis in oral squamous cell carcinoma. [Abstract]

2020 Oct 15;12(10):6235-6249. PMID: 33194026
Cancer Biother Radiopharm

Ultrasound-Enhanced Delivery of Salvianolic Acid F Targets CXCL5 to Suppress Lung Cancer Progression: Insights from In Vitro PC9 and H1299 Models. [Abstract]

2025 Sep 10. PMID: 40928959
Phytochem Lett

2025 Aug.
Genet Mol Biol

LTBP2 regulates cisplatin resistance in GC cells via activation of the NF-κB2/BCL3 pathway. [Abstract]

2024 Apr 5;47(2):e20230231. PMID: 38577985
Phytochem Lett

27 May 2022.
Cancer Biother Radiopharm

miR-205 Promotes Apoptosis of Cervical Cancer Cells and Enhances Drug Sensitivity of Cisplatin by Inhibiting YAP1. [Abstract]

2020 Jun;35(5):338-344. PMID: 32379984
Tohoku J Exp Med

HOXA1 Promotes Migration, Invasion and Cell Cycle, and Suppresses Cisplatin Sensitivity of Laryngeal Cancer Cells by Mediating AKT/mTOR Pathway. [Abstract]

2025 Mar 27;265(3):161-171. PMID: 39085122
Biotech Histochem

Downregulation of acetyl-CoA carboxylase induces ferroptosis and inhibits tumor growth in oral squamous cell carcinoma. [Abstract]

2025 Sep 12:1-9. PMID: 40937588
Genes Cells

SRPKs Homolog Dsk1 Regulates Homologous Recombination Repair in Schizosaccharomyces pombe. [Abstract]

2025 Jan;30(1):e13192. PMID: 39789818
STAR Protoc

Protocol for modeling acquired resistance to targeted therapeutics in adherent and suspension cancer cell lines via in situ resistance assay. [Abstract]

2024 Oct 5;5(4):103361. PMID: 39369385
Turk J Med Sci

Loss of WWOX contributes to cisplatin resistance in triple-negative breast cancer cells by modulating miR-182 and miR-214. [Abstract]

2024 Jul 2;54(5):1127-1134. PMID: 39473747
Int J Clin Exp Pathol

2017;10(3):3033-3042.
Gene Rep

2026 Jan 3;42:102413.
Ultrastruct Pathol

The effects of cisplatin and jaceosidin on SH-SY5Y neuroblastoma cells: an electron microscopic, molecular and biochemical study. [Abstract]

2023 Sep 3;47(5):388-397. PMID: 37246956
J Clin Pharm Ther

2024 Nov 15.
Int J Pharmacol

2025, 21(3), 453–463.
Complutense University of Madrid

2026.
University of Puerto Rico

2026.
Res Sq

2026 Jun 25.
bioRxiv

2026 Jun 19.
bioRxiv

2026 Jun 29.
SSRN

2026 Jun 16.
bioRxiv

2026 May 31.
bioRxiv

2026 May 1.
bioRxiv

Ferrous Iron Accumulation Is a Hallmark and Therapeutic Vulnerability of Therapy-Induced Senescence. [Abstract]

2026 May 23:2026.05.20.726695. PMID: 42239384
Res Sq

2026 May 20.
Harvard University

2026.
bioRxiv

2026 Apr 27.
University of Manitoba

2026 Apr.
bioRxiv

Sacituzumab Govitecan as an Effective Strategy for Sensitizing Chemoresistant HNSCC Cells to Senolytic Intervention. [Abstract]

2026 Apr 15:2026.04.13.718209. PMID: 42039381
bioRxiv

2026 Apr 23.
Res Sq

2026 Apr 21.
Res Sq

2026 Apr 28.
Authorea

2026 Mar 31.
bioRxiv

2026 Mar 18.
Res Sq

2026 Mar 3.
Biomed Pharmacother

Targeting ER stress in adrenocortical carcinoma: Celastrol as a novel therapeutic candidate. [Abstract]

2026 Feb 25:197:119156. PMID: 41747473
Res Sq

2026 Feb 26.
Preprints

2026 Feb 10.
SSRN

2026 Jan 26.
Res Sq

2025 Dec 10.
bioRxiv

2025 Dec 5.
SSRN

2025 Dec 2.
Preprints

2025 Dec 22.
bioRxiv

2025 Nov 6.
Res Sq

2025 Sep 7.
University of Kansas

2025.
Developments and Experiments in Health and Medicine

2025.
Res Sq

2025 Jul 20.
Michigan State University

2025.
SSRN

2025 Apr 10.
Res Sq

2025 Mar 16.
Pharmaceutical Science Advances

2025 Dec.
bioRxiv

2025 January 21.
Res Sq

2025 Feb 03.
bioRxiv

2025 January 22.
Research Square Preprint

2024 Aug 19.
Patent

US20240369511A1
Res Sq

2024 Nov 26.
SSRN

2024
Patent

US20240369511A1.
University of California, Irvine

2024.
Biomed Pharmacother

Gilteritinib reverses ABCB1-mediated multidrug resistance: Preclinical in vitro and animal investigations. [Abstract]

2024 Nov:180:117603. PMID: 39471652
Biomed Pharmacother

Paclitaxel-resistance facilitates glycolytic metabolism via Hexokinase-2-regulated ABC and SLC transporter genes in ovarian clear cell carcinoma. [Abstract]

2024 Nov:180:117452. PMID: 39341074
Exp Oncol

IN VITRO ANTICANCER ACTIVITY OF HISTATIN-1 COMBINATION WITH CISPLATIN IN HEAD AND NECK CANCER CELL LINES. [Abstract]

2024 Oct 9;46(2):101-109. PMID: 39396174
Preprints

2024 Jul 19.
bioRxiv

2024 July 23.
Res Sq

BMP receptor 2 inhibition regulates mitochondrial bioenergetics to induce synergistic cell death with BCL-2 inhibitors in leukemia and NSLC cells. [Abstract]

2024 Sep 12:rs.3.rs-5065904. PMID: 39315260
bioRxiv

2024 September 04.
bioRxiv

Low-Cost Robotic Manipulation of Live Microtissues for Cancer Drug Testing. [Abstract]

2024 Aug 6:2024.03.21.586169. PMID: 38586030
Res Sq

2024 Jun 13.
Heliyon

Investigating the potential role of α-SNAP in preventing chemotherapy-induced ovarian dysfunction: Insights from cellular and animal models. [Abstract]

2024 Jun 10;10(12):e32802. PMID: 38994045
Heliyon

OIP5-AS1 enhances the malignant characteristics and resistance to chemotherapy of pancreatic cancer cells by targeting miR-30d-5p/MARCH8. [Abstract]

2024 Jun 28;10(13):e33835. PMID: 39050450
Heliyon

SIAH2 is specifically expressed during cervical carcinogenesis, and closely relates to the abnormal proliferation of cervical epithelial cells. [Abstract]

2024 May 17;10(11):e31487. PMID: 38828323
Heliyon

HMGA2 promotes resistance against paclitaxel by targeting the p53 signaling pathway in colorectal cancer cells. [Abstract]

2024 May 20;10(11):e31431. PMID: 38845972
Heliyon

2024 May 13.
Res Sq

2024 May 8.
SSRN

2024 May 8.
SSRN

2024 Mar 20.
bioRxiv

Label-Free, Real-Time Monitoring of Cytochrome C Responses to Drugs in Microdissected Tumor Biopsies with a Multi-Well Aptasensor Platform. [Abstract]

2024 Feb 1:2024.01.31.578278. PMID: 38352494
Trop J Pharm Res

2024 Jan 29.
Heliyon

Thymoquinone alleviates cisplatin-induced kidney damage by reducing apoptosis in a rat model. [Abstract]

2024 Jan 17;10(2):e24840. PMID: 38304804
bioRxiv

2023 Nov 13.
SSRN

2023 Oct 11.
Research Square Preprint

2023 Sep 6.
Research Square Preprint

2023 Aug 31.
Research Square Preprint

2023 Aug 18.
Research Square Preprint

2023 Aug 11.
Research Square Preprint

2023 Jun 26.
Research Square Preprint

2023 Jul 20.
Preprints

2023 JUl 25.
Biomed Pharmacother

Patient-derived organoid culture of gastric cancer for disease modeling and drug sensitivity testing. [Abstract]

2023 Jul:163:114751. PMID: 37105073
Food Agricultural Sciences and Techmology (FAST)

2023 Jun 9.
SSRN

2023 Jun 15.
bioRxiv

Musashi-2 (MSI2) regulation of DNA damage response in lung cancer. [Abstract]

2023 Jun 14:2023.06.13.544756. PMID: 37398283
Dean Francis

2023 Jun.
Research Square Preprint

2023 May 22.
Patent

US20230129164A1.
Research Square Preprint

2023 Apr 13.
bioRxiv

2023 Apr 14.
bioRxiv

2023 Apr 17.
Research Square Preprint

2023 Apr 20.
Research Square Print

2023 Mar 27.
University of Brescia

2023 Feb 2.
SSRN

2023 Feb 27.
University of South Carolina

2022.
Patent

US20220362765A1.
Research Square Print

October 11th, 2022.
Research Square Print

October 17th, 2022.
J Oncol

SLC7A1 Overexpression Is Involved in Energy Metabolism Reprogramming to Induce Tumor Progression in Epithelial Ovarian Cancer and Is Associated with Immune-Infiltrating Cells. [Abstract]

2022 Sep 12;2022:5864826. PMID: 36131790
Universitat Autònoma de Barcelona

2022 Aug.
J Oncol

Exosomal CTCF Confers Cisplatin Resistance in Osteosarcoma by Promoting Autophagy via the IGF2-AS/miR-579-3p/MSH6 Axis. [Abstract]

2022 May 31:2022:9390611. PMID: 35693981
Oxid Med Cell Longev

Fructose-1,6-Bisphosphatase 2 Inhibits Oral Squamous Cell Carcinoma Tumorigenesis and Glucose Metabolism via Downregulation of c-Myc. [Abstract]

2022 May 6;2022:6766787. PMID: 35571245
Elife

The oncoprotein BCL6 enables solid tumor cells to evade genotoxic stress. [Abstract]

2022 May 3;11:e69255. PMID: 35503721
Research Square Print

2022 May.
Bioengineered

MiR-7-5p suppresses invasion via downregulation of the autophagy-related gene ATG7 and increases chemoresistance to cisplatin in BCa. [Abstract]

2022 Mar;13(3):7328-7339. PMID: 35300572
Research Square Preprint

2022 Feb.
bioRxiv

January 25, 2022.
Oxid Med Cell Longev

Silibinin Alleviates Muscle Atrophy Caused by Oxidative Stress Induced by Cisplatin through ERK/FoxO and JNK/FoxO Pathways. [Abstract]

2022 Jan 20:2022:5694223. PMID: 35096269
bioRxiv

January 13, 2022.
J Oncol

GPR30 Activation Promotes the Progression of Gastric Cancer and Plays a Significant Role in the Anti-GC Effect of Huaier. [Abstract]

2022 Jan 19:2022:2410530. PMID: 35096058
J Oncol

The Human Positive Cofactor 4 is a Promising Chemotherapeutic Target in Lung Adenocarcinoma. [Abstract]

2021 Dec 3;2021:9958483. PMID: 34899911
Bioengineered

ADAMTS-13-regulated nuclear factor E2-related factor 2 signaling inhibits ferroptosis to ameliorate cisplatin-induced acute kidney injuy. [Abstract]

2021 Dec;12(2):11610-11621. PMID: 34666603
Mater Sci Eng C Mater Biol Appl

Cellular defense system-destroying nanoparticles as a platform for enhanced chemotherapy against drug-resistant cancer. [Abstract]

2021 Dec:131:112494. PMID: 34857280
Authorea

October 28, 2021.
Research Square Preprint

2021 Oct.
Environ Toxicol

Lysosome Fe2+ release is responsible for etoposide- and cisplatin-induced stemness of small cell lung cancer cells. [Abstract]

2021 Aug;36(8):1654-1663. PMID: 33969609
Research Square Preprint

2021 Aug.
Research Square Preprint

2021 Jul.
bioRxiv

April 22, 2021.
University of Washington

2021. 28314681.
Oxid Med Cell Longev

Zoledronic Acid Enhanced the Antitumor Effect of Cisplatin on Orthotopic Osteosarcoma by ROS-PI3K/AKT Signaling and Attenuated Osteolysis. [Abstract]

2021 Mar 30:2021:6661534. PMID: 33859780
Aging (Albany NY)

PGC-1α alleviates mitochondrial dysfunction via TFEB-mediated autophagy in cisplatin-induced acute kidney injury. [Abstract]

2021 Mar 10;13(6):8421-8439. PMID: 33714196
J Haematol Stem Cell Res

2021; 1(1): 39-45.
Research Square Preprint

2021 Feb.
Journal of Haematology and Stem Cell Research

2021 Feb 1.
Research Square Preprint

2021 Feb.
J Biomater Tiss Eng

2020 Aug 10(8):1170-1175(6).
Research Square Preprint

2020 Nov.
Research Square Preprint

2020 Aug.
Research Square Preprint

2020 Aug.
J Bioma Ter Tiss Eng

2020 10(2):157-162.
Biomed Pharmacother

Enhancement of chemosensitivity by WEE1 inhibition in EGFR-TKIs resistant non-small cell lung cancer. [Abstract]

2019 Sep:117:109185. PMID: 31387179
Oxid Med Cell Longev

Bloom Syndrome Protein Activates AKT and PRAS40 in Prostate Cancer Cells. [Abstract]

2019 May 9:2019:3685817. PMID: 31210839
Oxid Med Cell Longev

ROS Reduction Does Not Decrease the Anticancer Efficacy of X-Ray in Two Breast Cancer Cell Lines. [Abstract]

2019 Mar 14:2019:3782074. PMID: 31001373
Biomed Pharmacother

Tongmai Yangxin pills anti-oxidative stress alleviates cisplatin-induced cardiotoxicity: Network pharmacology analysis and experimental evidence. [Abstract]

2018 Dec:108:1081-1089. PMID: 30372808
Oncotarget

Targeting the overexpressed ROC1 induces G2 cell cycle arrest and apoptosis in esophageal cancer cells. [Abstract]

2017 Apr 25;8(17):29125-29137. PMID: 28418860

Cisplatin purchased from MedChemExpress. Usage Cited in: Oncotarget. 2017 Apr 25;8(17):29125-29137. [Abstract]

Knockdown of ROC1 significantly enhances CDDP-induced apoptosis. TE1 and Kyse450 cells are transfected with siROC1 for 48 h and then treated with 1 μg/mL CDDP for 48 h. Knockdown efficiency and cleaved PARP are assessed by western blotting analysis. Protein expression is quantified and statically analyzed.

Solvente y solubilidad

In Vitro:

DMF : 10 mg/mL (33.33 mM; ultrasonic and warming and heat to 60°C; DMSO can inactivate Cisplatin's activity)

H₂O : 1 mg/mL (3.33 mM; ultrasonic and warming and heat to 60°C; DMSO can inactivate Cisplatin's activity)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.3328 mL

16.6639 mL

33.3278 mL

5 mM

0.6666 mL

3.3328 mL

6.6656 mL

10 mM

0.3333 mL

1.6664 mL

3.3328 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Calculadora de molaridad

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculadora de dilución

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: PBS

Solubility: 1 mg/mL (3.33 mM); Clear solution; Need ultrasonic

Protocol 2

Add each solvent one by one: Saline

Solubility: 2 mg/mL (6.67 mM); Clear solution; Need ultrasonic and warming and heat to 60°C

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Working solution concentration: 0.22 mg/mL

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact

MedChemExpress (MCE) .

Protocolo

All Cell Biology Signal Pathway Related Animals and Diseases

Autophagy
Autophagy is a process in which eukaryotic cells use lysosomes to degrade their own cytoplasmic proteins and damaged organelles under the regulation of autophagy related gene (Atg). Microtubule-associated proteins light chain 3 (LC3) is recognized as autophagy marker, which transfers from cytoplasmic LC3 (LC3-I) to membrane type (LC3-II). LC3-II/I ratio could be detected by Western Blot and fluorescence microscopy.
Ferroptosis Solutions
Ferroptosis is an iron-dependent, non-apoptotic form of regulated cell death characterized by lethal lipid peroxidation and sensitivity to suppression by iron chelators or lipophilic radical-trapping antioxidants. The core pathway links cystine uptake through system Xc−, glutathione availability, GPX4-dependent detoxification of phospholipid hydroperoxides, iron-dependent oxidative reactions, and polyunsaturated-phospholipid metabolism into a cell-death program that is biochemically and morphologically distinct from apoptosis, necrosis, and autophagy. The ferroptosis pathway is experimentally linked to phenotype through chemical and genetic perturbation. Erastin induces ferroptosis by inhibiting cystine uptake through system Xc− and weakening antioxidant defenses, while GPX4 inhibition or depletion causes lipid peroxide accumulation and ferroptotic cancer-cell death. ACSL4 and oxidizable arachidonoyl- or adrenoyl-containing phosphatidylethanolamines shape ferroptosis sensitivity by con
Lysosome and acidic-vesicle live-cell staining
Lysosome and acidic-vesicle live-cell staining detects acidic intracellular compartments by using membrane-permeant acidotropic probes that accumulate in low-pH vesicles, including lysosomes, late endosomes, autolysosomes, and acidic phagosomes. LysoTracker staining is commonly used as an intensity-based readout of acidic lysosomal compartment abundance or enlargement, while acridine orange produces green fluorescence in less concentrated compartments and red fluorescence after concentration-dependent accumulation in acidic vesicular organelles. Loss or reduction of acridine-orange red signal can be used as a readout of lysosomal membrane permeabilization or reduced acidic-vesicle integrity. This protocol is designed for live cultured cells and can be adapted for fluorescence microscopy, high-content imaging, plate-reader readout, or flow cytometry when the selected literature supports the readout. Because these dyes report acidotropic accumulation rather than lysosome identity alone,
Macroautophagy Solutions
Macroautophagy is a conserved lysosome-dependent degradation pathway in which cytoplasmic material is sequestered into double-membrane autophagosomes and delivered to lysosomes for degradation and recycling. The pathway supports cellular homeostasis during nutrient limitation, organelle stress, protein-aggregate accumulation, infection, differentiation, and tissue remodeling by coupling cargo sequestration, autophagosome maturation, lysosomal fusion, and degradation of cargo-derived macromolecules. The core molecular sequence includes initiation by nutrient- and stress-regulated autophagy machinery, autophagosome nucleation, LC3/ATG8-family conjugation to autophagosomal membranes, cargo selection through receptors such as SQSTM1/p62, autophagosome-lysosome fusion, and lysosomal degradation. LC3 was identified as a mammalian homolog of yeast Atg8 that localizes to autophagosomal membranes after processing, and p62/SQSTM1 was shown to connect ubiquitinated cargo with autophagic degradati
Genotoxicity/Mutagenicity Study
The bacterial reverse mutation assay detects point mutations that restore amino-acid prototrophy in auxotrophic Salmonella typhimurium or Escherichia coli tester strains; after exposure to a test article, mutagenic activity is read out as an increased number of revertant colonies on minimal agar compared with the vehicle control. The assay uses tester strains with different mutation targets so that base-substitution and frameshift mutagens can be detected, and testing is performed with and without exogenous mammalian metabolic activation because some chemicals require biotransformation to become mutagenic.

Pureza y Documentación

Select Batch:

Pureza: 99.98%

Assay: 99.98%

ee.: 99.98%

Ficha de datos (285 KB)
SDS (648 KB)
- English - EN (648 KB)
- Français - FR (648 KB)
- Deutsch - DE (648 KB)
- Norwegian - NO (648 KB)
- Español - ES (648 KB)
- Swedish - SV (648 KB)
- Italian - IT (648 KB)
- Korean - KR (648 KB)
- Portuguese - PT (648 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instrucciones de manejo (2659 KB)

Referencias

[1]. Wang X, et al. Requirement for ERK activation in cisplatin-induced apoptosis. J Biol Chem. 2000 Dec 15;275(50):39435-43. [Content Brief]

[2]. Cummings BS, et al. Cisplatin-induced renal cell apoptosis: caspase 3-dependent and -independent pathways. J Pharmacol Exp Ther. 2002 Jul;302(1):8-17. [Content Brief]

[3]. Park HR, et al. Enhanced antitumor efficacy of cisplatin in combination with HemoHIM in tumor-bearing mice. BMC Cancer. 2009 Mar 17;9:85. [Content Brief]

[4]. Shimeda Y, et al. Protective effects of capsaicin against cisplatin-induced nephrotoxicity in rats. Biol Pharm Bull. 2005 Sep;28(9):1635-8. [Content Brief]

[5]. Hall MD, et al. Say no to DMSO: dimethylsulfoxide inactivates cisplatin, NSC 241240, and other platinum complexes. Cancer Res. 2014 Jul 15;74(14):3913-22. [Content Brief]

[6]. Wu K, et al. Cisplatin inhibits the progression of bladder cancer by selectively depleting G-MDSCs: A novel chemoimmunomodulating strategy. Clin Immunol. 2018 Aug;193:60-69. [Content Brief]

[7]. Noha Alassaf, et al. Autophagy and necroptosis in cisplatin-induced acute kidney injury: Recent advances regarding their role and therapeutic potential. Front Pharmacol. 2023 Jan 30:14:1103062. [Content Brief]

[8]. Ryan M Williams, et al. Kidney-Targeted Redox Scavenger Therapy Prevents Cisplatin-Induced Acute Kidney Injury. Front Pharmacol. 2022 Jan 3:12:790913. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
H₂O / DMF	1 mM	3.3328 mL	16.6639 mL	33.3278 mL	83.3195 mL
DMF	5 mM	0.6666 mL	3.3328 mL	6.6656 mL	16.6639 mL
	10 mM	0.3333 mL	1.6664 mL	3.3328 mL	8.3319 mL
	15 mM	0.2222 mL	1.1109 mL	2.2219 mL	5.5546 mL
	20 mM	0.1666 mL	0.8332 mL	1.6664 mL	4.1660 mL
	25 mM	0.1333 mL	0.6666 mL	1.3331 mL	3.3328 mL
	30 mM	0.1111 mL	0.5555 mL	1.1109 mL	2.7773 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Bioz

Keywords

Cisplatin

859 Cited Publications

100 mg Obtener un presupuesto

Subscribe to the

MedChemExpress

Newsletter

Nombre del producto:
Referencia número:
Cantidad:
MCE Japan Authorized Agent:

Nombre del producto:
No. CAS:
Species:
Pureza:
Cantidad:

Cisplatin

Publications Citing Use of MedChemExpress (MCE) Cisplatin

Ver todos los productos específicos de isoformas Lipoxygenase